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Abstract
A major bottleneck in drug discovery is the production of soluble human 
recombinant protein for functional, biochemical and structural analyses. The 
level o f recombinant protein expression is controlled by a complex relationship 
between both biological and engineering variables. Due to the inter-play between 
these variables and standard experimental methods, the identification o f the key 
variables which lead to improved protein expression can sometimes be missed. 
This thesis presents a framework which underpins the generation o f large 
quantities of soluble recombinant protein in E. coli in a rapid and cost-effective 
manner. To achieve this goal, Design o f Experiments (DoE) was first employed 
in combination with microwell plate (MWP) fermentations to investigate the 
wide array of protein expression variables. These tools are well suited to high- 
throughput expression requirements as they afford large savings in time, cost and 
resource requirements. The information generated from these MWP experiments 
was then exploited to devise a strategy for reproducing the process within stirred- 
tank reactors (STRs).
The DoE methodology was first used to identify relevant protein expression 
variables including fermentation variables (media type and fermentation time), 
protein induction variables (inducer concentration and induction time) and 
environmental variables such as oxygen transfer rate, temperature and pH. Ten 
factors were screened overall at the microwell scale and three were investigated 
further through optimisation designs. The application o f DoE led to a robust 
understanding of the process and resulted in protein yields five-fold greater than 
those obtained under standard shake-flask conditions. The most significant 
factors were post-induction period and shaking speed, the latter o f which is 
strongly related to the mass transfer coefficient, kia.
In order to translate this stable and optimised small-scale expression system to a 
production-scale stirred-tank reactor (STR), an understanding o f the engineering 
parameters at both scales o f operation was crucial. This need was complicated by 
significant differences between the MWPs and STRs such as geometry, mode of
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aeration and agitation, and the effects of surface tension. In this work, the MWP 
fermentation results led to the hypothesis that operation at a constant kLa value 
would facilitate predictable scale translation. However, there currently exists 
very little published work on the characterisation o f within MWPs. Miniature 
oxygen probes were, therefore, used to characterise MWP kia  values directly via 
the static gassing-out method over a range o f square-well MWP formats and 
shaking speeds.
This information was then used to translate the performance of a 3ml MWP E. 
coli fermentation, on the basis o f matched kia, to STR working volumes o f 51 
and 451. The efficacy o f scale-up was confirmed by performing F  tests on pairs 
of profiles for cell growth and expression levels of recombinant firefly luciferase. 
This rapid, accurate and direct method o f kia  characterisation within MWPs 
enabled a 15,000-fold direct scale-up o f fermentation performance in terms of 
cell growth and protein expression from MWP to STR.
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Glossary
a significance level
Po constant term
Pi linear effect
Ph squared effect
Pu interaction effect
p viscosity, k g .m '.s '1
M-max maximum specific growth rate, h '1
P density, kg.m'3
CT standard deviation
TP probe response time, s
ai initial specific surface area, n f 1
af final specific surface area, m '1
Bo
'y
Bond number, pdv g/W, dimensionless
CER carbon-dioxide evolution rate, mmol.I'1.h'1
c P unsaturated oxygen fraction at time t, dimensionless
dt shaking amplitude, m
dv microwell vessel diameter, m
D 9 1diffusion coefficient, m .s'
D, impeller diameter, m
DoE Design of Experiments
DOT dissolved oxygen tension, %
FFL Firefly luciferase
Fr Froude number dt(27in)2/(2g), dimensionless
g
•y
acceleration due to gravity, m.s'
HTES High-throughput expression screening
HTPE High-throughput protein expression
HTS High-throughput screening
h a Mass transfer coefficient
MSBR Miniature stirred bioreactor
MWP Microwell plate
n shaking frequency, s '1
24
Islam 2007
N impeller speed, s"1
OFAT One-factor-at-a-time
OUR oxygen uptake rate, m m ol.r'.h '1
Pg power input to gassed liquid, W
Po power number, dimensionless
Pug power input to ungassed liquid, W
Q air flow rate, m3.s''
Q2 fraction of the response variation predicted by the model
(predictive R2)
R2 fraction of the response variation explained by the model
Re Reynolds number, pndv2/p, dimensionless
RLU Relative light units
Sc Schmidt number, p/(pD), dimensionless
SF Shake-flask
STR Stirred-tank reactor
t time, s
tm mass transfer time, s
V liquid volume, 1
vs superficial gas velocity, m .s'1
W wetting tension, N.m’1
Wb impeller blade width, m
jc, dimensionless coded value of the variable Xt
X biomass concentration (dry cell weight), g.l'1
Xt DoE variable
Y predicted response
Zj actual variable value o f X t
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1 Introduction
1.1 Drug discovery
1.1.1 The current direction o f drug discovery
It is widely accepted that virtually all human diseases except trauma has some 
basis in our genes (Collins, 1999). In April 2003, the Human Genome Project 
(HGP) completed a rough draft o f the human genome within which 20,000 to
25.000 genes were identified (Human Genome Sequencing Consortium, 2004). 
Extrapolations from the now complete genome sequence predict that between
2.000 and 3,000 genes favour interactions with drug-like chemical compounds 
(Russ and Lampel, 2005). Recent estimates state that there are only 268 
therapeutic targets which are targeted by at least one marketed drug (Zheng et 
al., 2006). The exposure o f this shortfall has provided the main impetus for a 
new wave o f drug discovery in the post-genomic era.
Since virtually all human diseases have a hereditary component, it is perhaps not 
so surprising that the vast majority o f today’s drug targets are gene-products, 
proteins (Dahl and Sylte, 2006; Tyers and Mann, 2003). For this reason, 
proteomics, the study of protein function, has recently become of burgeoning 
interest to the pharmaceutical industry.
The sequencing of the human genome and that of many pathogens has provided a 
sequence based framework for investigating proteomes (Hanash, 2003), opening 
the gateway for proteomics to emerge. As a result, there is now intense interest in 
applying proteomics to increase our knowledge of disease processes, develop 
new biomarkers for early detection and diagnosis of disease, and accelerate drug 
development (Hanash, 2003).
The HGP required high-throughput and cost-effective technology to process the 
immense amount of information contained within the human genome. The field 
of proteomics now presents a much greater challenge due to the far larger size,
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complexity and dynamic nature o f the human proteome. The need for high- 
throughput technology is, therefore, greatly amplified and lies at the core of 
today’s drug discovery effort.
1.1.2 Drug discovery process
The field o f drug discovery is highly diverse and complex and the exact process 
differs widely within the pharmaceutical industry. Figure 1.1 illustrates a generic 
drug discovery process. Although a sequential process is shown here, in reality a 
large number of iterative cycles may be involved. Thus, Figure 1.1 should be 
seen as the overall sequence o f steps required, but not as a literal depiction o f any 
given drug discovery program.
Pre-clinical Drug 
Development
Screening
Phase
Hits to Leads
Target
Discovery
Lead
Optimisation
Target
Validation
Figure 1.1 Generic process of drug discovery
The process description that follows is a brief and generalised overview. The first 
stage involves the identification of a suitable disease target, towards which the 
Human Genome Project and, subsequently, functional genomics has contributed 
tremendously (Debouck and Metcalf, 2000; Mundy, 2001). The vast majority of 
therapeutic targets are proteins (Bleicher et al., 2003; Dahl and Sylte, 2006; 
Lindsay, 2003) which originate either in humans or in infectious agents such as 
bacteria, fungi and viruses. The role and function of a therapeutic target is 
investigated and its chemical tractability or “druggability” evaluated.
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Target Validation aims to demonstrate that a molecular target is critically 
involved in a disease process and that modulation of the target is likely to have a 
therapeutic effect. This stage involves in vitro and in vivo biochemical analysis 
and provides fundamental information which will direct and aid the screening 
phase. For example, target validation may generate information relating to the 
relevant form of the target protein needed for screening e.g active or inactive, 
membrane bound or cytoplasmic.
The Screening Phase (or Hit Generation) o f the drug discovery process is broad 
in scope where various techniques can be applied to asses how effectively 
compounds interact with the target protein. Techniques such as bioassays, 
structure based methods (X-ray crystallography and Nuclear Magnetic 
Resonance) and biophysical techniques such as thermal denaturation and 
isothermal calorimetry are all used in the screening phase of modem drug 
discovery. The cost, time and throughput o f these techniques vary as does the 
level of detail obtained regarding the binding o f compounds to the target protein. 
These screening techniques require differing levels of target protein and so a 
flexible production capacity is required to accommodate these needs.
Traditionally, a functional biochemical assay would be used to screen compound 
libraries where a value for the inhibition o f the target protein could be calculated. 
This type of in vitro assay is the basis for High-Throughput Screening (HTS) 
where the assay is formatted onto microwell plates (MWPs) and compound 
libraries of >200,000 compounds can be screened in a timely fashion. Whilst the 
throughput of an HTS screen is very rapid, the sensitivity of the assay can be 
quite low with compounds requiring a low micro-molar potency to be detected. 
Therefore, smaller but more novel compounds could be missed in this type of 
screen. Although a value for the inhibition of the compound against the target 
protein is calculated in an HTS campaign, no information is generated regarding 
the actual binding mode of the compound to the protein. This information is 
highly valuable to the medicinal chemist when trying to optimise the potency and 
selectivity o f the compound.
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More recently, protein crystallography has emerged as a powerful screening tool 
for hit generation. Traditionally, protein crystallography has been used in the 
latter stages of the drug discovery process. However, advances in protein 
production, crystallisation and data collection have enabled this technique to be 
used in the screening phase. The generation of detailed structural information on 
how the compound interacts with the target protein is immensely powerful and is 
the key to designing more selective and potent drugs. The use of High 
Throughput Crystallography in structure based drug design has been enhanced by 
advances in in silico methods. Prior structural information can be used to enrich 
compound libraries with molecules that have been shown computationally to 
interact well with the target protein. Through iterative cycles of structure 
determination of protein/ligand complexes coupled to medicinal chemistry, 
detailed Structure Activity Relationships (SARs) can be generated.
The Hits to Leads phase builds up significant SAR data around the initial hits 
obtained from the screening phase. Chemical moeties with different 
functionalities are added onto the initial hit in an attempt to improve the binding 
of the compound to the target protein. These new compounds are then re­
screened to establish which o f the modifications have improved the potency of 
the compounds. The Lead Optimisation phase focuses on a few lead series that 
look the most attractive in terms o f potency, selectivity and physicochemical 
properties. Medicinal chemists take these lead compounds and alter their 
structures using all the knowledge gained thus far, drawing heavily from SAR 
data, to improve the drug qualities o f lead compounds such as stability, 
bioavailability and absorption, distribution, metabolism, and excretion (ADME) 
profiles. These drug candidates are then assessed in more extensive in vivo 
studies and animal models to generate pharmacokinetics (PK), 
pharmacodynamics (PD), ADME and toxicity data. If the profile of a lead 
compound is deemed to be promising then it progresses through to drug 
development.
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1.1.3 Drug discovery challenges
A study of therapeutics in clinical trials between 1991 and 2000 revealed an 89% 
average failure rate across ten large pharmaceutical companies (Kola and Landis,
2004). The scale o f this problem is compounded once the development time and 
cost for new drugs are considered. The average development time of all drugs 
that gained approval in 2002 was 12 years 10 months; the average development 
cost of a new drug in 2001 was approximately US $802 million (DiMasi et al., 
2003) and some authors believe the true cost may be more than double this 
amount (Adams and Brantner, 2006). In addition to these costs is the human cost 
of the failure to discover new treatments, and the cost in animal lives throughout 
the research process. Understanding the root causes of clinical drug failure and 
minimising attrition is, therefore, one o f the most important aims of today’s 
pharmaceutical discovery programmes (Nicholson et al., 2002).
The major causes of attrition in the clinic in 2000 were lack of efficacy, 
accounting for approximately 30 % of failures, and safety, accounting for a 
further 30 %, (Kola and Landis, 2004). The vast majority o f attrition occurs in 
clinical development (Kola and Landis, 2004) at which stage the cost of failure is 
very high (Bleicher et al., 2003; Nicholson et al., 2002). Early measures are, 
therefore, required to increase the understanding of drug properties within the 
drug discovery process.
The key to overcoming this obstacle is to obtain a more rigorous understanding 
of how drug candidates bind and interact with their protein targets (Stewart et al., 
2002). To this end, it is critical that a more detailed knowledge of protein and 
drug structures is generated at the screening phase of drug discovery. This would 
enable medicinal chemists to optimise the drug properties o f the lead molecules. 
For example, detailed knowledge of a target molecule’s binding site would 
facilitate in the design o f drug compounds with higher potency and selectivity 
(Blundell et al., 2002). This in turn would decrease the occurrence o f side 
reactions and might also improve efficacy and toxicity profiles, the leading 
factors in drug attrition.
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X-ray crystallography is perhaps the most commonly used tool for three- 
dimensional molecular structure determination (Blundell and Patel, 2004; 
Congreve et al., 2005; Kuhn et al., 2002; Stewart et al., 2002). The generation of 
sufficient quantities of soluble recombinant protein for the production of 
diffraction-quality crystals can present a bottleneck to the entire drug discovery 
process (Stewart et al., 2002). Furthermore, there is a growing requirement to 
increase the throughput of X-ray crystallography (Blundell and Patel, 2004; 
Congreve et al., 2005; Kuhn et al., 2002; Stewart et al., 2002). For instance, 
fragment-based lead-discovery is becoming increasingly popular for identifying 
better lead molecules so as to reduce attrition (Rees et al., 2004). Molecular 
fragments by their very nature are o f low chemical complexity and display 
limited functionality which results in a lower affinity in conventional biological 
assays (Gill et al., 2005). X-ray crystallography is able to detect low-affinity 
binding and so has emerged as a complimentary/replacement approach to 
traditional high-throughput screening (Rees et al., 2004). Furthermore, screening 
throughput itself may be driven higher as a result of the increased identification 
o f potential therapeutic targets from functional genomics research, as outlined in 
Section 1.1.2. Overall, therefore, there is intense interest in enhancing throughput 
by automating all steps o f protein crystallography, the first step of which is the 
rapid and cost-effective production o f soluble protein samples (Congreve et al., 
2005).
1.2 High Throughput Protein Expression
1.2.1 Choice of expression system
The choice of expression system can greatly affect the yield and activity of a 
protein (Blundell and Patel, 2004; Stewart et al., 2002). There is no universal 
expression system for heterologous proteins (Rai and Padh, 2001) and so the 
selection o f an appropriate system involves an assessment of the benefits and 
disadvantages of each system in relation to the application requirements. This 
project aims to establish a framework that will underpin the generation o f large 
quantities of soluble protein in a rapid and cost-effective manner. A model
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expression system is required, therefore, the properties of which should facilitate 
the development of the framework. A model expression host should:
i. grow rapidly;
ii. require simple and inexpensive substrates;
iii. express high yields of heterologous protein;
iv. lend well to high-throughput production, MWP growth, automation and 
scale-up.
An immediate choice would be a bacterial expression host as it meets all these 
requirements. Escherichia coli in particular is an ideal host as it grows rapidly 
with a short doubling time o f ~20 minutes (Singleton and Sainsbury, 2002), it is 
inexpensive to culture (Blundell and Patel, 2004; Hunt, 2005) and efficient 
expression of recombinant product to more than 50 % of total cell mass has been 
reported (Andersen and Krummen, 2002; Baneyx, 1999; Jana and Deb, 2005; 
Swartz, 2001). Moreover, a wealth o f information exists regarding its genetics 
and physiology which greatly facilitates gene cloning and cultivation (Rai and 
Padh, 2001).
1.2.1.1 Bacterial expression systems
Since E. coli is a simple organism, it is also highly amenable for growth within 
the MWP format using standard shaking incubators (Hunt, 2005). This utility 
allows many parameters to be analysed simultaneously in small volumes which, 
in turn, allows the rapid identification o f optimal expression conditions for the 
generation of large quantities o f recombinant protein.
These properties make E. coli the most widely used host in industry for 
recombinant protein expression, provided post-translational modifications o f the 
product are not required (Andersen and Krummen, 2002; Blundell and Patel, 
2004; Choi et a l, 2006; Graumann and Premstaller, 2006; Hunt, 2005; Rai and 
Padh, 2001; Stewart et al., 2002; Walsh, 2002).
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If diffraction-quality crystals are not readily obtainable using E. coli, then several 
alternative expression systems are available, each with its own unique 
combination o f benefits and disadvantages in relation to cost, ease o f use, and 
post-translation al modification profiles.
1.2.1.2 Yeast expression systems
Yeast systems present the favoured alternative host for expression of 
recombinant proteins for research, industrial and medical use (Rai and Padh,
2001) of which the most common strains are Saccharomyces cerevisiae and 
Pichia pastoris (Andersen and Krummen, 2002; Graumann and Premstaller, 
2006; Stewart et al., 2002). Yeasts have played a central role in many traditional 
biotechnological processes such as brewing and baking and so they, like E. coli, 
are very well characterised within modem biotechnology. Yeasts are simple 
eukaryotes and thus are able to perform a range of post-translational 
modifications required by many human proteins. They usually grow fast, but 
slower than E. coli, and are also able to secrete proteins to the culture medium 
(Graumann and Premstaller, 2006) which facilitates isolation and purification of 
the product. Although a variety o f therapeutic proteins have been manufactured 
in Saccharomyces cerevisiae, expression levels of heterologous protein are often 
low, typically representing less than 5 per cent of total cellular protein (Walsh,
2002).
1.2.1.3 Insect cell/baculovirus expression systems
Insect cell lines are also emerging as popular systems for overproducing 
recombinant proteins (Rai and Padh, 2001). Heterologous protein expression is 
usually mediated by the baculovirus expression system which is highly specific 
to the target cell line. The gene encoding the protein of interest is introduced into 
a non-essential region of the viral genome. The virus is then propagated within 
the insect cell culture and the recombinant protein is expressed in the process. 
The main advantage afforded by insect cells is that they are able to produce many
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of the post-translational protein modifications that occur in human cells (Davies, 
1994). The majority of proteins expressed within insect cells are, therefore, 
soluble (Rai and Padh, 2001). However, insect cells grow much slower than 
bacteria or yeasts with a doubling time o f approximately 24 hours (O'Reilly et 
al., 1992) and the cost and complexity o f the growth medium is usually high. 
Furthermore, expression levels of heterologous protein have thus far been highly 
variable (Walsh, 2002).
1.2.1.4 Mammalian expression systems
Proteins which require mammalian-specific post-translational modifications 
should ideally be expressed in mammalian cells (Rai and Padh, 2001). Chinese 
hamster ovary (CHO), human embryonic kidney (HEK 293) and non-secreting 
murine myeloma (NS0) cell expression systems have now established themselves 
as the predominant systems for mammalian expression (Andersen and Krummen, 
2002). Mammalian cell culture requires complex and expensive culture media 
(Rai and Padh, 2001; Walsh, 2002) and low product yields are often obtained 
(Rai and Padh, 2001). Furthermore, cell growth is slower and more complicated 
than the expression systems reviewed thus far. As such, they are not the first 
choice for high-throughput protein production.
1.2.1.5 Cell-free expression systems
Perhaps the most interesting emerging technology is that of cell-free expression 
systems. These include both more traditional systems using cell extracts and 
systems reconstituted from purified components (Kim and Swartz, 2001; 
Shimizu et al., 2001). The main advantages o f these systems over conventional 
in vivo systems are: (i) the target protein is the only protein synthesised which 
greatly simplifies the purification requirements, (ii) the reaction is rapid and can 
be carried out in small volumes and (iii) the absence of living cells makes the use 
of a wide range of different reaction conditions possible (Ozawa et al., 2005). A 
further advantage of this system is that chemical modifications for structural
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studies such as N 15 and C 13 labelling and Selino-Methionine labelling can be 
made in a more straight forward manner
Recombinant proteins are often expressed in more than one system during drug 
discovery (Janssen, 2004). A bacterial expression system may be used for initial 
studies to determine solubility or activity or to produce large amounts of protein 
for structural studies. In order to obtain higher activity or post-translational 
modifications, the same gene might then be expressed in eukaryotic cells (protein 
expression and purification techniques). Overall, Escherichia coli, remains the 
first choice of expression system for producing samples for protein 
crystallography (Blundell and Patel, 2004; Edwards et al., 2005). It will, 
therefore, be used as the model expression host in this project.
1.2.2 Mechanism of protein expression
In general, both constitutive and inducible systems have been described for E. 
coli where the latter dominate (Graumann and Premstaller, 2006). The expression 
of recombinant proteins induces a metabolic burden, which is defined as the 
amount of resources which are withdrawn from the host metabolism for 
maintenance and expression o f foreign DNA (Bentley and Kompala, 1990). 
Maximum productivity in recombinant E. coli is often achieved when the growth 
and production phases are separated by delaying the induction time until the cell 
density reaches a suitable value (Choi et al., 2006). This approach is especially 
important when the expression target is toxic to the cell (Baibas, 2001; Jana and 
Deb, 2005; Sorensen and Mortensen, 2005). The ideal expression vector tightly 
regulates gene expression to achieve rapid cell growth to sufficient densities 
before the induction phase.
E. coli strain BL21 (DE3) was chosen as the model expression system for this 
project. BL21 is a robust and commonly used strain for the expression of 
recombinant proteins (Sorensen and Mortensen, 2005). It is deficient of both the 
Ion protease and the ompT outer membrane protease (Grodberg and Dunn, 1988). 
The lack of two key proteases reduces degradation of heterologous proteins. The
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DE3 designation indicates that the strain contains the XDE3 lysogen that carries 
the gene for T7 RNA polymerase under control of the lac\JV5 promoter. This 
promoter contains a mutation in the consensus region of the lac promoter which 
increases its strength (Reznikoff, 1980). Expression of T7 RNA polymerase is 
inducible by isopropyl-p-D-thio-galactopyranoside (IPTG), a lactose analogue, 
which binds to the lac\ repressor and reduces its affinity for the lac operator; the 
overall expression mechanism is summarised effectively by Sorensen and 
Mortensen (2005).
The pET (plasmid for expression by 77 RNA polymerase) vector system was 
developed by Studier et al. (1990) for cloning and expressing recombinant DNA 
under control o f a T7 promoter. Due to the high selectivity of T7 RNA 
polymerase for the T7 promoter, transcription of target DNA by E. coli RNA 
polymerase in the absence o f T7 RNA polymerase is low enough to enable the 
expression of very toxic genes (Studier et al., 1990), which increases the 
applicability o f the model expression system. Furthermore, pET vectors confer 
antibiotic resistance upon their host and so serve as a selectable marker. The 
pET expression system is by far the most widely used currently in recombinant 
protein expression (Sorensen and Mortensen, 2005) and high levels o f success 
have been reported in obtaining diffraction-quality protein crystals originating 
from E. coli BL21 (DE3) cells transformed with the pET vector (Folli et al., 
2001; Goulding and Perry, 2003; Park et al., 2005; You et al., 2003).
1.2.3 Factors influencing soluble protein expression
Much research has been carried out into optimising soluble heterologous protein 
expression through host strain and vector development (for detailed reviews, see 
Baneyx, 1999; Georgiou and Valax, 1996; Hannig and Makrides, 1998; Jana and 
Deb, 2005; Sorensen and Mortensen, 2005; Weickert et al., 1996). A simpler and 
often equally effective approach is to manipulate the culture conditions 
(Georgiou and Valax, 1996). Relatively little research has been carried out in this 
area, however.
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Batch cultivation is the simplest way to produce a recombinant protein (Jonasson 
et al., 2002), and it is particularly appropriate for the MWP format. Several 
factors are reported to affect cell growth and soluble protein expression within 
this mode of fermentation. Fermentation variables such as media composition, 
pH, temperature and dissolved oxygen can affect transcription, translation, and 
proteolytic activities within a cell (Choi et al., 2006; Bird et al., 2004). Protein 
induction conditions such as pre-induction cultivation period, inducer 
concentration, post-induction cultivation period and the levels of fermentation 
variables during the induction phase also affect expression levels (Choi et al., 
2000; Jeong and Lee, 1999; Yim et al., 2001). In order to investigate these 
effects on expression levels of heterologous protein, it is vital that all other minor 
variables are controlled between batches.
The composition of the growth medium has significant effects on both the rate of 
cell growth and level o f product accumulation (Broedel et al., 2001; Jana and 
Deb, 2005). The translation o f different mRNAs, for example, is differentially 
affected by changes in the culture medium (Corisdeo and Wang, 2004). Fast 
growth due to high concentrations o f rapidly metabolised sugars is often 
associated with low productivity o f recombinant protein (Stanbury and Whitaker,
1993). Furthermore, Broedel et al. (2001) observed that the optimal medium 
composition for soluble protein expression differed between proteins.
It is well established (Riesenberg, 1991) that E. coli growth is inhibited when the 
following nutrients are present above certain concentrations (shown in brackets): 
glucose (50 g .l1), phosphorous (10 g.l'1), magnesium (8.7 g.l"1), ammonia (3 g.l" 
'), iron (1.15 g.l'1) and zinc (0.038 g.l’1). It is, therefore, important to develop 
media in which these components are present at non-inhibitive concentrations.
While defined media are generally used to obtain high-cell densities (Sang,
1996), complex media are often employed in industrial settings because o f lower 
costs and more robust cell growth (Diaz-Ricci et al., 1990). Although 
fermentations in complex media are more prone to variation due to varying 
nutrient compostion and quality (Jonasson et al., 2002; Sang, 1996), the vitamins
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and macromelocular precursors provided by the media are often necessary to 
obtain high levels of recombinant protein (Diaz-Ricci et al., 1990; Jonasson et 
al., 2002).
A major challenge in the production of heterologous protein at high cell density 
is the formation of acetate, a lipophilic agent that inhibits cell growth (Jana and 
Deb, 2005; Luli and Strohl, 1990). The wide range of detrimental effects on the 
growth o f E. coli caused by acetate accumulation is reviewed in detail by 
Shiloach and Fass (2005). Acetate is produced when the culture is grown in the 
presence of glucose or under oxygen limiting conditions (Kleman and Strohl,
1994) and it is important to maintain the acetate concentration below a certain, 
inhibitory level (Jonasson et al., 2002). One way of achieving this is by using 
glycerol in preference to glucose as the carbon substrate (Holms, 1996; Korz et 
al., 1995); at least one study has demonstrated a two-fold increase in 
recombinant protein expression from E. coli cultures grown on glycerol 
compared to those grown on glucose (Lee et al., 1997).
The pH of the culture medium can also affect product yield. One benefit o f 
avoiding acetate formation is that it minimises the pH disturbance which is of 
particular concern with respect to MWP cultures where pH control is not 
routinely available. The optimal pH range for E. coli growth is approximately 6-8 
(Ingraham and Marr, 1996) and several studies have also observed optimal 
recombinant protein production in E. coli within this pH range (Dien et al., 2001; 
Ryan and Parulekar, 1990; Wang et al., 2005). Although relatively little 
information exists on the behaviour of pH-uncontrolled systems, Calik et al. 
(2006) reported higher cell concentrations and product yields from batch 
fermentations with no pH control compared to those with pH control.
Temperature is another important variable. Cultivation at reduced temperature 
slows down cell growth and protein synthesis (Peng et al., 2004). Although this 
generally leads to a lower final biomass concentration, the amount of soluble 
recombinant protein is usually increased. These factors contribute to a higher 
solubility of foreign proteins (Schein, 1989) and the technique has proved
38
1. Introduction Islam 2007
effective in producing a number o f proteins which are typically poorly expressed 
(Vasina and Baneyx, 1997). The reason why cultivation at a lower temperature of 
-30  °C favours the native state is related to a number of factors, including a 
decrease in the propensity o f hydrophobic interactions which cause proteins to 
aggregate (Georgiou and Valax, 1996; Kiefhaber et al., 1991), a slower rate of 
protein synthesis (Georgiou and Valax, 1996), the partial elimination of heat 
shock proteases (Chesshyre and Hipkiss, 1989) and an increase in the expression 
of E. coli chaperones (Ferrer et al., 2003; Mogk et al., 2002).
Oxygen is an essential nutrient for the aerobic growth of E. coli (Andersen and 
von Meyenburg, 1980; McDaniel et al., 1965), but at the same time it is the most 
difficult to supply because o f its low solubility (Li et al., 1992). For this reason 
the oxygen demand may become the limiting factor o f E. coli growth, if it 
exceeds the oxygen transfer capacity o f the fermentation vessel (Maier and 
Buchs, 2001). This is more likely to occur if rapidly metabolised sugars such as 
glucose, which lead to high oxygen demand, are available in high concentrations 
(Stanbury and Whitaker, 1993). The issue o f oxygen demand is particularly 
significant to shaken MWP cultures, where oxygen supply, provided solely by 
surface aeration, may be poor.
There are no definitive rules regarding the effect of oxygen supply on expression 
levels of recombinant protein. This is because there are relatively few published 
studies in this area and furthermore, those that do exist observe differing trends. 
In a study by De Leon et al. (2003), the maximum production of active penicillin 
acylase by E. coli was obtained at a dissolved oxygen tension (DOT) o f 1 %. In 
contrast, Bhattacharya and Dubey (1997) reported a drastic decrease in the level 
o f target protein (Msp\ methylase) in recombinant E. coli under oxygen-deficient 
conditions. This variable trend was summarised by Li et al. (1992) who 
examined the effects of dissolved oxygen levels on the level of biomass, plasmid 
content and the levels o f chloramphenicol acetyltransferase and beta- 
galactosidase within four recombinant strains of E. coli. The optimal dissolved 
oxygen concentration for the specific activity o f recombinant proteins was found 
to be dependent on both the host strain and the particular recombinant product. In
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light o f these studies, oxygen should prove to be an interesting variable for 
investigation.
The optimal conditions for inducing recombinant protein expression are highly 
dependent upon the characteristics o f the target protein and thus the extent of the 
imposed metabolic burden (Donovan et al., 1996). In many cases the inducer 
concentration is optimised to balance the decreasing yields of recombinant cells 
following induction with increasing cellular levels of target protein (Bentley et 
al., 1991). For soluble cytoplasmic proteins, this optimal level is usually 
approximately 1 mM IPTG (Bentley et al., 1991; Donovan et al., 1996). When 
product expression is low and/or does not significantly affect cell growth, overall 
heterologous protein yield is maximised by inducing expression throughout the 
entire growth phase (Donovan et al., 1996). However, if expression of the 
recombinant protein does impose a significant metabolic burden, induction at or 
beyond middle stage o f exponential growth may prove optimal (Bentley et al., 
1991; Donovan et al., 1996; Lee, 1996; Peng et al., 2004).
A common limitation of the studies mentioned so far is that they fail to 
adequately study the combined effect o f variables on heterologous protein 
expression. Thus no account is made for interactions between the large number 
o f variables. An objective of this project is to address this shortfall.
1.2.4 Microscale processing
A wide range of variables affect heterologous protein expression levels as 
described in Section 1.2.3 and numerous experiments are, therefore, required to 
adequately characterise the total complement o f interactions and effects. 
Microscale processing techniques are rapidly emerging as a means of satisfying 
the demands placed by High Throughput Protein Expression (HTPE) studies. 
Through the miniaturisation and automation of fermentation, these techniques 
allow for vast savings in time, money (especially where expensive media or 
substrates are involved), space and manpower (Kumar et a l, 2004; Lye et al.,
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2003; Maier and Buchs, 2001). This also enables a wider range of process 
variables to be examined (Lye et al., 2003).
The pressing need for reproducible and scalable high-throughput cultivation 
technology has identified several areas of research interest (Weuster-Botz et al.,
2005). These interests draw a parallel with the direction of research that followed 
the emergence of conventional bioreactors. For example, a quantitative 
understanding of the engineering parameters associated with the operation of 
small-scale fermentation vessels such as the hydrodynamics and mass transfer 
characteristics, is of primary concern (Fernandes and Cabral, 2006). The ability 
to measure online process parameters such as dissolved oxygen, temperature and 
pH is also needed. Appropriate sensors have been developed towards these 
purposes for a range of small-scale bioreactors including shake-flasks, miniature 
stirred bioreactors (MSBRs), and MWPs.
The shake-flask represents the classical parallel reactor used in biotechnology 
(Weuster-Botz, 2005). Scientists have used cell cultivation in shake-flasks as a 
means of process development for the past fifty years (Betts and Baganz, 2006), 
with volumes ranging from ca. 10 ml to 500 ml (Buchs, 2001). These reactors are 
inexpensive, easy to use and largely impervious to mechanical complications 
(Betts and Baganz, 2006; Kumar et al., 2004). Recently, instrumented shake- 
flasks have become available, which allow for the monitoring of pH and DOT 
levels online (Anderlei and Buchs, 2001; Wittmann et al., 2003). Other 
parameters such as the oxygen transfer rate (OTR) and carbon dioxide evolution 
rate (CER) can now also be measured online. A major limitation, however, is that 
shake-flask fermentations are not typically automated. Sampling, for example, 
requires the removal of the shake-flasks from the shaking device, thus 
interrupting oxygen supply (Kumar et al., 2004).
Miniature stirred bioreactors based on conventional STRs have been developed 
as an alternative to traditional shaken systems for early-stage process 
development (Betts and Baganz, 2006; Hsu and Wu, 2002; Harms et al., 2006; 
Kostov et al., 2001; Lamping et al., 2003; Zanzotto et al., 2004; Zhang et al.,
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2006). Despite their small size, temperature, pH and dissolved oxygen can be 
monitored and controlled at desired levels within MSBRs. They are also 
relatively easy to scale-up due to similarities in geometry and in methods of 
aeration and agitation with conventional bioreactors. The use of these reactors is, 
however, severely limited by their high costs relative to other small-scale devices 
and also the difficulties of their integration with high-throughput screening 
technologies (Kumar et a l,  2004; Weuster-Botz, 2005).
MWPs are perhaps the most popular choice for the screening stages o f high- 
throughput bioprocess development (Weuster-Botz et a l, 2005). They have been 
used to grow a wide range of cell lines including bacteria (see Kumar et al., 2004 
for a review), yeast (Hammonds et a l,  1998; Janssen, 2004), insect cells (Bahia 
et al., 2005; Chambers et al., 2004) and also mammalian cells (Davies et al., 
2005; Deshpande et al., 2004; Micheletti et al., 2006). They offer all the 
advantages o f shake-flasks with the added benefit of being highly amenable to 
process automation. Their ability to perform many identical reactions in parallel 
with very small volumes (Betts and Baganz, 2006) endows them with the 
greatest high-throughput capability out o f all the miniature bioreactor formats 
mentioned thus far.
MWPs typically contain 6, 12, 24, 48, 96 or 384 wells, with up to 1536 and 3456 
wells now available for ultra high-throughput screening (UHTS) (Mere et al., 
1999). MWPs are available in a range of geometries, well volumes and materials 
of construction and are reviewed in detail by Lye et al. (2003) and Betts and 
Baganz (2006).
The processing of MWPs can be automated using robotics with modem pipetting 
and dispensing systems, centrifuges, etc (Kumar et al., 2004). A wide range of 
commercially available automated platforms is reviewed by Lye et al. (2003). 
Instruments and methods have been developed for pH measurements (Elmahdi et 
al., 2003; John et al., 2003a; Weiss et al., 2002) and dissolved oxygen 
measurements (see Table 1.1). Now, MWPs with integrated sensors are 
commercially available and are reported by Betts and Baganz (2006). A major
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bottleneck in the use of MWPs for cultivation is the risk of cross-contamination 
(Kumar et a l, 2004). Evaporation o f medium is also a critical factor particularly 
for slow growing organisms. These limitations can be reduced with the use of 
oxygen-permeable sealing membranes, a variety of which are reviewed by 
Zimmermann et a l (2003).
Table 1.1 summarises the existing research into microscale mixing within the 
aforementioned reactor formats. The mass transfer coefficients (foa) o f shake- 
flasks and MSBRs are well characterised over a range of geometries and working 
volumes and the two formats share similar Ida ranges. In contrast, the majority o f 
research into MWPs has focussed on the 96 well format, which is probably due 
to the frequency o f its use in industry (Kensy et a l,  2005). Subsequently, the 
research is also limited with respect to the range of working volumes 
investigated. For these plates, the majority o f kLa values are in the lower range, 
below 180 h 1. The notable exception here is the extreme kLa value reported 
Kensy et a l (2005) of 1600 h '1 for a 48 well plate, which is comparable to that of 
a conventional STR. Clearly, there is a need for further investigation in this area, 
but this research has already demonstrated the potential for MWPs to exhibit 
similar mixing characteristics to that o f conventional STRs.
1.2.5 Reporter genes
The term reporter gene is used to define a gene with a readily measurable 
phenotype that can be easily distinguished over a background of endogenous 
proteins (Alam and Cook, 1990). This characteristic is highly desirable when 
choosing a suitable product model for the investigation of high throughput 
protein expression. Moreover, reporter gene assays are largely quantitative and 
rapid, requiring no prior protein purification. This facilitates the accurate analysis 
and comparison o f recombinant protein expression levels under a range of 
culture conditions.
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Table 1.1 Summary o f microscale research into mixing and oxygen transfer 
carried out in a range o f small-scale vessels including the shake flask (SF), 
miniature stirred bioreactor (MSBR) and microwell plate (MWP). 'The terms 
static gassing-out and dynamic gassing-out are used in accordance with the 
definitions provided by Stanbury and Whitaker (1993).
Reactor Format
Working
Volume
(ml)
kLa
Of1)
Method1 Reference
SF (unbaffled) 2 - 1 6 0 <565 Sulphite oxidation Maier et al. (2004)
SF (unbaffled) 100 1 0 -5 4 Static gassing-out Van Suijdam et al. (1978)
SF (baffled) 200 144-482
SF (baffled/ 50 -  200 35 - 400 Sulphite oxidation Henzler and Schedel
unbaffled) and oxygen balance 
(E. coli / S. tendae)
(1991)
MSBR 6 100-400 Static gassing-out Lamping et al. (2003)
MSBR 1 <500 Sulphite oxidation Harms et al. (2006)
MSBR 2 1 0 -4 4 n/a Rostov et al. (2001)
MSBR 0.15 2 0 -7 5 Static gassing-out Zhang et al. (2006)
MSBR 18 <480 n/a Betts and Baganz. (2006)
MWP (96 well) 0.2 < 150 Bio-oxidation o f  
catechol
Ortiz-Ochoa et al. (2005)
MWP (96 well) 0.2 < 130 Dynamic gassing-out 
(C. glutamicum )
John et al. (2003b)
MWP (24 well) 0.07 < 180 Static gassing-out and Doig et al. (2005)
MWP (96 well) 0.2 < 180 linear growth o f  strict
MWP (384 well) 1.2 < 100 aerobe (B. subtilis)
MWP (96 well) 0.5 < 188 Oxygen balance {P. 
putida)
Duetz et al. (2000)
MWP (48 well) 0.3 < 1600 Sulphite oxidation Kensy et al. (2005)
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The variety of available reporter genes is very broad. Some commonly used ones 
include chloramphenicol acetyltransferase (CAT), p-galactosidase, bacterial and 
firefly luciferases, alkaline phosphatase and green fluorescent protein (GFP) 
(Naylor, 1999; Welsh and Kay, 1997; Wood, 1995).
The luc gene from the firefly (Photinus pyralis) is one of the most widely used 
reporter genes (Roda et a l, 2004; Urbain, 2001; Welsh and Kay, 1997) and it is 
also well-suited for application within this project. The assay has a broad linear 
range o f up to 7-8 orders of magnitude (Joyeux et al., 1997) and, unlike (3- 
galactosidase, no endogenous activity exists within E. coli for the luciferases 
(Wood, 1995), a property which contributes to the highly sensitive nature o f the 
assay (Alam and Cook, 1990). The luc gene encodes a single polypeptide which 
imparts a low metabolic burden upon the expression host in contrast to the 
bacterial luciferase operon which codes for five polypeptides (Hakkila et al.,
2002). Furthermore, firefly luciferase shows little toxicity (Welsh and Kay,
1997) and requires no posttranslational modifications (Bronstein et al., 1994).
Luciferase activity is proportional to the total light emission of the reaction 
scheme shown below (Bronstein et al., 1994):
firefly luciferase + Mg2+
ATP + D-luciferin + 0 2 ----------------------------------► C 02 + AMP + PPj + oxyluciferin
+ light (560nm)
The requirement of D-luciferin, an exogenous substrate, makes the use o f an end­
point assay for soluble protein yield possible. In contrast, if bacterial luciferse, 
was used as a reporter, it would be necessary to monitor light emission 
continuously because the corresponding reaction would proceed automatically 
from endogenous substrates upon induction of the reporter genes (Hakkila et al., 
2002).
The luciferase assay is also well suited to the high-throughput screening format 
unlike the CAT assay which is laborious, expensive and relatively insenstitve
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(Suto and Ignar, 1997). GFP is also relatively insensitive, because of a 
considerable background signal due to cellular autofluorescence (Hakkila et al., 
2002; Naylor, 1999). Moreover, the accumulation of GFP, narrow linear range 
and low turnover make it also unsuitable for any high throughput investigation 
(Naylor, 1999).
1.3 Design of Experiments
1.3.1 Description and benefits over traditional approaches
High-throughput protein expression (HTPE) studies rely on screening a large 
number of expression parameters. Most approaches, including high-throughput 
expression screening (HTES), are unstructured and result in only a limited 
understanding o f the system. The task o f accurately determining the optimal 
expression conditions, therefore, can be resource intensive. This requirement 
may prove prohibitive above a certain number o f variables.
The one-factor-at-a-time (OFAT) method represents a more systematic approach 
to HTPE studies. This approach is illustrated in Figure 1.2 (a), for a system 
influenced by two parameters. This is representative of a simple biological 
system in which interactions between variables may exist. Here, the OFAT 
approach fixes factor X2 and varies factor Xi until a maximum response is 
observed. Then, factor Xi is fixed at its apparent optimum level and factor X2 is 
varied until a new optimum response is observed. In this scenario OFAT analysis 
fails to identify the optimal conditions as it is unable to account for the 
interaction o f factors.
Statistical Design of Experiments (DoE) is able to overcome the limitations of 
traditional HTPE approaches. DoE is a structured and efficient approach for 
determining the mathematical relationship between multiple factors affecting a 
process and the output(s) of that process as illustrated in Figure 1.3.
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\region
Factor X
(N
X
Factor X
Figure 1.2 Response contour plot of a system influenced by two factors, 
investigated using OFAT (a) and DoE (b). Individual experiments are also shown 
[ • ] •
The DoE approach is illustrated in Figure 1.2 (b), the same system for which the
OFAT methodology was previously demonstrated. Here, a small experimental 
design is applied in which the two factors are varied simultaneously. Due to the 
symmetry of the experimental design, certain predictions about the system’s 
behaviour can be made. In this scenario, it is possible to predict the direction in
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which the optimal region is likely to be found. Subsequent designs will be able to 
determine the precise location of the optimal region.
Factors,
System / process
Response(s),
Y
Factors,
X
DoE
1
---------►
--------- ► Representative
-------- ►--------- ► model--------- ►
Predicted
Y’
Figure 1.3 The DoE procedure in which system or process is modelled, enabling 
the prediction of response values from defined factor levels.
In summary, DoE offers three clear advantages over other HTPE methods. 
Firstly, as mentioned previously, DoE is able to account for interactions between 
factors. Design of Experiments is also able to estimate experimental error by 
considering the overall difference between observed response values and those 
predicted by the mathematical model. In this way, real effects can be 
distinguished from experimental error. Finally, in quantifying the real effects, 
DoE is able to produce reliable maps of the investigated process or system from 
which the optimal region can be identified. This last point is of key importance to 
bioprocess development, where fermentation optimisation is a crucial precursor 
to successful scale-up; results obtained under sub-optimal conditions such as
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oxygen limitation are likely to be misleading (Buchs, 2001; McDaniel et al., 
1965).
1.3.2 Pre-experimental steps
The first step in implementing DoE is the problem formulation and its objective 
is to establish and clarify the intentions underlying an experimental investigation. 
The problem formulation considers six aspects: (1) the experimental objective, 
(2) factors, (3) responses, (4) model, (5) design, and (6) worksheet.
1.3.2.1 Experimental objective
The exact aims of DoE depend on the stage o f an investigation/experimental 
process to which it is applied. Design of Experiments need not be applied to 
every stage of the experimental process, but it is often prudent to break down an 
investigation into several stages. These stages, which are discussed further in 
Chapter 3, normally include familiarisation, screening, finding the optimal 
region, optimisation, robustness testing and mechanistic modelling (Eriksson et 
al., 2000). By characterising the system gradually in this way, the cost of 
resources is minimised. By comparison, going straight into an optimisation 
design with little or no prior knowledge o f a system would require huge amounts 
of resources and would defeat the overall purpose of DoE.
1.3.2.2 Specification of factors
Here, the factors relevant to the current experimental objective are listed and 
categorised according to whether they are quantitative or qualitative, controlled 
or uncontrolled, etc. The range and levels o f each factor are specified, and this is 
influenced by the experimental objective; in screening, factors have relatively 
large ranges and are varied over only two levels whereas during optimisation, 
factor ranges are narrow, involving three or more levels per factor. If factor 
transformations are required, they must be done at this stage, prior to generation 
o f a worksheet. One heuristics approach is to transform a factor where the range
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varies by more than 10-fold. Finally, factor levels are coded between values o f -1 
and +1 to facilitate later-stage data analysis.
1.3.2.3 Specification o f responses
Appropriate process performance indicators should have been identified at the 
familiarisation stage of the experimental process and are listed here.
1.3.2.4 Model selection
Selection of a model at this stage is partly constrained by the experimental 
objective. If screening was selected, a linear or interaction polynomial model will 
suffice, whereas a quadratic polynomial model is the minimum requirement for 
optimisation. This is intuitive because linear and interaction polynomial models 
have no optimum.
1.3.2.5 Generation o f an experimental design and creation of a worksheet
The choice of experimental design is intimately linked to the specified model, 
and hence experimental objective, but also to the number of factors, their levels 
and whether they are quantitative or qualitative. Some of the most commonly 
used classical designs include fractional factorial, full factorial and composite 
designs (Table 1.2). Two-level fractional factorial and full factorial designs are 
used for screening and yield linear and interaction models. These designs can 
also be used for optimisation if each factor is varied over a minimum of three 
levels. The last row of Table 1.2 displays composite designs which are used in 
optimisation.
The abovementioned designs are all of regular geometry and so each is only 
applicable to a regular experimental region. Where the experimental region is 
irregular, i.e. when certain factor combinations are not permitted, computer-
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generated D-optimal designs are employed. These designs allow for the removal 
of unfeasible experiments from the overall candidate set before a design is 
generated. An algorithm then computes the optimal design region from the 
remaining experiments. D-optimal designs offer several other advantages 
including the capability of investigating qualitative factors within the 
experimental region.
Once an appropriate design is selected, its corresponding algorithm is used to 
generate a worksheet in which the required experiments are specified.
1.3.3 Post-experimental steps
The analysis of experimental data generated through DoE consists o f three 
stages. The first stage, evaluation o f  raw data, focuses on the general trends and 
irregularities within the data. The second stage, regression analysis and model 
refinement involves calculating the actual terms within the regression model and 
evaluating its overall accuracy. The use o f  the regression model constitutes the 
final stage of analysis where the model is used to map the process and determine 
the optimal factor settings.
1.3.3.1 Evaluation o f raw data
A large variety of tools are available at this stage of analysis. A replicate plot, for 
example, illustrates the size of replicate error relative to the overall response 
variation. A histogram o f  response illustrates the distribution of a response which 
should be continuous and normally distributed under ideal circumstances. 
Otherwise, the response may need to be transformed in which case a Box-Cox 
plot serves as a guide towards the correct response transformation. An N- 
probability plot is a useful tool for detecting deviating experiments, or outliers. If 
an outlier is detected, a decision can be made to repeat the experiment, omit it 
from the design or simply leave it as it is.
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Table 1.2 Pictorial representation of various experimental designs. The star at 
the centre of each design represents centre-point experiments.
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1.3.3.2 Regression analysis and model refinement
Two important diagnostic tools at this stage include the R2/Q* performance 
indicators and analysis of variance, ANOVA. The R2 and Q2 values vary between 
0 and 1 and represent the fraction of the response variation explained and 
predicted by the model, respectively. These performance indicators should be 
used in conjunction with ANOVA, which formally tests if a given model explains 
a significant fraction of the response variation and whether the unexplained 
fraction is due to noise or model error. During optimisation, these performance 
indicators can be used to monitor the performance of a model as terms are 
removed via the coefficient plot until the overall model performance no longer 
increases. A parity plot of observed vs. predicted response values can then be 
used to illustrate final model performance.
1.3.3.3 Use of regression model
The purpose of a regression model depends upon the experimental objective. For 
screening, the model is used as a guide to determine which factors may have 
strong effects on the process. For optimisation, the model is used to map the 
process via response contour/surface plots and predict the optimal factor 
settings.
1.3.4 Relevant studies incorporating DoE
Given the large number of culture parameters which are known to affect soluble 
protein expression, the task of optimising expression levels is large and complex. 
The possibility exists that a thorough understanding of this complex relationship 
will result in significant improvements in expression levels. Currently, however, 
this opportunity has not been fully exploited.
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The recent application o f methods which analyse the effects o f simultaneously 
varying several parameters, such as the method of DoE, is certainly a step in the 
right direction. Unfortunately, the majority of relevant studies are limited by a 
small number of investigated parameters and/or incomplete application of the 
DoE toolset. For example, the parameters investigated by most studies can 
broadly be grouped by one of three categories: media formulation (Adinarayana 
and Ellaiah, 2002; Galindo et al., 1990; Hounsa et al., 1996; Nikerel et al., 2005; 
Ren et al., 2006; Sunitha et al., 1999; Zhang, 2006), growth conditions (Dutta et 
al., 2004; El Helow et al., 2000; Roebuck et al., 1995) or induction parameters 
(Cao, 2006; Swalley et al., 2006; Urban et al., 2003; Wang et al., 2005; Xie et 
al., 2003). By investigating only a small number of parameters, it is unclear 
whether these studies have fully optimised protein expression levels. 
Furthermore, these studies do not consider the effects of engineering parameters 
and so the results are o f limited benefit to scale-up.
The mathematical model which results from the implementation of DoE serves 
as a very powerful predictive tool when applied correctly. However, further 
investigation into the abovementioned reports reveals that some authors conduct 
statistical analyses on their regression models, but then do not utilise this 
information to alter their models accordingly (Adinarayana and Ellaiah, 2002; 
Nikerel et al., 2005; Ren et al., 2006; Wang et al., 2005). Other authors do not 
perform statistical analyses and so it is difficult to evaluate which of the 
investigated factors are important (Dutta et al., 2004; El Helow et al., 2000; 
Hounsa et al., 1996; Sunitha et al., 1999). In two other studies, the models are 
not stated (Galindo et al., 1990; Urban et al., 2003) and this severely limits the 
interpretation of results.
1.4 Scale-up of protein expression
The protein generated from small to medium scale expression studies may, in 
some instances, be sufficient for downstream purposes. In many cases the 
generation of protein for high throughput screening, secondary selectivity assays
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or a structural biology campaign may require gram quantities o f protein over a 
long period of time. It is therefore highly desirable to produce single preparations 
of the protein whenever possible, which minimises batch-to-batch variability and 
reduces the demand placed on resources. For such larger-scale production o f 
protein, shake-flask cultures can be employed, but for volumes in excess o f 10 1, 
the use o f stirred-tank reactors (STRs) is more commonplace (Hunt, 2005).
Successful scale-up means that a process has been designed and built giving a 
predictable increase in production capacity (Reisman, 1993). More specifically, 
the aim here is to translate the data generated from HTPE studies to production 
scale rapidly and accurately (Freyer et al., 2004). The optimal conditions 
determined from screening at small-scale are also likely to provide the 
environment for the production o f high quantities of soluble protein (Hunt,
2005). To achieve accurate and rapid scale-up, it is first necessary to understand 
the total environment of the cell (Young, 1979) and consider how this changes 
with scale. The total environment may encompass the biological, chemical and 
physical variables relating to fermentation (Freyer et al., 2004; Junker, 2004). A 
complete catalogue of these factors is also detailed extensively by Reisman 
(1993).
Biological factors are largely associated with the state of the inoculum, i.e. the 
number of generations associated with its development, phase of growth o f 
inoculum cells, cell density and cell viability. These variables also extend to 
secreted products and their interactions, inhibitory factors and cell-cell 
interactions. Chemical factors typically include the type and concentration of pH 
control and protein induction agents, composition and quality o f nutrients, water 
quality and foam formation. Physical factors include bioreactor configuration, 
aeration, agitation and chemical homogeneity, temperature control, pressure and 
method of medium sterilisation. This list is by no means exhaustive and serves as 
a general guide for all cell culture systems.
Some factors will have little effect on the system but may still cause an undesired 
deviation from predicted operation. These factors typically include ambient
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temperature, humidity and variability in raw material composition. They should 
be identified and regulated as far as possible so as to establish a fine degree o f 
process control.
Some variables are not easily translated. For example the host of physical 
variables which arise upon scale-up due to the physical geometrical difference 
between an MWP and an STR requires further investigation. Ordinarily, these 
variables are summarised by engineering parameters such as impeller tip speed, 
superficial gas velocity, mixing time or power per unit volume (Junker, 2004). 
Traditional scale-up techniques prescribe that one or more these parameters 
should remain constant upon scale-up. In the context of MWPs these parameters 
are either inapplicable or difficult to characterise. Moreover, the significance of 
certain phenomena such as surface tension effects may not be shared between 
scales. Thus many established scale-up correlations are unusable. Yet without 
proper process characterisation, it is likely that traditional scale-up problems 
such as those presented by Humphrey (1998) would be amplified.
Initial studies have suggested that scaling-up on the basis o f a constant mass 
transfer coefficient (faa) appears to be the most appropriate approach when 
dealing with microorganisms growing under aerobic conditions (Ferreira-Torres 
et al., 2005; Micheletti et al., 2006). Adequate oxygen provision remains a 
significant challenge for aerobic growth in shaken MWP fermentations (Maier 
and Buchs, 2001) and results obtained under oxygen limiting conditions are 
likely to be misleading particularly for scale-up purposes (Buchs, 2001; 
McDaniel et al., 1965). Considerable effort, therefore, has been put recently into 
the characterisation within MWPs o f engineering parameters such as kLa.
Different kLa characterisation techniques such as sulphite oxidation (Hermann et 
al., 2003; Kensy et al., 2005), dynamic gassing-out (Duetz and Witholt, 2001) 
and enzymatic methods (Duetz and Witholt, 2004; Ortiz-Ochoa et al., 2005) have 
been employed. These methods are, however, often time consuming, labour 
intensive and in the case of the sulphite oxidation technique, notoriously non- 
robust (Van't Riet and Tramper, 1991). Furthermore, unless experiments are
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conducted in fermentation broth, results may be deceiving due to rheological 
differences (Stanbury and Whitaker, 1993).
Recently, however, miniature oxygen probes have been used to characterise 
oxygen transfer directly via the static gassing-out method (John et al., 2003b; 
Doig et al., 2005), which overcomes many of the aforementioned complexities 
and enables the same measurement principle to be applied at both microwell and 
larger scales. Doig et al. (2005) also presented a kLa correlation derived from 
round-well MWPs. These advances represent valuable tools in the rapid and 
accurate scale-up of MWP fermentations.
1.5 Thesis aims and objectives
The overall aim of this project is to establish a generic framework that will 
underpin the generation of large quantities of soluble protein in E. coli in a rapid 
and cost-effective manner. Specific objectives will be:
• to determine the key components and overall structure of the framework 
and explore the practical issues of implementing the framework 
components within this project. The framework is outlined in Chapter 3 
and then refined through practical experimentation in subsequent 
chapters;
• to demonstrate the sequential application of DoE in engineered 
microwell experiments for the optimisation of soluble protein expression 
in E. coli. This will be described in Chapter 4;
• to characterise the engineering environment in microwell cultures and 
define a reliable basis for the reproducible scale-up of optimised culture 
conditions. This will be described in Chapter 5;
• to show that the insights gained at the microwell scale can inform pilot- 
scale operation. This will be described in Chapter 6;
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• to provide a thorough and quantitative analysis of the inherent time and 
cost savings provided by the current framework over traditional 
approaches. This will be discussed in Chapter 7.
• to explore how the current framework may be developed towards further 
industrial applications. This will be discussed in Chapter 8.
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2 Materials and methods
2.1 Introduction
The aim of this chapter is to provide a clear description o f all the materials and 
methods used in this research. Section 2.2 describes the preparation of 
fermentation media used in this work, the bacterial expression system and the 
preparation of inoculum for all subsequent fermentations. Section 2.3 describes 
the experimental design and fermentation procedures for microwell plate 
fermentations with the aim of identifying the optimal conditions for recombinant 
soluble protein expression. This section also illustrates the procedures for 
standard shake-flask fermentations from which the soluble protein yield serves as 
a reference. Section 2.4 describes the methods for characterising the mass 
transfer coefficient, as a basis for scale-up at all scales of fermentation. The 
scale-up of microwell plate fermentations on the basis of constant kua is 
described in Section 2.5, together with statistical procedures for evaluating the 
similarity of performance between fermentations. Section 2.6 describes the 
quantitative assay procedures used in this work for biomass concentration, 
glycerol concentration and relative soluble firefly luciferase activity.
2.2 General methods
2.2.1 Media preparation
All chemicals used were purchased from Sigma-Aldrich Chemical Company 
(Dorset, UK) unless stated otherwise and reverse osmosis (RO) water was used 
throughout. The three media types used were prepared as follows:
Luria Bertani (LB): 5 g.l'1 yeast extract, 10 g.l"1 tryptone and 10 g.l'1 NaCl, pH 
7.2;
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Terrific Broth (TB): 24 g.l'1 yeast extract, 12 g.l'1 tryptone, 4.0 ml.I'1 glycerol 
(100 %), 2.31 g.l'1 KH2P 04 and 12.54 g.l'1 of K2H P04, pH 7;
Glucose M9Y (GM9Y): 5 g.l'1 yeast extract, 4.0 g.l'1 glucose, 1 g.l'1 NH4C1, 
0.5 g.l'1 NaCl, 241 mg.l'1 M gS04, 11 mg.l'1 CaCl2, 6.0 g.l'1 Na2H P04 and 3.0 g.l'
1 KH2P 04, pH 6.9.
GM9Y media was obtained from Athena Environmental Sciences (Baltimore, 
MD, USA). The glycerol and glucose components were filter sterilised through a 
0.2 pm filter (Sartorius Ltd, Epsom, U.K.). The phosphate components were heat 
sterilised separately and added to the respective media using aseptic technique. 
All other media components were combined as dry powders and were heat 
sterilised for 20 min at 121 °C. After sterilisation, all media formulations were 
supplemented with 30 mg.l'1 kanamycin to prevent contamination and hence 
uncontrolled depletion of the media.
2,2.2 Bacterial expression system
The bacterial strain E. coli BL21 (DE3) (Invitrogen, Paisley, UK) was used as 
the expression host for all experiments. This strain is deficient in two key 
proteases (Ion protease and the ompT outer membrane protease) which results in 
a reduced degradation o f heterologous protein. This strain contains the XDE3 
lysogen which carries the gene for T7 RNA polymerase under control o f the 
/crcUV5 promoter. Expression o f T7 RNA polymerase is inducible by isopropyl- 
p-D-thio-galactopyranoside (IPTG), a lactose analogue, which binds to the lac\ 
repressor and reduces its affinity for the lac operator.
The gene encoding a thermally stable mutant of firefly luciferase (FFL) (Law et 
al., 2006) was provided as a kind gift by Lumora Ltd (Cambridge, UK) and 
subsequently cloned into a pET30a expression vector (Novagen, Nottingham, 
UK). This vector, which confers kanamycin resistance upon its host, expresses 
recombinant DNA under the control o f a T7 promoter. Due to the high selectivity 
o f T7 RNA polymerase for the T7 promoter, transcription of target DNA by E. 
coli RNA polymerase in the absence of T7 RNA polymerase is very low.
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2.2.3 Inoculum preparation
E. coli BL21 (DE3) cells were transformed with pET30a-FFL using standard 
methods (Maniatis et al., 1989) and grown overnight at 37 °C on Luria Bertani 
(LB) agar plates containing 30 mg.l'1 kanamycin. A single colony o f E. coli 
BL21 (DE3) transformed with pET30a-FFL was transferred to a 2 1 shake-flask 
using a sterile loop. Shake-flasks contained 500 ml of either LB, TB or GM9Y 
depending on the experiments to be performed. Cultures were grown overnight at 
37 °C and 200 rpm in a Multitron incubator shaker (Infors, Bottmingen, 
Switzerland). Cultures grown in the appropriate medium were used for 
subsequent inoculation o f microwell plate (MWP) experiments described in 
Section 2.3.
For the MWP and stirred-tank reactor (STR) fermentations described in Section
2.5, glycerol-cell stocks were used for inoculation of these fermentations. 
Glycerol-cell stocks were prepared in the following manner. Aliquots of 0.85 ml 
of the abovementioned overnight culture were mixed thoroughly with 0.15 ml of 
glycerol previously sterilised by autoclaving at 121 °C for 20 min. These 
glycerol-cell stocks were stored in 2 ml eppendorf tubes (Eppendorf, Cambridge, 
UK) at -80 °C. When required, glycerol-cell stocks were thawed at room 
temperature and transferred to a 2 1 shake-flask containing 500 ml TB. Cultures 
were grown overnight at 37 °C and 200 rpm in a ISF-l-V incubator shaker 
(Adolf Ktihner AG, Birsfelden, Switzerland) and used to inoculate the 
fermentations described in Section 2.5.
2.3 Methods for optimisation of soluble protein expression at the 
microwell scale
2.3.1 Microwell plate (MWP) fermentations
Three different deep-well polypropylene MWPs were used in this work: (PI) 48 
rectangular wells, flat bases (Whatman PLC, Middlesex, U.K.), (P2) 24 square 
wells, round bases (Whatman PLC) and (P3) 24 square wells, pyramidal bases
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(DOT Scientific Inc. Burton, MI, USA). These plates are described in further 
detail in Table 2.1.
For the initial familiarisation and screening experiments (Sections 2.3.2 and
2.3.3), an overnight E. coli culture was prepared as described in Section 2.2.3 
and used to inoculate 40 ml of LB, TB or GM9Y sterile media such that an initial 
OD600 of 0.1 was obtained (an initial OD600 of 0.001 was used for the 
familiarisation experiments described in Section 2.3.2). Aliquots of the 
inoculated media were transferred into one o f the three MWPs and the plates 
were sealed with gas permeable membranes (ABgene, Epsom, UK) to minimise 
the loss of liquid due to evaporation. Cultures were grown in a HiGro incubator- 
shaker (GeneMachines, Huntingdon, UK), with an orbital shaking diameter o f 8 
mm, under the experimental conditions described in Table 2.2. Optical density 
measurements at a wavelength o f 600 nm (OD600) of broth samples were made 
both immediately prior to and again after protein induction and were 
subsequently converted into dry cell weight measurements as described in 
Section 2.6.1. FFL was expressed as an intracellular enzyme by the addition to 
each well o f 20 pi isopropylthiogalactosidase (IPTG) solution at the appropriate 
concentration. After the induction period, cells were harvested by centrifugation 
at 4 °C for 10 min at 3000 rpm using an Eppendorf 5417R centrifuge 
(Cambridge, UK) and samples were stored at -80 °C. Identical methods were 
adopted for optimisation experiments (Section 2.3.4) but only TB media was 
used and the levels of the factors were altered as described in Table 2.2.
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Table 2.1 Description of MWP geometries used throughout this work. All 
dimensions are given in mm, correct to the nearest mm. Drawings not to scale.
Plate PI Plate P2 Plate P3
Total volume 48 wells x 5 ml.weir1
24 wells x 
10 ml.well'1
24 wells x 
10 ml.well'1
Plan view of well
17
< >
17
< >
17
17
< >
17
Side view of well 41
A
32
V
38
± .
8
"A
Table 2.2 Specification o f factors and settings investigated within 
familiarisation, screening and optimisation experiments. Pre-I and post-I are 
abbreviations for pre-induction and post-induction, respectively. Plate PI had 48 
rectangular wells with flat bases, plate P2 had 24 square wells with round bases 
and plate P3 had 24 square wells with pyramidal bases. aThe familiarisation 
experiments had a lower shaking speed o f 50rpm. bAn upper liquid fill volume of 
2 ml was used in conjunction with the 48-well plate to prevent splashing.
Name Abbr. Units
Experimental settings
Familiarisation / Screening Optimisation
Growth medium X] -
Glucose M9Y, LB Broth, 
Terrific Broth
Terrific Broth
Plate geometry *2 - PI, P2, P3 P3
Liquid fill volume *3 ml 1, 2a,3 1 ,2 ,3
Pre-I temperature X4 °C 17, 37 27
Pre-I shaking speed x5 rpm 100b, 500 100,300, 500
Pre-I period *6 h 2 ,6 1 ,4 ,7
Inducer concentration x7 pM 50, 1000 500
Post-I temperature Xg °C 17,37 23 ,3 0 ,3 7
Post-I shaking speed x9 rpm 100b, 500 100,300, 500
Post-I period X|0 h 3, 15 6, 12, 18
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2,3.2 Design of MWP familiarisation experiments
Ten factors were initially chosen for investigation towards experimental 
familiarisation. These factors are specified in Table 2.2 and the rationale for their 
selection will be discussed further in Section 4.2.1. A D-optimal design (Eriksson 
et al., 2000) was chosen to generate an appropriate experimental plan. D-optimal 
designs are capable o f handling both quantitative variables (time, concentration, 
etc.) and qualitative variables (media type, plate geometry, etc.). They also allow 
for the removal of experiments which have unfavourable factor combinations 
from the initial candidate set o f experiments. For example, preliminary 
experiments had shown that excessive splashing would occur within the 48-well 
plates at a shaking speed of 500 rpm, above a liquid fill volume of 2 ml. 
Unfavourable factor combinations were thus removed from the candidate set 
prior to generation o f the experimental plan. A logio transformation of the 
inducer concentration factor range was also made at this time. The general 
approach is to transform any factor range which spans one or more orders of 
magnitude, so as to preserve the orthogonal shape of the design region (Eriksson 
et al., 2000).
Table 2.3 shows the D-optimal familiarisation design in which ten factors were 
investigated in 30 experimental runs. Two replicated centre-point experiments 
were included for estimation of pure error. The soluble protein yield results 
shown in Table 2.3 will be discussed in detail in Chapter 4. All factors were 
varied over two levels (low and high) and for statistical calculations the actual 
levels of each variable {Xj) were coded as x, according to the following 
relationship:
2z - z max - z minx  = _ j  1 q .A)
1 _  m a x  _ m i n  '  'z, -  z,
where z, is the actual variable value of X, and the superscripts “max” and “min” 
denote the maximum and minimum values used.
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Table 2.3 D-optimal design matrix for the initial assessment of soluble protein 
yield at the familiarisation stage. Quantitative variables are coded at low (-1), 
medium (0) and high (+1) levels.
Observations X] *2 x3 x4 *5 *6 x7 Xg x9
Mean soluble 
X |0 protein yield 
(RLU.m l1)
N1 M9Y PI 0 1 1 -1 0 -1 -1 -1 0
N2 M9Y PI 0 1 -1 1 0 -1 -1 -1 1221
N3 M9Y PI 0 -1 1 1 -1 1 1 1 404587
N4 LB PI 0 -1 -1 1 -1 -1 -1 1 136
N5 TB PI 0 1 -1 1 0 1 -1 1 6947
N6 LB PI -1 1 -1 -1 -1 1 1 -1 0
N7 TB PI -1 -1 1 -1 0 -1 1 1 0
N8 TB PI -1 -1 1 -1 -1 1 1 -1 129
N9 M9Y P2 1 -1 -1 -1 -1 1 -1 1 2748
N10 M9Y P2 1 -1 -1 1 0 1 1 -1 0
N il LB P2 1 1 -1 -1 0 -1 1 1 319
N12 TB P2 1 1 1 -1 -1 -1 -1 -1 0
N13 TB P2 1 -1 1 -1 0 -1 1 1 59
N14 M9Y P2 -1 1 1 -1 -1 1 -1 -1 11260
N15 LB P2 -1 -1 1 1 -1 -1 -1 1 128
N16 LB P2 -1 -1 1 1 0 1 1 -1 0
N17 TB P2 -1 1 -1 1 0 1 -1 1 9983
N18 TB P2 -1 1 -1 1 -1 -1 1 -1 0
N19 M9Y P3 1 1 1 1 -1 -1 1 1 60559
N20 LB P3 1 -1 -1 -1 -1 -1 -1 -1 0
N21 LB P3 1 1 1 1 0 1 1 -1 0
N22 TB P3 1 -1 1 1 -1 1 -1 -1 0
N23 TB P3 1 1 -1 -1 -1 1 1 1 374457
N24 M9Y P3 -1 -1 -1 -1 0 1 -1 1 350
N25 M9Y P3 -1 -1 -1 -1 0 -1 1 -1 0
N26 M9Y P3 -1 1 1 1 -1 -1 1 1 6896
N27 LB P3 -1 1 1 -1 0 1 -1 1 4922
N28 TB P3 -1 -1 -1 1 0 -1 -1 -1 0
N29 M9Y PI 0 0 0 0 0 0 0 0 78111
N30 M9Y PI 0 0 0 0 0 0 0 0 4076
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Each experimental run was performed in quadruplicate and the mean soluble 
protein yield was recorded. A linear model was then fitted to the data and 
assumed the following form:
r  = /?0 +X /3 ,* , (2.2)
where Y is the dependent variable (soluble protein yield), po is the independent 
term and /?,■ are the regression coefficients related to the main effects. The size of 
each coefficient is proportional to the influence of a particular factor on the 
response and can be used to determine which factors should be investigated 
further.
2.3.3 Design o f MWP screening experiments
The ten factors identified at the familiarisation stage were investigated further 
through a set of screening experiments. The aim here was to elucidate which of 
the factors influenced soluble protein yield the most. Identical procedures used in 
the familiarisation stage were adopted here, but with altered factor ranges, as 
specified in Table 2.2. The D-optimal experimental design for the screening 
experiments is shown in Table 4.2.
2.3.4 Design o f MWP optimisation experiments
A Central Composite Face (CCF) design was employed to determine the optimal 
levels of the key variables identified from initial screening experiments. This 
design requires each factor to be varied over three levels only (low, medium and 
high) and fewer runs are needed compared to an equivalent Box-Behnken or 3- 
level full factorial design (Eriksson et al., 2000). All factors were coded as 
described in Section 2.3.2. Table 4.3 shows the experimental plan for 
optimisation in which six factors were investigated in 50 experimental runs. Six 
replicated centre-point experiments were also included for estimations o f pure
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error. Each experimental run was performed in quadruplicate and the mean 
response values were recorded.
The behaviour of the system was modelled using the following equation:
Y = Po + Z P'x> + Z Pvx'xj + Z P»x> (2'3)
where /?,, and /?,, are the regression coefficients corresponding to the second-order 
interactions and squared main effect terms, respectively. Regression coefficients 
whose confidence intervals included zero were removed from the model in a 
step-wise manner, starting with the least significant terms. The resulting 
regression model for soluble protein yield was maximised and this enabled the 
prediction of the optimal factor settings. A verification experiment was then 
performed at these settings and factors which did not appear in the model were 
maintained at their mid-point values.
2.3.5 Reference shake flask fermentations
An aliquot of 50 ml overnight E. coli culture, prepared as described in Section
2.2.3, was used to inoculate 1 1 o f TB medium supplemented with 30 mg.l'1 
kanamycin in a Nalgene 2 1 baffled shake flask (VWR International Ltd, 
Leicestershire, U.K.). This culture was grown at 27 °C and 185 rpm in a 
Multitron incubator shaker (Infors, Bottmingen, Switzerland). The culture was 
induced with 0.5 mM IPTG when the OD600 reached 1.0 at approximately 2 h 40 
min. After a 4 h induction period, cells were harvested by centrifuging 1 ml 
aliquots of culture at 4 °C for 10 min at 3000 rpm in an Eppendorf 5417R 
centrifuge (Cambridge, UK). Samples were subsequently stored at -80 °C.
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2.4 Methods for characterisation of bioreactor mass transfer 
coefficients (kLa)
2.4.1 Measurement of MWP kLa values
The MWPs described in Section 2.3.1 were modified such that three wells on 
each plate had a small oxygen sensor spot (Precision Sensing GmbH, 
Regensburg, Germany) mounted flush with the inside wall of each well. The 
principle of the sensor operation is based on the quenching of luminescence 
caused by collisions between molecular oxygen and luminescent dye molecules 
on the surface of each sensor spot. The sensor spots were located as close as 
possible to the base of each well. Consequently, a minimum liquid fill volume of 
2 ml (rounded up to the nearest ml) was required to completely submerge the 
sensor spot in each well of plate PI at all shaking speeds. Similarly, a minimum 
liquid fill volume of 3 ml was required for plates P2 and P3. Miniature optical 
oxygen probes (Precision Sensing GmbH) were then mounted in line with the 
sensors, through the outer wall o f each plate. Each probe was connected via optic 
fibres to a light emitting diode (LED) to illuminate the sensor spots and also to a 
photodetector (Precision Sensing GmbH) to measure the light intensity. The 
overall setup is illustrated in Figure 2.1.
TB medium was used for all kLa characterisation experiments at the MWP scale. 
An aliquot 0.2 ml.I'1 polypropylene glycol was first added to the medium after 
sterilisation, as would be used in subsequent STR kta characterisation 
experiments to prevent foaming. Aliquots of 2ml of this TB medium were then 
added to the modified wells of plate PI and 3ml to those of plates P2 and P3. 
Oxygen probes were calibrated at 0 % air saturation at room temperature 
immediately after exposing the medium in each well to a blanket of nitrogen for 
a period o f 20 min. Similarly, the probes were calibrated at 100 % air saturation 
at room temperature immediately after a 20 min period of pumping air 
continuously into the headspace above the medium in each well.
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Plate wall
Well wall
Mini-optical 
oxygen probe
To optic fibres, light 
emitting diode and 
photodetector
Oxygen 
sensor spot
Mounting screw 
for oxygen probe
Acrylic support for 
sensor spot
Figure 2.1 Cross-sectional diagram illustrating the setup of a microwell plate 
modified with the oxygen sensor system as described in Section 2.4.1.
kLa measurements were made for each plate at five different shaking speeds (100, 
200, 300, 400 and 500 rpm) on an Infors Orbitec orbital shaker (Bottmingen, 
Switzerland). This orbital shaker has an identical orbital shaking diameter (8 
mm) to that of the HiGro incubator-shaker used in MWP fermentation 
experiments (Section 2.3.1). The dynamic gassing-out technique (Van't Riet, 
1979) was used for all kLa measurements. The appropriate agitation speed was 
selected and a blanket of nitrogen was placed over the wells until the dissolved 
oxygen tension (DOT) reached zero. At this point the nitrogen supply was 
removed, the plate was sealed with a gas permeable membrane (ABgene, Epsom, 
UK) and the rate at which the DOT increased was recorded. Each measurement 
was performed in triplicate.
The response time for the oxygen probe was measured as follows. A 3 ml aliquot 
of water was first added to the modified well of plate P3 and the plate was 
shaken at 500 rpm so that the oxygen concentration reached 100 % saturation. A 
2 ml aliquot of 2 M Na2S0 3  was then added to the well, and the time taken for 
the oxygen concentration to reach 37 % was recorded. This procedure was
69
2. Materials and Methods Islam 2007
repeated 4 times. The mean probe response time was relatively long (25 s) 
compared to those quoted in the literature (Van't Riet, 1979) so it was necessary 
to account for this when calculating h a  values. This was achieved using the 
following expression (Lamping et al., 2003):
C,= / - r . lm eXP - t  exp \ Xp J (2.4)
where Cp is the undissolved fraction of oxygen at time t, rp is the probe response 
time and tm=l/kLa. An iterative approach was then used to solve this equation for 
h a  at each time point between 20 % and 80 % oxygen saturation. From these 
results, a mean value for h a  was calculated.
2.4.2 Specific air-liquid surface area measurements in MWPs
Doig et al (2005) previously established a correlation for the prediction of h a  
values in MWPs. In order to adapt the correlation for use with the MWP 
geometries used in this study, it was necessary to measure the specific air-liquid 
surface area in the wells over same the range of conditions used in the h a  
experiments (Section 2.4.1). All wells in plates P2 and P3 were each filled with 3 
ml RO water and shaken at one o f six different speeds (0, 100, 200, 300, 400 and 
500 rpm) on an Infors Orbitec orbital shaker at 23 °C for 4 h. The mean 
evaporation rate over this period was measured. The evaporation rate from plate 
PI was measured in the same way, but using a liquid fill volume of 2 ml per well 
and an upper shaking speed of 400 rpm to avoid splashing. Once this evaporation 
rate data was measured, the specific air-liquid surface areas were calculated 
according to Equation 2.5:
af  _ shaken evaporation rate ^
a' unshaken evaporation rate
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where a/ and a, are the specific air-liquid surface areas (m 1) in the wells under 
shaken and unshaken conditions, respectively. The values for at were 68 m '1 for 
plate PI and 96 m '1 for plates P2 and P3.
Previous trial experiments had shown the evaporation rates from MWPs covered 
with gas-permeable membranes to be very small and hence difficult to measure 
accurately. Consequently, and in contrast to all other MWP experiments 
conducted thus far, the experiments here were performed without the use o f gas- 
permeable membranes. Although this would increase the rates of evaporation, the 
ratio o f the shaken evaporation rate to the unshaken evaporation rate should 
remain constant for each MWP. Consequently, the values of a/  should also 
remain the same.
2.4.3 Measurement o f stirred-tank reactor (STR) kLa values
Two different sizes of STR were used in this work. The first vessel (Figure 2.2) 
was a 7.5 1 BioFlo 110 (New Brunswick Scientific Co., Inc., Edison, NJ, USA) 
which had two six-bladed Rushton turbine impellers connected to a top-driven 
impeller shaft. The second vessel was a 75 1 LH (formerly LH Fermentation, 
Reading, U.K.) and had three six-bladed Rushton turbine impellers attached to a 
bottom-driven impeller shaft. The 75 1 LH had the following approximate 
dimensions: 0.92 m internal vessel height, 0.33 m internal vessel diameter, 0.11 
m impeller diameter.
In accordance with the MWP experiments, TB medium was used for all kLa 
characterisation experiments at the STR scale. The 7.5 1 STR was first filled with
4.5 1 o f TB medium, excluding the phosphate components, and the entire vessel 
was autoclaved at 121 °C for 20 min. Similarly, the 75 1 STR was filled with 40.5 
1 of TB medium excluding the phosphate components and the vessel was steam- 
sterilised in place at 121 °C for 20 min. The phosphate components were 
sterilised separately in an autoclave and added aseptically to each vessel, raising 
the final working volumes to 5 1 in the 7.5 1 STR and 45 1 in the 75 1 STR. An
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aliquot 0.2 ml.l'1 polypropylene glycol was added to all media after sterilisation, 
to prevent foaming during experimentation.
VERTICAL SECTION THROUGH U-U*
V
179
SECTION THROUGH V - V’
-H 31 h-
u
Figure 2.2 Dimensions o f BioFlo 110 7.5 1 STR used in this study. All 
dimensions are given in millimetres. A = impeller shaft; B = impeller disc; C = 
impeller blade; D  = baffle. Impeller spacings are set according to the vessel 
manufacturer’s guidelines.
The DOT probes (Mettler-Toledo Ltd., Leicester, U.K.) were calibrated at 100 % 
air saturation at 23 °C by sparging air into each vessel at a rate of 1 vvm for 20 
min. The 0 % air saturation calibration was made by placing the probe in a 
stream of nitrogen gas outside the vessel.
In accordance with the MWP experiments, the dynamic gassing-out technique 
was again used to measure values at the STR scale. Measurements were 
performed at four different impeller speeds (200, 400, 600 and 800 rpm) in the
7.5 1 STR and five impeller speeds (200, 400, 600, 800 and 1000 rpm) in the 75 1 
STR. Nitrogen was first sparged through the medium in each vessel at a rate o f 1 
vvm at the predetermined impeller speed. Once the DOT level had fallen to zero, 
the gas supply was switched rapidly to air at a flow rate o f 1 vvm and the rise in
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DOT was recorded. All measurements were carried out in triplicate at room 
temperature. For each vessel, the response time for the oxygen probe was 
measured five times at each agitation speed using a standard procedure (Dunn 
and Einsele, 1975). The mean probe response time was relatively high, varying 
between 28 s and 46 s, and so it was again accounted for when calculating kLa 
values as described Section 2.4.1.
2.5 Scale-up of microwell plate fermentations
2.5.1 MWP fermentations
An overnight culture o f E. coli, prepared as described in Section 2.2.3, was used 
to inoculate 40 ml o f TB media such that an initial OD600 of 0.1 was obtained. 
Aliquots of 3 ml inoculated media were then transferred into all wells of plate P3 
and the plate sealed with a gas permeable membrane (ABgene, Epsom, UK). 
Cultures were grown in a HiGro incubator-shaker (Genomic Solutions, Ann 
Arbor, MI, USA) under the conditions described in Table 2.4 and FFL 
expression was induced by the addition to each well of 20 pi IPTG solution to a 
final concentration o f 500 pM. The run order of all fermentations was 
randomised in order to prevent any uncontrolled variables from producing 
systematic effects on the results. For example, several plates were prepared 
simultaneously for each fermentation batch; the time delay in inoculating all the 
wells in sequence represented an uncontrolled variable, the effects of which were 
minimised through run-order randomisation.
Samples of 50 pi fermentation broth were taken at regular intervals for biomass 
growth measurements as described in Section 2.6.1. Samples o f 1.2 ml 
fermentation broth were also taken at regular intervals for glycerol and FFL 
measurements. These samples were first clarified by centrifugation at 14,000 rpm 
for 10 min at 4 °C using an Eppendorf 5417R centrifuge (Cambridge, UK). The 
supernatant was assayed for glycerol, as described in Section 0, and the cell 
pellets were stored at -80 °C for subsequent FFL analysis, as described in Section
2.6.3. All sampling occurred in duplicate from separate sacrificial wells.
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Dissolved oxygen profiles were obtained from the unsampled modified wells as 
described in Section 2.4.1. All MWP fermentations were performed in duplicate.
Table 2.4 Specification of factors and settings investigated during the scale-up o f 
microwell plate fermentations. Pre-I and post-I are abbreviations for pre­
induction and post-induction, respectively. abThe MWP fermentation conditions 
described here have been adopted from experiments N32 and N36, respectively, 
form the optimisation experiments (Section 4.4).
Factor Units k,a = 247 h’1 kfa = 55 h’1
Plate P3a 7.5 1 75 1 Plate P3b 7.5 1
Liquid Fill volume 1 3 x 1(U 5 45 3 x 10‘3 5
Pre-I temperature °C 27 27 27 27 27
Pre-I shaking speed / 
agitation rate rpm 500 721 645 300 242
Pre-I period h 7 7 7 4 4
Inducer concentration pM 500 500 500 500 500
Post-I temperature °C 37 37 37 30 30
Post-I shaking speed / 
agitation rate rpm 500
721 645 300 242
Post-I period h 18 18 18 12 12
2.5.2 STR fermentations at equivalent kLa conditions
These fermentations were performed within both the 7.5 1 and the 75 1 STRs. All 
probes were manufactured by Mettler-Toledo Ltd. (Leicester, U.K.). The pH 
probes on both vessels were calibrated outside the vessel using standard buffers 
at pH 4.01 and 7.00 supplied by Mettler-Toledo Ltd. Approximate calibrations 
for the DOT probes were made outside the vessel using gaseous air and nitrogen 
for the 100 % and 0 % air saturation calibrations, respectively. Once all 
calibrations were made, the probes were placed in their appropriate locations 
within each vessel. The vessels were then filled with TB medium and sterilised 
as described in Section 2.4.3. After the sterilisation procedure, the phosphate 
components were added aseptically to each vessel and an aliquot of kanamycin 
was added to each vessel through a 0.2 pm filter (Sartorius Ltd, Epsom, U.K.) to 
a final concentration o f 30 mg.l'1.
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At this stage the calibration o f the pH and DOT probes were rechecked and 
recalibrated as appropriate. A 10 ml aliquot of media was sampled from each 
STR using aseptic techniques, and the pH was measured on a Mettler-Toledo 
MP220 pH meter. This measurement was used to adjust the pH readout from 
each STR accordingly. The 100 % air saturation calibration was checked after 
sparging air into each vessel at a rate o f 1 vvm for 20 min at 27 °C using an 
agitation speed of 200 rpm.
An overnight E. coli culture, prepared as described in Section 2.2.3, was used to 
inoculate each vessel to an initial OD600 of 0.1. At this point a sample of 
inoculated media was taken from the 75 1 vessel and used for the parallel MWP 
fermentations as described in Section 2.5.1. The air supply was set to 1 vvm and 
cultures were grown under the conditions described in Table 2.4. The pH was left 
uncontrolled in accordance with the MWP fermentation operation. An aliquot of 
IPTG solution was added to each vessel to a final concentration of 500 pM at the 
appropriate time point through a 0.2 pm filter (Sartorius Ltd, Epsom, U.K.).
Feedback loops were set up on both vessels to monitor and control foam levels 
by way of automatic additions o f polypropylene glycol MW = 2025 (VWR 
International Ltd, Leicestershire,U.K.). Temperature, DOT, pH and agitation 
speed were continuously recorded on both vessels using BioComand Plus 
software version 3.28 (New Brunswick Scientific Co.) on the 7.5 1 STR and 
MTX-Propack software (formerly Acquisition Systems, Berkshire, UK) on the 
75 1 STR. On-line exit gas composition was measured using a Prima 600 mass 
spectrometer (formerly VG Gas Analysis Ltd., Cheshire, U.K.).
Samples of 50 pi fermentation broth were taken at regular intervals for OD600 
measurements as described in Section 2.6.1. Samples of 1.2 ml fermentation 
broth were also taken at regular intervals for glycerol and FFL measurements. 
These samples were first rapidly clarified by centrifugation at 14,000 rpm for 10 
min at 4 °C using an Eppendorf 5417R centrifuge (Cambridge, UK). The 
supernatant was assayed for glycerol, as described in Section 0, and the cell
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pellets were stored at -80 °C for subsequent FFL assaying, as described in 
Section 2.6.3.
2.5.3 Statistical analyses offermentation kinetic profiles
Microcal Origin version 6.0 (Northampton, MA, USA) was used in the 
modelling of fermentation profiles. To evaluate the effect of scale on 
fermentation performance, response profiles of biomass growth, glycerol 
utilisation and soluble protein yield were compared between the MWP and 7.5 1 
scales and also between the MWP and 75 1 scales. Assuming no difference (the 
null hypothesis), one model would adequately describe both sets of data for a 
given response, and any observed differences would be purely due to chance. 
However, if in fact fermentation scale did have an effect on performance (the 
alternative hypothesis), then each set o f data for a given response would be 
discrete and separate models would be required to fit the two data sets. The basis 
for this approach is described further by Motulsky and Christopoulos (2003).
Both hypotheses were tested simultaneously using the models described in Table
2.5. The degrees o f freedom (DF) from separate model fits were first summed 
and labelled DFsep. The residual sum of squares (RSS) from each model were 
also summed and labelled RSSsep. Then, both data sets were combined, the same 
model type was refitted and new values for DF and RSS, labelled DFcomb and 
RSScomb. respectively, were determined. RSSsep is expected to be smaller than 
RSScomb, simply because more predictor variables are available when separate 
models are used. The key question is whether or not this difference lies within 
the expected range for normal experimental error, assuming the null hypothesis is 
true. To answer this, a statistical test was performed, the first part of which 
involved calculating the F  ratio:
F {RSSamh- R S S j ! R S S !tJl
(2 .6)
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The corresponding p  value was then calculated. The p  value is the probability of 
achieving a difference (in RSS values) as large as or larger than observed if the 
null hypothesis (no effect o f scale) was true. If the p  value were above a certain 
threshold, typically 0.05, it would be possible to conclude that the observed 
difference is due purely to chance and hence the effect o f scale is insignificant.
Table 2.5 Description of functions used to model each fermentation response 
profile, where y  is the fermentation response level at time /, yo is the initial 
response level and a, b and c are arbitrary constants.
Response name Model type Model equation
[Biomass]
(growth phase only)
[Glycerol]
[Soluble protein]
Logistic
One site competition
Extreme peak function
In
a
1 + e -h(l- c)
1 + 10('-log/»
y  -  To + cex p (-ex p (-d ) ~ d  + 1) 
where d  = ———
2.6 Analytical procedures
2.6.1 Quantification o f biomass concentration
For the MWP fermentations, OD600 measurements of broth samples were made 
using a Spectronic Helios Alpha spectrophotometer (Thermo Electron 
Corporation, Hemel Hempstead, U.K.). For the STR fermentations, OD600  
measurements were made using a Jenway 6400 spectrophotometer (Essex, U.K.). 
For each measurement, 50 pi o f fermentation broth was first diluted in 1000 pi o f 
corresponding media (1:21 dilution) before measuring OD6oo-
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A calibration curve (Figure 2.3) for biomass concentration versus O D6oo was 
generated from separate shake-flask fermentations of E. coli in each media 
preparation (LB, TB and GM9Y media). Fermentation samples were collected in 
triplicate at a minimum of four different time points and their OD600 recorded. 
These samples were filtered through a 0.2 pm, 25 mm diameter filter (Whatman 
PLC, Middlesex, U.K.) and the filter was dried to constant weight using a HG53 
Halogen Moisture Analyser (Mettler-Toledo Ltd., Leicester, U.K.). The dry cell 
weight was calculated from the increase in weight from the original empty filter. 
A calibration curve was obtained and used to convert all OD6oo measurements 
into dry cell weight per litre broth (g .f1) measurements.
Optical density at 600nm (TB)
0 4 8 12 16
2
O
CO_l
O)
o> O)
1
O)
1
0
2 4 60
Optical density at 600nm (LB, GM9Y)
Figure 2.3 Calibration curve for optical density and dry cell measurements o f E. 
coli grown in LB ( ), GM9Y ( -e - ) and TB ( - A -  ) medium. The following
lines of best-fit are obtained: y = 0.342x, R2 = 0.967 (LB), y = 0.387x, R2 = 
0.998 (GM9Y), y = 0.497x, R2 = 0.964 (TB).
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2.6.2 Quantification o f glycerol concentration
Glycerol concentrations were measured using a commercially available kit 
(Megazyme International Ireland Ltd. Co. Wicklow, Ireland).
The general reaction principles of the assay are as follows. Glycerol is 
phosphorylated by adenosine-5’-triphosphate (ATP) to L-glycerol-3-phosphate in 
the reaction catalysed by glycerokinase (GK.) (Equation 2.7):
Glycerol + ATP —(GK) > L - glycerol - 3 - phosphate + ADP (2.7)
The adenosine-5’-diphosphate (ADP) formed in the reaction is reconverted by 
phosphoenolpyruvate (PEP) with the aid of pyruvate kinase (PK) into ATP with 
the formation of pyruvate (Equation 2.8):
ADP + PEP (Pig > ATP + pyruvate (2.8)
In the presence o f the enzyme L-lactate dehydrogenase (L-LDH), pyruvate is 
reduced to L-lactate by reduced nicotinamide-adenine dinucleotide (NADH) with 
the production NAD+ (Equation 2.9):
Pyruvate + NADH + H + (1'1PM-) > L-lactate + NAD+ (2.9)
The amount of NAD+ formed in the above reaction pathway is stoichiometric 
with the amount of glycerol. The NADH consumption is measured directly by 
the decrease in absorbance at 340 nm (Anon., 2005).
The change in absorbance (AAgiyCeroi) was then used to calculate the glycerol 
concentration according to the following formula:
V x MW
C =  -j  * AA , , (2.10)
8 x d x v
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where c is the glycerol concentration (g.F1), V = final volume (ml), MW = 
molecular weight o f glycerol (g.m of1), e = molar extinction coefficient = 6300 
(l.mol '.cm '1), d = light path (cm), v = sample volume (ml).
2.6.3 Quantification o f relative soluble firefly luciferase activity
The assay for FFL enables a quantitative value o f expressed soluble protein to be 
derived and requires no prior purification of the enzyme. Cell pellets were 
thawed on ice and resuspended in 500 pi BugBuster (Abgene, Epsom, UK). An 
aliquot o f 50 pi DNase I (Burgess Hill, UK) at a concentration of 1 mg.ml'1 was 
added and the samples were incubated for 20 min on ice. Lysates were clarified 
by centrifugation at 14,000 rpm for 10 min. A 5 pi aliquot of lysate was mixed 
with 200 pi o f Luciferase Assay Buffer (LAB) containing 10 mM MgS0 4 , 10 
mM Tris pH 7.8, 0.5 mM ATP, 0.47 mM luciferin, 0.27 mM co-enzyme A and
31.5 mM dithiothreotol, in a Nalgene 96-well plate (VWR, Loughborough, UK). 
The activity o f luciferase was measured using a SpectraMAX Gemini XS 
luminometer (Molecular Devices, Winnersh, UK) according to the reaction 
scheme shown below:
FFL + M^+
ATP + D-luciferin+ Q  ------------------— >
C 0 2 + AMP + PPi + oxyluciferin + light (560nm) (2.11)
The luminescence profile o f each sample was recorded at room temperature over 
a period o f 20 min. An example o f a typical luminescence profile, where 
measurements of Relative Light Units (RLU) are made, is shown in Figure 2.4.
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Figure 2.4 Example o f standard luminescence profiles from samples of the 
replicate MWP fermentations described in Section 2.3.1, taken at identical time 
points. Measurements made as described in Section 2.6.3.
For samples with particularly high soluble protein yields, the reaction shown in 
Equation 2.11 proceeded too rapidly and peak luminescence often occurred 
before measurements could be made as illustrated in Figure 2.5 (a). In order to 
obtain a usable luminescence profile from these samples, lysates were First 
diluted 20-fold in 100 mM Tris pH 7.8 prior to the addition of LAB. This 
resulted in a luminescence profile that enabled maximum peak heights to be 
obtained within the experimental time frame (Figure 2.5 (b)). The peak height of 
each luminescence profile is proportional to the luciferase activity (Bronstein et 
al., 1994) and so for each luminescence profile, the mean of the four largest 
luminescence values was recorded. This value was then divided by the original 
microwell liquid fill volume to give the soluble protein yield in units o f RLU.mf
i
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Figure 2.5 Typical luminescence profiles for the replicate samples within each 
MWP fermentation. For samples with particularly high soluble protein yields, the 
reaction proceeded very fast and the peak was often missed (a). In these 
scenarios, the lysates were first diluted 20-fold in 100 mM Tris pH 7.8 prior to 
the addition of LAB which resulted in more standard profiles (b).
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2.6.4 Analytical software
MODDE software version 7.0 (Umetrics, Windsor, UK) was used for 
experimental design o f the MWP fermentations (Sections 2.3.2 to 2.3.4 
inclusive) and the subsequent regression analysis and process modelling. 
Microcal Origin version 6.0 (Northampton, MA, USA) was used in the statistical 
data analysis of fermentation profiles (Section 2.5.3). It was also used for figure 
design. Microsoft Excel 2002 was used to solve Equation 2.4 for the calculation 
o f all kid  values and also to calculate p  values during the statistical analyses of 
fermentation profiles (Section 2.5.3).
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3 A framework for the rapid optimisation of soluble 
protein expression in E. coli
3.1 Aims and objectives
As described in Section 1.5 the overall aim of this project is to establish a generic 
framework which underpins the generation o f large quantities o f soluble 
recombinant protein in E. coli in a manner which is both rapid and cost-effective. 
To achieve this goal, various tools and technologies will need to be combined 
and applied in a novel manner. The aim of this chapter is to provide the 
conceptual framework to achieving this goal. Specific objectives are:
• to determine the key components of the framework and its overall 
structure (Section 3.2);
• to explore the practical issues of implementing the framework 
components within this project (Sections 3.3).
3.2 Framework design
3.2.1 Introduction
The challenge of rapidly generating large quantities of protein may be split into 
two principal stages: (1) small scale protein expression characterisation followed 
by (2) scale-up of optimised protein expression. A wide range of development 
tools is available to aid in achieving these goals. In the following sections, the 
most appropriate tools are selected and a framework for their implementation is 
proposed.
3.2.2 Component specification
The first stage of the framework involves the characterisation o f protein 
expression. A wide range o f variables affects heterologous protein expression
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levels, as described in Section 1.2.3, and numerous experiments are normally 
required to characterise such a complicated process. Design of Experiments is 
able to greatly reduce the number o f these characterisation experiments (Section
1.3), whilst providing a high level of process understanding which also aids in 
subsequent scale-up. This high degree o f characterisation coupled with the 
significant savings in time and costs places DoE at the heart of the project 
framework.
In order to generate the characterisation data in a rapid and cost-effective 
manner, experiments should be performed at small scale as discussed in Section
1.2.4. Microscale experimentation complements DoE in that material 
requirements are reduced and experimental throughput is increased through 
parallel operation and potential automation. A framework component which 
includes microscale experimentation would thus prove highly beneficial.
The second stage o f the framework involves the scale-up of protein expression in 
order to access larger quantities o f protein. The final scale o f fermentation 
required is dependent on both the demands of the specific drug-discovery 
campaign and the expression characteristics of the target protein. The second 
stage o f the framework will thus involve the reproduction of microscale protein 
expression levels over a range o f scales. Separate strategies for laboratory scale 
and pilot scale expression will form the components of this stage of the 
framework.
In order to minimise the time and costs o f scale-up, these strategies should 
incorporate the information generated from the DoE / microscale stage of 
experimentation. The optimal fermentation conditions determined from small- 
scale characterisation experiments, for example, are likely to mirror those at 
larger scales (Hunt, 2005). These optimal conditions should provide some 
indication of the key process scale-up parameters and the overall scale-up 
strategy should also take account o f this.
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3.2.3 Framework structure
Having specified the key components, the next design step is to arrange these 
components within an optimal framework configuration such as that illustrated in 
Figure 3.1. The target protein and expression system proceed through to the first 
stage of the framework: protein expression characterisation. Here, suitable 
factors and responses are specified and experimental designs are generated 
through DoE. These fermentations are performed within microwell plates 
(MWP) and the data generated is used to guide subsequent experimental designs. 
This cycle continues until the optimum expression conditions have been 
identified.
The target protein and expression system then proceed through to the second and 
final stage o f the framework: scale-up o f optimised protein expression levels. 
The process information gathered thus far, such as optimal expression conditions 
and potential key scale-up parameters is used to design an appropriate scale-up 
strategy and this strategy is implemented up to the laboratory scale. Then, the 
successful strategy is refined in light o f any new information emerging from 
laboratory scale fermentations and applied to reproduce MWP protein expression 
levels at the pilot scale.
3.3 Framework implementation
3.3.1 Protein expression characterisation
3.3.1.1 Background
The experimental designs within this framework are greatly influenced by the 
properties of microscale experimentation. The implementation aspects of both 
components will, therefore, be considered simultaneously.
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Target protein and
expression system
Design of 
Experiments (DoE)
Microscale
experimentation
Pilot scale
strategy
Laboratory scale 
strategy
Gram quantities of
target protein
Figure 3.1 Overview o f the proposed framework for large-scale optimised 
protein expression. The numbered arrows represent information streams. The 
specification of factors and responses is determined by the particular target 
protein and expression system (1) and DoE is used to design the subsequent 
microscale experiments (2). Several rounds o f expression studies are required to 
determine the optimal process conditions in a time and cost efficient manner. The 
information gathered from each round is used to generate subsequent 
experimental designs (3) until the optimal conditions are found. The process 
knowledge which emerges from the DoE / microscale experiments should 
provide insight into larger (laboratory) scale performance and thus it should be 
incorporated into the appropriate scale-up strategy (4). Similarly, the knowledge 
gained from the laboratory scale strategy should inform the subsequent pilot 
scale strategy (5), thereby enabling the production of gram quantities of target 
protein (6).
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The stages involved in DoE were first reviewed in Section 1.3.2 and included 
familiarisation, screening, finding the optimal region, optimisation, robustness 
testing and mechanistic modelling. Not all stages are relevant to the objectives of 
this project, however. Mechanistic modelling, for example, is usually only 
attempted when there is a need to establish a theoretical model within a field and 
this lies beyond the scope of the current work. Similarly, robustness testing is 
mainly performed when reproducible product quality is o f key importance. Since 
the expressed reporter protein has no application as a product, robustness testing 
is unnecessary. Finally, finding the optimal region does not constitute a primary 
DoE objective and it will thus be considered alongside the screening stage.
Overall, the three primary experimental objectives of this work are 
familiarisation, screening and optimisation. Figure 3.2 illustrates the 
implementation sequence and characteristics of these stages towards the goal of 
obtaining a process map. As each stage is completed, the number o f potentially 
significant variables is reduced whilst the degree of process characterisation is 
increased. The specific implementation aspects o f each stage are discussed in the 
following sections.
3.3.1.2 Familiarisation
Familiarisation serves as perhaps the most important stage within the overall 
framework. As the name suggests, the purpose o f this stage is to gain familiarity 
with the process under investigation. The accuracy of information generated here 
will affect the number of experiments required to locate and characterise the 
optimal region, the reproducibility o f response data and the success o f the 
subsequent scale-up strategy. Thorough planning of the familiarisation 
experiments is thus crucial.
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Figure 3.2 Implementation sequence of the stages o f DoE applied in this work 
(arrows) towards the goal of obtaining a reliable process map. As each stage is 
completed, the number o f potentially significant variables is reduced whilst the 
degree o f process characterisation is increased.
The first step involves identifying all variables which may affect the process 
under investigation and this may be accomplished using insight gained from 
published literature, past experience or simple experimental designs. Some 
factors will have little effect on the system but may still cause an undesired 
spread around the ideal result. These factors typically include ambient 
temperature, humidity and variability in raw material composition. By 
developing techniques for controlling undesired sources of variation, it should be 
possible to establish a fine degree o f process control and the accuracy of 
information gained from the process should thus be improved. In contrast, factors 
which are thought to have the potential to significantly affect the system, such as 
those described in Section 1.2.3, should be targeted for investigation through 
DoE.
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A key requirement here is that factors are chosen to provide insight into larger 
scale performance and thus that the microwell experiments are performed in a 
defined engineering environment (Fernandes and Cabral, 2006). Initial studies 
have suggested that scaling-up on the basis o f a constant oxygen mass transfer 
coefficient, Ata, appears to be the most appropriate approach when dealing with 
microorganisms growing under aerobic conditions (Ferreira-Torres et al., 2005; 
Micheletti el al., 2006). Factors which are thought to influence kLa, such as 
MWP shaking speed and fill volume should, therefore, also be included for 
investigation. Their optimisation should enhance culture conditions and provide 
insight into scale-up criteria for optimal fermentation performance.
The next step involves choosing responses that are relevant to the goals o f the 
investigation and developing the appropriate response measurement techniques. 
Several responses will be considered throughout this project including cell 
growth and soluble protein yield. The corresponding assays will need to be 
compatible with both DoE and microscale processing techniques in that they 
should be rapid, sensitive, and quantitative, involving minimal processing to 
further reduce costs and facilitate potential automation.
Overall, the parameter assumptions and experimental methods developed thus far 
should be improved through experimentation before progressing through to the 
next stage o f DoE, screening.
3.3.1.3 Screening
The key purpose of screening is to identify the most influential factors and 
provide an estimate for their appropriate ranges. Here, factors are commonly 
investigated over only two levels and so a relatively low number o f experiments 
is required (Eriksson et al., 2000). For soluble recombinant protein production, 
the appropriate screening design should be capable o f handling not only a large 
number of factors, but also a mixture of qualitative and quantitative variables.
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It is usually possible to gauge if a screening design has captured the optimal 
settings, but the results do not lend themselves well to extrapolation. Therefore, 
if the optimal region appears to lie outside o f the screening window, it may be 
necessary to perform an additional number o f extra scouting experiments prior to 
optimisation.
3.3.1.4 Optimisation and process mapping
The goal of optimisation is to reveal the nature of the mathematical relationship 
between factors and responses and thus produce an accurate map or model o f the 
system under investigation. The corresponding designs vary factors over 3 to 5 
levels and so involve more experiments per factor than screening designs. The 
model can then be used to accurately determine the optimal factor settings, 
assuming they lie within the optimisation window.
3,3,2 Scale-up strategy: laboratory scale
A strategy for translating optimal DoE results from MWP fermentations to a 
laboratory scale STR is then needed and is underpinned by the ability to 
predictively scale-up microwell results. This need is complicated by stark 
differences between microwell plates and stirred tank reactors such as geometry, 
the method of aeration and agitation and the effects of surface tension. Scaling- 
up on the basis o f constant kLa has the potential of overcoming the 
aforementioned complications as it corresponds to an overall measure of 
agitation and aeration.
Regardless o f the basis for scale-up, the key scale-up parameter(s) will first have 
to be characterised over a range o f conditions at both the MWP scale and 
laboratory scale STR. It should then be possible to translate MWP fermentation 
performance to the larger scale. Several sets o f fermentation conditions should be 
investigated to provide an estimate for the range of conditions over which 
successful scale-up can be achieved.
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3.3.3 Scale-up strategy: pilot scale
The scale-up strategy developed at the laboratory scale should also provide the 
foundation for an effective pilot scale strategy. For example, the techniques 
developed at the laboratory scale for measuring the key scale-up parameter(s) 
should also be applicable at this scale o f operation. The range of scale-up 
conditions over which successful scale-up can be achieved may also be similar.
At this scale of operation, however, many minor sources of process variation 
may arise. These include method o f inoculum preparation, method of 
sterilisation, quality of media components, etc. In combination these may cause a 
significant deviation from predicted performance. These variables should, 
therefore, be taken into account when designing the appropriate scale-up 
strategy. By this stage it should be possible to produce large amounts of target 
protein under optimal conditions.
3.4 Summary
The aim o f this chapter was to provide a conceptual framework for generating 
large quantities of soluble recombinant protein in E. coli in a manner which is 
both rapid and cost-effective. The key components and overall structure of the 
proposed framework were specified in Section 3.2 and in Section 3.3 the 
practical issues of framework implementation were explored. In the following 
chapters, the practical details o f the framework are determined through 
experimentation. Chapter 4 will address protein expression characterisation and 
Chapters 5 and 6 will tackle the translation of microscale fermentation 
performance to the laboratory scale and pilot scale, respectively.
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4 Optimisation of soluble protein expression at the 
microwell scale*
4.1 Aims and objectives
The first stage o f the proposed framework (Section 3.3.1) involves the 
optimisation o f soluble protein expression at the microwell scale. This is covered 
in this chapter which addresses the application o f DoE and the performance of 
experiments at the microwell scale. The specific objectives of this chapter are:
• to develop appropriate experimental techniques and identify potential 
variables influencing protein expression through initial familiarisation 
experiments (Section 4.2);
• to screen the selected variables to identify those which produce the most 
significant effects on the expression system and estimate the factor ranges 
which are likely to encompass the optimal settings (Section 4.3);
• to confirm the identify o f the important factors and model their effect on 
soluble protein expression (Section 4.4);
• to improve the predictive ability o f the resultant model through statistical 
analysis, to pinpoint the optimal settings of the important factors and 
verify the model’s practical capability (Section 4.5).
4.2 Experimental familiarisation
4.2.1 Specification o f variables
The first objective of the familiarisation experiments was to identify the variables 
influencing soluble protein expression and their appropriate ranges for the system 
under investigation. Ten factors were initially chosen for investigation and these 
are described in Table 4.1. This selection of factors is generic and could be
fThe majority o f the results presented in this chapter have been published as: Islam,R.S., Tisi,D., 
Levy,M.S., and Lye,G.J. (2007) Framework for the Rapid Optimization of Soluble Protein 
Expression in Escherichia coli Combining Microscale Experiments and Statistical Experimental 
Design. Biotechnology Progress. 23, 785-793.
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applied to the study of soluble protein production in microwells for any inducible 
E. coli expression system. Medium types were chosen from commonly used 
complex media and plate formats were chosen such that a range of geometries 
was present. The chosen screening temperatures, IPTG concentrations and post­
induction periods were adopted from a study by Urban et al. (2003) who also 
investigated recombinant protein expression using the pET vector and an 
identical strain o f E. coli. The IPTG concentrations used, 50-1000 pM, are also in 
line with those used in other E. coli expression systems (Cao, 2006; Swalley et 
al., 2006). Previous experiments near centre-point conditions had shown the mid­
exponential growth phase to occur at ~4 h and so the boundaries for the pre­
induction growth period were positioned symmetrically around 4 h. In contrast to 
other DoE studies, shaking speed and liquid fill volume were included as factors 
since these strongly influence the oxygen transfer rate into the wells (Hermann et 
al., 2003). The upper shaking speed was limited by the speed of the HiGro 
incubator-shaker and the upper liquid fill volume was chosen such that excessive 
splashing was avoided within the wells at the highest shaking speed.
4.2.2 Development o f response measurement techniques
The second objective was to identify suitable responses and develop the 
appropriate measurement techniques. An obvious response was that of biomass 
concentration, for which optical density measurements would provide a good 
indication and which have the potential to be made rapidly in a high-throughput 
manner. These observations would be made during the optimisation experiments 
at specific time points throughout the course of each microwell plate 
fermentation. The time points immediately following the growth and induction 
periods were deemed most appropriate for these initial measurements.
Another key measurement was that o f soluble protein yield. Although general 
assay procedures for FFL are described in the literature, it was necessary to 
develop an assay which met the specific requirements of this work. Firstly, all 
assay procedures were adapted to the MWP format. Following this, the relative 
quantities of assay reagents were adjusted to suit the range of expression levels
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particular to these fermentation conditions. Finally, it was necessary to again 
develop assay procedures which were compatible with the demands o f high- 
throughput automated processing (Lye et al., 2003). The final version o f the 
assay procedure used throughout this study is described in Section 2.6.3.
Table 4.1 Specification o f factors and settings investigated within 
familiarisation, screening and optimisation experiments. Pre-I and post-I are 
abbreviations for pre-induction and post-induction, respectively. Plate PI had 48 
rectangular wells with flat bases, plate P2 had 24 square wells with round bases 
and plate P3 had 24 square wells with pyramidal bases. aThe familiarisation 
experiments had a lower shaking speed of 50rpm. bAn upper liquid fill volume of 
2 ml was used in conjunction with the 48-well plate to prevent splashing.
Experimental settings
Factor name Abbr. Units __________________________________
Familiarisation / Screening Optimisation
Growth medium Xl - LB, TB, GM9Y TB
Plate geometry x2 - PI, P2, P3 P3
Liquid fill volume X3 ml 1, 2a,3 1 ,2 ,3
Pre-I temperature x4 °C 17, 37 27
Pre-I shaking speed X5 rpm 100b, 500 100,300. 500
Pre-I period X6 h 2 , 6 1 ,4 ,7
Inducer concentration X7 pM 50, 1000 500
Post-I temperature X8 °C 17, 37 23, 30, 37
Post-I shaking speed x9 rpm 100b, 500 100,300, 500
Post-I period Xio h 3, 15 6 , 1 2 , 18
4.2.3 Method development through experimentation
In order to evaluate the cell culture and analytical techniques developed methods 
thus far, a trial set o f 30 DoE experiments was performed from a screening 
design according to the factor settings described in Table 4.1. The mean soluble 
protein yield results from these experiments are shown in Figure 4.1. 
Approximately 40 % of the experiments resulted in protein yields undetectable 
by the assay with the average soluble protein yield per fermentation being 32,230
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RHJ.ml'1. For comparison, shake flask fermentations were also performed under 
standard expression conditions as defined in Section 2.3.5. These fermentations 
were run in duplicate and a mean soluble protein yield of 552,000 RLLI.ml*1 (a = 
12.9 %) was obtained.
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Figure 4.1 Column chart illustrating the variation of soluble protein yield from 
MWP familiarisation experiments. Experiments performed as described in 
Section 2.3.1.
Due to the low protein yield measurements and the high incidence of zero-value 
measurements, subsequent regression analysis was severely impeded. However, 
the goal of familiarisation is to gain some initial experimental experience with 
the system under investigation. Consequently, several changes were made to the 
experimental procedure, two of which were key. Firstly, the volume of inoculum 
was increased to raise the starting OD600 from 0.001 to 0.1. Secondly, the lower 
shaking speed was raised to lOOrpm, as shaking at 50rpm was observed to 
produce virtually no mixing in the wells.
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4.3 Screening experiments
Building upon the knowledge and experience gained from the familiarisation 
stage, the objective o f the screening experiments was to rapidly explore the 
influence of a wide range of factors on soluble protein yield. Detailed 
information on biomass growth and protein expression kinetics was sacrificed at 
this stage in order to rapidly identify the main factors influencing soluble protein 
yield. On completion of the screening experiments, a regression model was fitted 
to the soluble protein yield data (Table 4.2); note that the particular screening 
design used here did not support the quantification of interaction effects, only 
main effects. A fourth root transformation was then performed on these values in 
order to render their distribution approximately normal and hence maximise the 
Q2 value for the fitted model. This subsequent model yielded R2 and Q2 values of 
0.86 and 0.63 respectively which indicated that 8 6  % of the response variation 
was explained by the model and 63 % of the response variation was predicted by 
the model. These R2 and Q2 values suggested that the resulting model provided 
information of sufficient accuracy for creating a subsequent optimisation design.
The significance o f each screening factor on soluble protein yield is illustrated in 
the coefficient plot shown in Figure 4.2. It can be clearly observed that, of the 
qualitative factors, LB medium and plate PI contributed to the lowest soluble 
protein yields. In contrast, TB medium and plate P3 resulted in the highest 
soluble protein yields. There are several reasons why growth in TB could have 
resulted in the highest soluble protein yields. This medium is not only rich in 
nutrients such as yeast extract and tryptone, it also contains a defined carbon 
source, glycerol. Coupled to this, TB contains significant amounts of KH2PO4 
and K2HPO4 , (2.31 g.l' 1 and 12.54 g .f 1 respectively) which provide some level of 
buffering capacity against any disturbance in pH within the medium during 
fermentation. In contrast, LB medium contains no defined carbon source and no 
phosphate components and has almost five times less yeast extract than TB.
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Table 4.2 D-optimal screening design matrix for the initial assessment o f soluble 
protein yield. Quantitative variables are coded at low (-1), medium (0) and high 
(+1) levels according to the factor levels specified in Table 4.1.
Observations * 1 * 2 X} X4 X5 x6 x7 x8 x9 X| 0
Mean soluble 
protein yield 
(RLU.m l1)
N1 M9Y P3 - 1 - 1 1 1 1 - 1 - 1 - 1 2.422
N2 M9Y P3 - 1 1 1 1 - 1 - 1 - 1 1 228.491
N3 M9Y P3 - 1 - 1 1 - 1 1 1 1 - 1 53.632
N4 LB P3 - 1 1 - 1 1 - 1 1 1 1 512.598
N5 TB P3 - 1 1 - 1 - 1 1 1 1 1 1.693.240
N 6 M9Y P3 1 - 1 - 1 - 1 - 1 - 1 1 1 906.256
N7 LB P3 1 - 1 - 1 - 1 1 - 1 - 1 - 1 440
N 8 LB P3 1 1 1 - 1 - 1 1 - 1 - 1 53.519
N9 TB P3 1 1 - 1 1 1 - 1 1 - 1 58.193
N10 TB P3 1 - 1 1 1 - 1 1 1 1 329,012
N il M9Y P2 - 1 1 - 1 1 1 - 1 1 - 1 547
N12 LB P2 - 1 - 1 - 1 1 - 1 - 1 1 - 1 1,366
N13 LB P2 - 1 - 1 1 - 1 1 - 1 1 1 34,999
N14 TB P2 - 1 1 1 - 1 - 1 - 1 - 1 1 395,539
N15 TB P2 - 1 - 1 - 1 - 1 - 1 1 - 1 - 1 102,534
N16 M9Y P2 1 - 1 - 1 1 - 1 1 - 1 - 1 41,042
N17 M9Y P2 1 1 1 1 - 1 1 - 1 1 171,085
N18 M9Y P2 1 1 1 - 1 1 - 1 1 1 7,800
N19 LB P2 1 1 1 1 1 1 1 - 1 943
N20 TB P2 1 - 1 - 1 - 1 1 - 1 - 1 1 147,394
N21 M9Y PI - 1 1 - 1 - 1 1 1 - 1 - 1 480
N22 M9Y PI - 1 - 1 - 1 - 1 - 1 1 1 1 852,391
N23 LB PI - 1 1 - 1 1 - 1 - 1 - 1 1 87,764
N24 LB PI - 1 - 1 1 1 1 1 - 1 1 43,145
N25 TB PI - 1 - 1 - 1 1 1 1 - 1 1 321,696
N26 TB PI - 1 1 1 - 1 - 1 - 1 1 - 1 10,359
N27 TB PI - 1 - 1 1 1 - 1 - 1 1 - 1 1 1 . 0 2 0
N28 TB P3 0 0 0 0 0 0 0 0 1,241,740
N29 TB P3 0 0 0 0 0 0 0 0 1,220,350
N30 TB P3 0 0 0 0 0 0 0 0 1,243,840
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Figure 4.2 Coefficient plot with confidence intervals (set at 95%) for soluble 
protein yield obtained from screening experiments. The size of each bar (or 
coefficient) represents the relative importance of that factor upon soluble protein 
expression. A positive coefficient for a quantitative factor indicates that an 
increase in that factor, relative to its centre-point level, would result in an 
increase in soluble protein yield. The opposite is true for negative coefficients. 
Qualitative factors, such as medium type, have no centre-point levels and so the 
coefficients displayed are relative to one another. Factors and experimental 
conditions as described in Table 4.1.
Intermediate levels o f soluble protein expression were obtained with Glucose 
M9Y. Unlike LB medium, Glucose M9Y medium contains phosphate 
components and a defined carbon source in the form of glucose. This carbon 
source, however, provides limited benefits in comparison to glycerol which is 
present in TB medium. Glucose is a rapidly metabolised sugar which is 
associated with low recombinant protein yields (Stanbury and Whitaker, 1993). 
Unlike glycerol, it is also converted to acetate which is detrimental to the growth 
of E. coli (Jana and Deb, 2005; Luli and Strohl, 1990).
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The plate geometry was also shown to causes diverse effects. This is especially 
significant since other publications examining protein expression in microwell 
formats have not fully investigated this factor (Cao, 2006; Nikerel et al., 2005; 
Ren et al., 2006; Swalley et al., 2006; Urban et al., 2003; Wang et al., 2005; 
Zhang, 2006). Plate P3, which has 24 wells each with a square cross-section and 
a pyramidal bottom, had the most significant and positive effect on soluble 
protein yield. The large wells provide an increased surface area per unit volume 
for oxygen transfer and the edges along the pyramidal bottoms produce a baffling 
effect which further promotes mixing and aeration (Doig et al., 2005; Duetz et 
al., 2000; Lye et al., 2003). Plate P2, which has 24 wells each with a square 
cross-section and a round bottom, resulted in intermediate soluble protein yields. 
The lowest soluble protein yields were observed with plate PI, which has 48 
wells each with a rectangular cross-section and a flat bottom. The wells o f plate 
PI are small, each well with a cross-sectional area less than half those of the 
other plates. This would lead to a significant reduction in oxygen transfer 
capability due to the reduced air-liquid surface area within each well. The 
increased importance o f surface tension effects as well as diameter decreases 
would exacerbate this problem.
The most significant quantitative factors (Figure 4.2) included the pre-induction 
(pre-I) and post-induction (post-I) periods and the post-I temperature. The post-I 
period had a positive coefficient, indicating that higher soluble protein yields are 
obtained at the higher setting (15 h). The highest soluble protein yields overall 
were obtained from the centre-point experiments where the post-I period was 9 h. 
This additional information suggested that the post-I period centre-point in the 
subsequent optimisation design should be positioned close to 9 h. The location of 
the window for post-I period would, therefore, be moved by +3 h for 
optimisation. The post-I temperature also had a positive coefficient. The upper 
limit was already at 37 °C, the optimum for E. coli, and so only the lower limit 
would be raised for optimisation experiments.
In many cases it is prudent to maximise the number of healthy cells prior to the 
addition of an inducer, which often retards cellular growth (Bentley et al., 1991;
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Donovan et al., 1996; Lee, 1996; Peng et al., 2004). Results from the screening 
experiments suggest differently, however. The negative coefficient for the pre-I 
period shows that, on average, higher soluble protein yields are obtained at the 
low setting of 2 h corresponding to lower cell densities prior to induction. For the 
optimisation experiments, the pre-I period range would be increased by 2 h 
overall symmetrically around the original centre-point.
While the coefficients for shaking speed, both pre- and post-induction, and also 
the liquid fill volume were not seen to have a significant impact on soluble 
protein yield (Figure 4.2), it was decided to retain them for subsequent 
optimisation experiments over their existing ranges. As previously mentioned in 
Section 4.2.1, these parameters are known to strongly influence kia  and hence 
the oxygen transfer rate into the wells (Hermann et al., 2003). Since the 
optimisation experiments are expected to produce higher cell densities and 
protein yields, oxygen mass transfer limitations may appear and so it would be 
prudent to include these three factors in the next stage of the design procedure. If 
any o f these parameters were to become significant under optimised conditions it 
would provide important insight for scale-up of the optimised process.
The remaining two quantitative factors o f pre-I temperature and inducer 
concentration both appeared to be insignificant (Figure 4.2). Although some 
circumstances exist under which screening designs may return false-negative 
results for factor relevance the decision was made to dismiss these factors in 
favour of a reduction in the number o f variables targeted for further investigation 
and optimisation. Since the centre-point experiments produced the highest 
soluble protein yields, both pre-I temperature and inducer concentration would 
be fixed near their centre-point levels for optimisation studies.
4.4 Optimisation experiments
Having identified the key factors influencing soluble protein yield in Section 4.3, 
the aim o f the optimisation experiments was to study a smaller number o f factors,
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over refined ranges, in more detail. The investigated factors are specified in 
Table 4.1. For the optimisation experiments the measured biomass dry cell 
weight pre- and post induction was also included as a response so as to provide 
extra insight into the relationship between cell growth and protein expression. 
The results for these experiments are summarised in Table 4.3. Here, it can be 
seen that there was a three-fold increase in the highest measured soluble protein 
yield (5.39 x 106 R L ll.m l1) compared to the maximum obtained in the initial 
screening experiments (1.69 x 106 RLU.mr1).
On completion of the optimisation experiments, soluble protein yield values were 
transformed by taking the fourth root as described in Section 4.3. The initial 
optimisation model consisted of 27 terms ( 6  main effect terms, 6  square terms 
and 15 two-level interaction terms). Model terms that were not significant were 
then removed in a hierarchical manner; if a main effect term was removed then 
all higher order terms containing that factor, such as square terms and interaction 
terms were also removed. The remaining model coefficients for soluble protein 
yield are shown in Figure 4.3 and their associated statistics are given in Table 
4.4. Confidence intervals, set at 95 %, show the intervals or limits within which 
there was a 95 % chance of finding the true values of the model coefficients. A p  
value indicates the probability that a given model coefficient has an insignificant 
effect on the response. It is evident, therefore, from Table 4.4 that all coefficients 
in the final optimisation model are significant at p < 0.05.
Only three of the original six factors were found to influence soluble protein 
yield significantly: the pre-I and post-I shaking speed and the post-I period. The 
square terms for both shaking speeds were significant indicating that the 
optimum levels for these factors lay within the ranges studied. The fact that both 
these shaking speeds have become significant factors in the optimisation 
experiments is a consequence o f the higher biomass concentrations achieved ( > 8  
g.l'1) and the further enhancement obtained in soluble protein yield. Both o f these 
will increase the oxygen demand o f the culture making oxygen transfer, and 
hence shaking speed, a key parameter.
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Table 4.3 CCF design matrix for the optimisation of soluble protein yield. DCWj 
and DCWf refer to dry cell weight measurements immediately prior to induction 
and immediately following the induction period respectively. All variables are 
coded at low (-1 ), medium (0 ) and high (+ 1 ) levels according to the factor levels 
specified in Table 4.1. Predicted mean soluble protein yields are calculated from 
Equation 4.1.
Observations x3 x5 X6 x8 x9 X| 0
Mean
DCWj
(g-1-1)
Mean
DCWf
(g .f )
Mean soluble protein 
yield (RLU.m l1)
Measured Predicted
N1 -1 -1 -1 -1 -1 -1 0.09 0.60 199.625 124,038
N2 -1 1 -1 -1 1 -1 0.09 1.10 144,839 245,718
N3 1 -1 -1 -1 1 -1 0.07 0.55 106,421 489,412
N4 1 1 -1 -1 -1 -1 0.09 0.32 75,637 45,207
N5 -1 -1 1 -1 1 -1 0.74 3.34 710.852 489,412
N6 -1 1 1 -1 -1 -1 4.90 4.87 15,679 45,207
N7 1 -1 1 -1 -1 -1 0.47 0.81 210,553 124,038
N8 1 1 1 -1 1 -1 3.02 3.60 77,194 245,718
N9 -1 -1 -1 -1 1 1 0.08 5.16 1,955,840 980,053
N10 -1 1 -1 -1 -1 1 0.09 1.05 705,421 147,452
N il 1 -1 -1 -1 -1 1 0.07 0.77 527,654 319,833
N12 1 1 -1 -1 1 1 0.12 3.30 1,270,210 553,720
N13 -1 -1 1 -1 -1 1 0.74 1.17 149,192 319,833
N14 -1 1 1 -1 1 1 3.01 3.38 84,983 553,720
N15 1 -1 1 -1 1 1 0.52 5.19 2,804,730 980,053
N16 1 1 1 -1 -1 1 2.81 2.44 106,785 147,452
N17 -1 -1 -1 1 1 -1 0.05 0.87 150,716 489,412
N18 -1 1 -1 1 -1 -1 0.11 0.77 132,055 45,207
N19 1 -1 -1 1 -1 -1 0.09 0.45 135,652 124,038
N20 1 1 -1 1 1 -1 0.11 1.61 429,209 245,718
N21 -1 -1 1 1 -1 -1 0.75 1.13 87,900 124,038
N22 -1 1 1 1 1 -1 2.85 3.67 289,720 245,718
N23 1 -1 1 1 1 -1 0.61 5.33 1,481,220 489,412
N24 1 1 1 1 -1 -1 2.89 2.42 27,639 45,207
N25 -1 -1 -1 1 -1 1 0.11 1.32 128,921 319,833
N26 -1 1 -1 1 1 1 0.13 5.05 368,363 553,720
N27 1 -1 -1 1 1 1 0.08 5.52 564,253 980,053
N28 1 1 -1 1 -1 1 0.12 0.90 114,381 147,452
N29 -1 -1 1 1 1 1 0.44 2.13 593,970 980,053
N30 -1 1 1 1 -1 1 2.96 2.25 95,179 147,452
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N31 1 -1 1 1 -1 1 0.54 1.01 164.592 319.833
N32 1 1 1 1 1 1 2.86 3.17 565.823 553.720
N33 0 -1 0 0 0 0 0.24 5.26 2.233.070 1.804.860
N34 0 1 0 0 0 0 0.66 3.46 1.858.960 1.111.250
N35 -1 0 0 0 0 0 0.78 5.44 1.726.340 3.248.830
N36 1 0 0 0 0 0 0.68 5.31 2.341.450 3.248.830
N37 0 0 -1 0 0 0 0.10 2.75 1.115.710 3.248.830
N38 0 0 1 0 0 0 2.18 5.19 4.264.530 3.248.830
N39 0 0 0 0 0 -1 0.91 4.82 3.257.280 2.546.740
N40 0 0 0 0 0 1 1.07 8.18 5.388.800 4.086.950
N41 0 0 0 -1 0 0 0.65 5.24 2.945.420 3.248.830
N42 0 0 0 1 0 0 0.91 7.37 2.751.670 3.248,830
N43 0 0 0 0 -1 0 0.59 1.37 498.272 537.454
N44 0 0 0 0 1 0 0.91 5.45 3.031.590 1.459,700
N45 0 0 0 0 0 0 0.44 5.61 3,423.950 3.248,830
N46 0 0 0 0 0 0 0.59 5.64 3.249.220 3.248.830
N47 0 0 0 0 0 0 0.53 5.60 3,630,600 3.248.830
N48 0 0 0 0 0 0 0.73 5.72 3,317.380 3,248,830
N49 0 0 0 0 0 0 0.98 6.24 4.068.960 3.248.830
N50 0 0 0 0 0 0 0.89 5.80 4,126,540 3,248,830
This also provides an early indication o f the significance of agitation and aeration 
conditions upon scale-up if the optimised results are to be reproduced at larger 
scales. Although the post-I period was significant, the lack of a significant square 
term implied that its optimum setting lay outside of the range studied; the 
positive coefficient suggested it lay beyond 18h.
Figure 4.4 shows the response surface plot of pre- and post induction shaking 
speed with respect to soluble protein yield. Since shaking speed was shown to 
have such a significant effect on soluble protein yield it is logical to deduce that 
mixing and aeration are important factors. The existence of an optimum shaking 
speed was at first surprising. However, visual observations indicated that at the 
higher speeds splashing occurred within each well leading to the formation o f a 
liquid film on the underside of the gas permeable membrane. This would have 
increased resistance to oxygen transfer (Zimmermann et al., 2003) resulting in 
oxygen limitation of the culture and decreased soluble protein yield. Also, while
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high oxygen transfer rates may benefit cell growth, high growth rates do not 
normally favour expression of heterologous protein which is the main response 
variable in this study (Broedel et al., 2002; Stanbury and Whitaker, 1993).
Figure 4.3 Coefficient plot for final optimisation model (Equation 4.1), complete 
with confidence intervals (set at 95 %) for soluble protein yield (Y transformed 
as Y025). The original model consisted of 27 terms. However, terms whose 
confidence interval included the value zero were deemed insignificant and so 
were removed from the model in a hierarchical manner. Factors and experimental 
conditions as described in Table 4.1.
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Figure 4.4 Response surface plot showing influence of pre-I and post-l shaking 
speed on soluble protein yield (all other optimisation factors at their centre-point 
levels). Response surface generated using Equation 4.1.
Overall the three key variables identified at this stage strongly affect both cell 
growth rate and final biomass concentration. Analysis o f the raw factor 
combinations (Table 4.3) suggests that the highest soluble protein yields are 
obtained under conditions which promote both a slow growth rate during protein 
synthesis and a high final biomass yield.
4.5 Regression analysis and process modelling
The final stage in the application o f DoE involves analysis and verification o f the 
model. Model analysis helps to provide insight into any experimental issues that 
may not be accounted for in the model. Model validation involves experimental 
verification o f model predictions under conditions not specifically tested in the 
experimental design. Regression analysis o f the reduced optimisation model for 
soluble protein yield (Table 4.4) indicated that 82 % of the response variation 
was explained by the model and 76 % o f the response variation was predicted by 
the model. Figure 4.5 shows the correlation between measured and predicted
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soluble protein yield values. The predictive power o f the regression model is 
generally good but the 76 % value suggests that aspects o f the system being 
studied were behaving in an unpredictable manner.
Table 4.4 Estimated regression coefficients o f the reduced optimisation model 
for soluble protein yield (Equation 4.1). The corresponding p-values and 
confidence intervals are also shown. Variables as described in Table 4.1.
Variable Coefficient Standard error p  value
95% confidence 
interval (±)
Constant 42.455 1.250 < 0 . 0 0 1 2.520
Pre-I shaking speed -2.093 0.830 0.015 1.672
Post-I shaking speed 3.841 0.830 < 0 . 0 0 1 1.672
Post-I period 2.507 0.830 0.004 1.672
(Pre-I shaking speed): -7.895 2.538 0.003 5.115
(Post-I shaking speed)* -11.538 2.538 < 0 . 0 0 1 5.115
/?-’ = 0.817:0-’ = 0.760
4 5 -
4 0 -
3 0 -
8  2 0 -
3010 15 20 25 35 40 5045
Predicted (soluble protein yield)025 (RLU.ml1)025
Figure 4.5 Parity plot showing measured and predicted soluble protein yields for 
optimisation experiments. Predicted values obtained from Equation 4.1. Solid 
line represents line o f parity.
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Analysis o f Variance (ANOVA) was performed on the residual sum o f squares 
(SSrcsid). the results for which are shown in Table 4.5. SSreSid is comprised o f the 
sum o f two components: the experimental error, or the pure error sum o f squares 
(SSpo) and the model error, the lack o f fit sum o f squares (SS|0r). ANOVA 
revealed that SS|0r was the major contributor to SSrcs,d (SS|0r ~ 1023). with the 
pure error associated with the replicate experiments being relatively very low
(SSpc ~ 6).
Table 4.5 ANOVA results for analysis o f the reduced optimisation model 
(Equation 4.1) for soluble protein yield.
Source
Degrees of 
freedom 
(DF)
Sum of 
squares 
(SS)
Mean square 
(MS)
F statistic p  value
Total 50 48390.100 967.802
Constant 1 42752.100 42752.100
Total
Corrected
49 5637.980 115.061
Regression 5 4608.540 921.709 39.396 <0.001
Residual 44 1029.440 23.396
Lack of Fit 39 1023.050 26.232 20.547 0.002
Pure Krror 5 6.384 1.277
It's possible this lack o f fit was due to the removal o f too many terms from the 
model; it may have been prudent to leave significant interaction and square terms 
in the model even if their corresponding main effect terms were shown to be 
insignificant. Uncontrolled factors and/or mechanisms may also have been 
present. A number o f experiments were seen to generate extremely low soluble 
protein yields despite having relatively high biomass concentrations. On 
inspection o f these cultures, cells were seen to have aggregated at the end o f the 
fermentation and the broth had a viscosity consistent with that o f lysed cells. If 
cells within these cultures did indeed lyse disproportionately to other
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experiments, it would have represented a new mechanism, unaccounted for by 
the existing experimental design. Secondly, in experiments where the culture was 
shaken gently, cells were seen to adhere to the surface o f the wells complicating 
OD measurements and sampling o f the wells. Overall, however, the distribution 
o f responses (Figure 4.6) shows that the current experimental window is ideally 
placed around a highly variable region o f the system. Furthermore, the general 
trends seem to have been captured well since both the R2 and Q2 values are high 
and acceptable for such a complex system
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Figure 4.6 Histogram o f responses for (soluble protein yield)0 25 from the 
optimisation experiments (Table 4.3).
To test the accuracy o f the regression model, two verification experiments were 
performed at the predicted optimal factor settings. The final regression model 
was comprised o f the coefficients shown in Table 4.4 and assumed the form:
7 025 = 42.46 -  2.09x5 + 3.84x9 + 2 .5 lx10 -7 .9 0 x52 -1  1.54*2 (4.1)
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From this equation the predicted optimal factor settings were pre-I shaking speed 
= 270 rpm, post-I period ~ 18h and post-I shaking speed = 330 rpm. All other 
factors were maintained at their mid-point levels (Table 4.1). The mean soluble 
protein yield measured experimentally at these predicted optimal settings was 
3.26 x 106 RLU .m f1 (o = 14.5 %) and the corresponding pre-I and post-I mean 
biomass concentrations were 1.01 g .f1 and 6.88 g .f1 respectively. The mean 
soluble protein yield obtained was equivalent to just over 76 % o f the predicted 
optimum o f 4.25 x 106 R LU .m r1. This result suggested the model is highly 
predictive however, some lack o f fit o f the model does occur. For comparison, 
shake flask fermentations were also performed under standard expression 
conditions (Section 2.3.5). These fermentations were run in duplicate and a mean 
soluble protein yield o f 552,000 R LU .m r1 (a = 12.9 %) was obtained. Overall, 
the soluble protein yield measured under the predicted optimum conditions is 
almost 6-fold greater than that obtained under reference shake flask conditions.
Finally, Figure 4.7 shows the variation o f soluble protein yield modelled as a 
quadratic function o f  pre- and post-induction biomass yield, over which lies a 
scatter plot o f experimental observations. The model is able to largely explain the 
variation in soluble protein yield, with an R value o f 0.87 and thus several 
conclusions can be drawn. When the pre-induction biomass is high, ~ 3 g . f 1, the 
resultant post-induction biomass concentration remains relatively constant. The 
addition o f IPTG at high biomass concentrations seems to prevent further growth 
o f cells. Furthermore, the soluble protein yields measured at these levels are all 
relatively small (<1 x 106 R L U .m l1). In contrast, the highest soluble protein 
yields generally correspond to both a relatively low pre-induction biomass 
concentration, below ~ 1 g.F1, and high post-induction biomass concentration, 
above ~ 5 g.F1.
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Figure 4.7 Contour plot showing variation o f soluble protein yield (RLU.mr1) 
with respect to pre-induction dry cell weight (DCW,) and final dry cell weight 
(DCWf). Model used to generate contours was a least squares quadratic fit: 
logio(soluble protein yield) = 11.36 -  0.13x(DCW,) + 0.50x(DCWf) - 
0.12x(DCW,)2 -  0.02x(DCWf)2 + 0.09x(DCW,)x(DCWf). Data used to generate 
model are taken from Table 4.3 and are superimposed over the contour plot. 
Dashed line represents line o f parity.
4.6 Sum m ary
The aim o f this chapter was to optimise soluble protein expression at the 
microwell scale. Towards this aim a generic framework was developed, 
comprising four key stages: familiarisation, screening, optimisation and 
regression analysis towards generating a process map.
Ten factors were initially identified at the familiarisation stage (Section 4.2) 
using a combination o f  experience and literature studies. Relevant system 
responses were identified and the appropriate measurement techniques were 
developed. A simple experimental design was also applied to further develop the 
experimental methods. The ten selected factors were subsequently screened
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(Section 4.3) and six were chosen for further investigation through optimisation. 
The optimisation stage (Section 4.4) identified three significant factors and their 
effects on soluble protein expression levels were modelled. This model was 
subsequently improved through statistical analysis and the m odel's predictive 
ability verified through experimentation (Section 4.5).
In comparison to other HTPE approaches, the application o f DoE led to a 
significant decrease in the number o f experiments performed. Ten variables w ere 
studied at both the familiarisation and screening stages (2 qualitative variables at 
3 levels and 8 quantitative variables at 2 levels) and six were studied at 
optimisation (6 quantitative variables at 3 levels). The total number o f factor 
combinations for these three experimental designs is 2(32. 28) + 36= 5,337. This is 
a large, potentially expensive, and time consuming number o f experiments to 
perform. In contrast, the DoE approach required just 110 experiments (a 98 % 
reduction) and led to a high degree o f process understanding, as evidenced by the 
results for verification o f  the process model. At each stage o f the DoE process, an 
increased understanding o f the expression system was achieved. This is clearly 
illustrated in Figure 4.8 which demonstrates the significant improvements in 
maximum soluble protein yields obtained from the familiarisation, screening and 
optimisation experiments. Overall, the maximum soluble protein yield was 
increased more than 9-fold compared to reference conditions.
The use o f parallel microwell scale fermentations also helped to reduce the 
experimental timeframes. These timeframes could be further reduced if all 
experiments required by DoE were automated. Importantly, shaking speed and 
liquid fill volume, two factors that have a strong influence on oxygen mass 
transfer into microwells (Hermann et al., 2003) were included as factors in the 
experimental design. The fact that shaking speed was one o f the most significant 
factors in the optimisation model illustrates its importance when performing 
microwell fermentations. It also suggests that careful control o f agitation and 
aeration conditions upon scale-up o f the optimised culture conditions will be 
important in maintaining the optimal balance between cell growth and protein 
expression.
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Figure 4.8 Comparison o f maximum soluble protein yields obtained from the 
familiarisation, screening and optimisation experiments. Dashed line indicates 
the mean soluble protein yield measured from shake flask experiments under 
standard expression conditions (Section 2.3.5).
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5 Scale-up of MWP fermentation performance to 7.5 1 
STR scalef
5.1 A im s and objectives
Following the optimisation o f soluble protein expression at the microwell scale 
in Chapter 4. the next stage o f the proposed framework (Section 3.3.2) involves 
implementing an appropriate scale-up strategy which will enable the rapid 
reproduction o f MWP fermentation performance within a laboratory scale STR. 
Given the significance o f shaking speed on protein expression in Chapter 4 
(Figure 4.3) and its impact on oxygen transfer (Hermann et al., 2003), kLa was 
considered to be an important scale-up parameter. Initial studies have also 
suggested that scaling-up on the basis o f constant kia appears to be the most 
appropriate approach when dealing with microorganisms growing under aerobic 
conditions (Ferreira-Torres et al., 2005; Micheletti et al., 2006).
The aim o f this chapter is, therefore, to establish kLa as a suitable basis for scale- 
up o f MWP results and to determine the range o f kLa values over which this 
scale-up strategy is valid. Specific objectives are:
• to measure the variation o f  kia over a range o f operating conditions 
within both the MWP and 7.5 1 STR scales (Sections 5.2 and 5.3);
• to validate these measurements through comparisons to existing 
correlations (Sections 5.2 and 5.3);
• to perform MWP and 7.5 1 STR scale fermentations at matched kia  values 
(Section 5.4);
• to use established statistical techniques to demonstrate the equivalence, or 
otherwise, o f fermentation kinetic profiles at the two scales (Section 5.4).
+The majority of the results presented in this chapter have been submitted for publication as: 
Islam.R.S.. Tisi.D.. Levy.M.S.. and Lye.G.J. (2007) Scale-up of E. coli growth and recombinant 
protein expression conditions from microwell to laboratory and pilot scale based on matched k,a. 
Biotechnology and Bioengineering. In press, doi: 10.1002/bit.21697
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5.2 Measurement and correlation of MWP kLa values
The initial stage o f the scale-up strategy involved characterising and correlating 
MWP kia  values over a range o f  operating conditions. First, the static-gassing 
out technique was used to generate dissolved oxygen tension (DOT) profiles for 
each o f the MWP geometries studied in Chapter 4. These experiments are 
described in Section 2.4.1 and a sample o f the resultant DOT profiles is shown in 
Figure 5.1 (a). The range o f kLa values measured from such profiles is illustrated 
in Figure 5.2 (a) and kia is observed to increase with increasing shaking speed in 
all cases (the raw data from which Figure 5.2 was constructed is given in 
Appendix A). This figure also compares the measured kia values with those 
predicted from the correlation o f Doig et al. (2005) for a 24-well plate with a 
circular cross-section and flat base (the closest geometry to those used here):
The experimental kia  values shown in Figure 5.2 (a) are significantly larger than 
those predicted. This is most probably due to the improved oxygen mass-transfer 
characteristics o f square versus round well plate formats (Duetz and Witholt, 
2004; Hermann et al., 2003).
In order to broaden the application o f the Doig et al. (2005) correlation to include 
square well plates, the original correlation was modified. The Bond and Schmidt 
numbers were first removed from the correlation since these groups do not vary 
with shaking speed (the only variable investigated here in the k/,a experiments). 
The sub-correlation for prediction o f cif /  a, was then altered to the following 
form:
7 1 - l r  n  r>  0  6 8  r*  0 .3 6  77* 0  8 6  n  0 .03k {a -  31.35.ZA<7;.Re ..Sc .Fr .Bo (5.1)
In —  = a.Fr (5.2)
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Figure 5.1 Example DOT profiles obtained across the full range o f shaking / 
agitation speeds within (a) the MWP (plate P3) and (b) the 7.5 1 STR. 
Experiments were performed as described in Section 2.4. A logarithmic 
transformation o f time is displayed on the x-axes such that the full range o f 
profiles for each bioreactor may be easily distinguished in one figure.
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Figure 5.2 Comparison o f predicted and measured MWP and af/a* values: (a) 
the correlation for kLa presented by Doig et al. (2005) (Equation 5.1) was used to 
predict kLa values for plates PI [ •  ], P2 [ A ] and P3 [ ■ ]; (b) Equation 5.2 was 
used to predict af/at values for plates PI [ o ], P2 [ A ] and P3 [ □ ] and the 
modified Doig correlation (Equation 5.3) was fitted to these data and used to 
predict kia  values for plates PI [ •  ], P2 [ A ] and P3 [ ■ ]. Values predicted 
from Equations 5.2 and 5.3 lie close to the line o f parity [ — ] and so are in good 
agreement with the corresponding experimental values, kia  values were 
measured as described in Section 2.4.1 and values for af/a t were measured as 
described in Section 2.4.2 and. Error bars indicate one standard deviation around 
the mean.
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where Fr is the Froude number and a, and b are constants. This alteration 
ensured that both sides of the equation would tend towards zero as the shaking 
speed approached zero. Equation 5.2 was then fitted to each set of specific air- 
liquid surface area measurements (Appendix A) within the three MWP 
geometries. The af / a, values predicted are in excellent agreement with those 
obtained experimentally as illustrated by the open symbols in Figure 5.2 (b).
These specific air-liquid surface area measurements were also used to model the 
variation o f ki with respect to shaking speed in the same manner as Doig et al. 
(2005). This model was combined with Equation 5.2 and the following modified 
correlation for square well plates as used here was obtained:
k ,a  = 3.94 ✓ I (T*.(D/c/, )a ,.R e" '1 .exp(aFrh) (5.3)
The corresponding values for a and b, respectively, were 1.66 and 2.47 for plate 
PI, 0.70 and 1.51 for plate P2, and 0.88 and 1.24 for plate P3. Figure 5.2 (b) also 
illustrates the good agreement between kLa values (solid symbols) predicted from 
Equation 5.3 with those obtained experimentally. Plate P3 is seen to yield the 
highest ^ a  values under the conditions studied. As it also showed the highest 
soluble protein yields (Figure 4.2) during protein expression characterisation, this 
MWP format was chosen for subsequent scale-up studies.
5.3 Measurement and correlation of 7.5 1 STR kLa values
The next stage of the scale-up strategy involved characterising and correlating 
laboratory scale STR faa values over a range of operating conditions. The static- 
gassing out technique was again used to generate DOT profiles, in this case 
within a conventional 7.5 1 STR as described in Section 2.4.3, and a sample of 
the resultant DOT profiles is shown in Figure 5.1 (b). The range o f faa values 
measured from such profiles (Figure 5.3) span a similar range to those obtained 
in the MWP experiments and faa is again observed to increase with increasing 
agitation speed (the raw data from which Figure 5.3 was constructed is given in
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Appendix A). Figure 5.3 also compares the experimental kLa values with those 
determined from the correlations of van’t Riet (1979). For pure water (coalescing 
medium) and strong ionic solutions (non-coalescing medium), respectively:
kLa = 0.026 - ± .0 .5
(5.4)
k ,a  = 0.002
\ v  J (5.5)
PA/QA/.rri2)
Figure 5.3 Comparison of experimental 7.5 1 STR kia values with those 
predicted by van't Riet (1979) (Equations 5.4 and 5.5) for pure water [ — ] and 
strong ionic solutions [ — ] at an air flow rate of 1 vvm. Values for Pg are 
calculated from Equation 5.6. Error bars indicate one standard deviation around 
the mean.
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In both cases Pg in the 7.5 1 STR was estimated according to the correlation 
proposed by Hughmark (1980):
The experimental faa values shown in Figure 5.3 lie mainly within the 
boundaries enclosed by the correlations for pure water and strong ionic solutions. 
This is expected as faa measurements made here were performed in a complex 
nutrient medium (as described in Section 2.2.1), which is of an ionic strength 
intermediate to the phases used by van’t Riet.
Visual observations o f the 7.5 1 STR showed that all faa values above ~ 200 h '1 
were obtained under conditions where there was good gas-liquid distribution 
within the vessel. Under the agitation conditions used at lower kLa values, 
however, there appeared to be poor gas dispersion within the vessel.
5.4 Fermentations at matched kLa values
5.4.1 Selection 0/ k La values and experimental conditions
The next stage of the scale-up process involved performing MWP and 7.5 1 STR 
fermentations at two sets o f kLa values, ‘high’ and ‘low’ so as to provide an 
estimate for the range o f faa values over which successful scale-up could be 
achieved.
Figure 5.4 illustrates the variation o f faa values achieved in relation to shaking / 
agitation speed in both the MWP and the 7.5 1 STR. From this figure, the 
observed range o f common faa values is between 38 h '1 and 247 h '1, 
corresponding to MWP shaking speeds of between 270 and 500 rpm. Figure 5.4
(5.6)
where P = P ox p x  N* x Dt5 (5.7)
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also shows the least squares model fits o f the kia  data with respect to shaking / 
agitation speed. For the MWP and the 7.5 1 STR, respectively, these are:
kLa = 0.00170 n2 - 0.400 n + 21.5 (5.8)
kLa = 0.402 N -  42.6 (5.9)
These models yielded R2 values o f 0.99 and 0.90 respectively, indicating good 
overall explanations of the response variation. The difference in kia  profiles 
observed here (curved versus linear) is most probably due to the increased 
significance o f surface tension effects at the microwell scale (Hermann et al., 
2003).
3 0 0 -
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'.C
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600400 8000 200
Shaking / agitation speed (rpm)
Figure 5.4 Variation of experimental kLa values with shaking speed for plate P3 
[ ■ ] and with agitation speed for 7.5 l STR [ □ ]. The dashed lines represent 
boundaries on the common range o f faa values measured at both scales. The 
solid lines represent least-squares model fits o f the faa data, described by 
Equations 5.8 and 5.9. Error bars indicate one standard deviation around the 
mean.
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Equations 5.8 and 5.9 were then combined and rearranged to obtain a 
relationship between MWP and 7.5 1 STR shaking / agitation speeds at matched 
kLa\
N = 0.00424 n2 - 0.996 n + 160 (5.10)
This equation enabled the prediction o f suitable agitation speeds within the 7.5 1 
STR on fermentation scale-up. Appropriate fermentation conditions were then 
chosen from the optimisation experiments o f Section 4.4 using the following 
criteria. A single shaking speed would be required throughout each fermentation 
in order to minimise the variation in kLa. This shaking speed should correspond 
to a scalable kLa value and should, therefore, be in the range of 270 to 500 rpm. 
The next requirement was for a minimum fill volume of 3ml per well - the same 
volume in which MWP kLa values were determined (Section 2.4.1). The final 
requirement was for a long overall fermentation time so that large comparative 
data sets could be generated. These criteria narrowed down the choice of 
experiments to N36 for the ‘low’ faa control and N32 for the ‘high’ faa control, 
the conditions o f which are described in Table 2.4.
5.4.2 MWP fermentation kinetics
Figure 5.5 illustrates a typical MWP fermentation profile at a ‘high’ faa value of 
247 h '1 and Table 5.1 shows a summary o f kinetic parameters for the same 
fermentation. Exponential growth started at ~ 2 h exhibiting a maximum specific 
growth rate, pmax, of 0.63 h '1. At 7 h, the cells were induced with 500 pM IPTG 
and ~ 30 min later, the dissolved oxygen tension fell to a minimum of 0 %. The 
DOT began to rise again at ~ 10 h which coincided with the end of the growth 
phase. The biomass concentration reached a maximum of -  7.9 g .f1 around 12 h. 
This coincided with the depletion o f glycerol, the main carbon substrate. At the 
same point, the soluble protein yield also appeared to reach a maximum of 3.0 x 
106 RLU.mr1. After this time the level o f expressed FFL fell rapidly suggesting 
utilisation of proteins by E. coli as a more complex source of carbon and energy 
once the glycerol was depleted (Garcia-Arrazola et al., 2005).
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Figure 5.5 MWP (plate P3) fermentation kinetic profiles at high kLa (247 h '1). 
Profiles show biomass concentration [ -b- ], soluble protein yield [ •  ], glycerol 
concentration [ -A -  ] and DOT [ — ]. Arrow indicates time of induction. 
Experiments performed as described in Section 2.5.1.
Table 5.1 Summary of kinetic parameters for fermentations performed at the 
microwell and laboratory scales at matched kia values. Parameters calculated 
from Figures 5.5 to 5.8 inclusive. NA indicates data not obtainable.
Variable Units
kt a  = 247 h' 1 k,a = 55 li"
MWP vs.. 7.5 1 STR MWP vs. 7.5 1 STR
CERmax mmol.r'.h' 1 NA 41 NA 5.4
OURmax mmol.rVh"1 NA 51 NA 5.0
Pmax h- 1 0.63 0.59 0.63 0.49
Vyxmax g-1-1 7.9 7.7 5.4 2.3
[Soluble protein]max RLU.mr1 2.9 x 106 3.2 xlO 6 5.7 xlO 6 2.2 xlO 6
Specific 
[soluble protein]max
RLU.mg' 1 3.8 x 10s 4.2 x 105 1.1 xlO 6 9.8 xlO 5
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MWP experiments were also performed at a ‘low’ faa value of 55 h '1. The 
kinetic response parameters from these fermentations are also described in Table
5.1 and the corresponding response profiles are illustrated in Figure 5.6. In 
comparison to the high kLa experiment, cells were found to be still growing by 
the end of the post-induction period though the DOT profile suggested this was 
under oxygen limited conditions. The maximum biomass concentration measured 
at this time point, 5.4 g .f1, is significantly lower than that obtained from the high 
^ a  experiment. Interestingly, however, the maximum soluble protein 
concentration at the lower faa was almost twice as large at 5.7 x 106 RLU.ml1. 
There was no observed decrease in FFL expression as the cells never reached the 
stationary phase and it is likely there was no depletion of glycerol (data not 
available) as observed within the "high’ kia  experiment. These results reflect a 
trend observed in Chapter 4 (Figure 4.7), where fermentation conditions 
promoting slow growth often produced the highest soluble protein yields.
100 -
8 0 -
6 0 -
4 0 -
2 0 -
0 -I
d_i
-O1'5.
c<D
Iao
-Q
Time (h)
6x10®
5x10®
4x10®
3x10®
2x10*
1x10®
0
25
Figure 5.6 MWP (plate P3) fermentation kinetic profiles at low a (55 h"1). 
Profiles show biomass concentration [ -e- ], soluble protein yield [ •  ] and DOT 
[ ••• ]. Arrow indicates time of induction. Experiments performed as described in 
Section 2.5.1.
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5.4.3 7.51 STR fermentation kinetics
Figure 5.7 shows the fermentation profiles obtained within the 7.5 1 STR, at a 
matched kia  o f 247 h '1. Exponential growth started at -  2 h with a corresponding 
Umax o f 0.59 h '1 (Table 5.1). At 7 h, the cells were induced as in the MWP 
experiment. Approximately 1 h post-induction, the DOT fell to a minimum o f ~ 
20 %, and the CER and OUR reached a maximum of 41 mmol.I'1.h'1 and 51 
mmol.I'1.h'1 respectively. At -12  h there was a sharp change in these profiles, 
coinciding with the depletion o f glycerol. The biomass and soluble protein 
concentrations both reached a maximum at this time of 7.7 g.l'1 and 3.2 x 106 
RLU.ml'1 respectively. The measured rise in pH after this point is consistent with 
protein deamination as a result o f  protein being used as a secondary carbon and 
energy source (Garcia-Arrazola et al., 2005) and could again account for the 
decrease in the expressed levels o f FFL. Further insight may have been gained 
through analysis o f the rates o f biomass accumulation (dX/dt), product 
accumulation (dP/dt) and substrate utilisation (dS/dt). For example, if whilst 
dS/dt=0, a point o f inflection for dX/dt coincided with that for dP/dt, it would 
provide additional evidence that protein was used as a secondary carbon source.
As with the MWP studies experiments were also performed at the 7.5 1 scale at a 
‘low’ matched kva value o f 55 h '1. The kinetic parameters from these 
fermentations are described in Table 5.1 and the corresponding response profiles 
are illustrated in Figure 5.8. The biomass concentration was seen to be still 
increasing by the end o f the post-induction period, in comparison to the high kia 
experiment where the stationary phase had been reached much earlier. The 
maximum biomass and soluble protein concentrations measured at this time 
point, 2.3 g .f1 and 2.2 x 106 RLU.ml'1 respectively, are lower than those obtained 
from the high kia  experiment (Table 5.1). This retarded growth and protein 
expression in the stirred-tank bioreactor is attributed to the poor gas-liquid 
dispersion observed at the low impeller speed. The maximum CER and OUR 
values were also -  10-fold lower than those observed within the ‘high’ kia 
experiment.
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Figure 5.7 7.5 l STR fermentation kinetic profiles at high kia (247 h'1): (a) 
offline data shows biomass concentration [ -b- ], soluble protein yield [ •  ] and 
glycerol concentration [ -A- ]; (b) online data shows DOT [ — ], OUR [ — ], CER 
[ — ] and pH [ — ]. Arrows indicate time of induction. Experiments performed 
as described in Section 2.5.2.
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Figure 5.8 7.5 l STR fermentation kinetic profiles at low kLa (55 h '1): (a) offline 
data shows biomass concentration [ -b - ] and soluble protein yield [ •  ]; (b) 
online data shows DOT [ — ], OUR [ — ], CER[ — ] and pH [ — ]. Arrows 
indicate time of induction. Experiments performed as described in Section 2.5.2.
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5,4.4 Scale comparisons
For operation at a ‘high’ kia  o f 247 h"1, the kinetic parameters summarised in 
Table 5.1 are largely similar between the MWP and 7.5 1 STR scales. In these 
experiments similar final biomass concentrations and maximum yields o f soluble 
protein were obtained. The maximum specific soluble protein yields were also 
very similar and occurred at almost identical time points at both scales o f 
operation. In contrast, experiments at a ‘low’ kia  o f 55 h '1 showed significant 
differences at the MWP and 7.5 1 scales (Table 5.1). There was significant 
variation both in the biomass concentrations achieved and also the biomass 
growth profiles.
Figure 5.9 further illustrates the similarity, or otherwise, o f fermentation profiles 
between the scales for each kia  value. The complete data sets of the variation o f 
biomass concentration, soluble protein yield and glycerol concentration from 
each scale are presented as parity plots for experiments at a kia o f 247 h '1 (Figure 
5.9 (a)) and 55 h '1 (Figure 5.9 (b)). It is evident that data gathered from ‘high’ kia  
fermentations are very similar, with all measurements lying close to the line of 
parity. This is in marked contrast to the data from the ‘low’ kia  fermentations. In 
combination with the summary data in Table 5.1 these results show that at ‘high’ 
kLa values, where there is good gas-liquid distribution at both scales, effective 
scale-up of MWP fermentation results can be achieved at matched kLa values.
For experiments at the ‘high’ kia  value, a rigorous statistical comparison o f the 
fermentation data obtained at both scales was also performed with regard to 
kinetic profiles for cell growth, protein expression and substrate utilisation. 
Appropriate models were fitted to each profile data set (Appendix B) and 
analysed as described in Section 2.5.3. This analysis examines the similarity of 
data sets over the entire course o f cell growth and provides a better indication of 
how well the MWP fermentation results are reproduced at larger scales.
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Figure 5.9 Parity plots comparing fermentation kinetics between MWP (plate 
P3) and 7.5 1 STR for biomass yield [ □ ], soluble protein yield [ •  ] and glycerol 
concentration (x2) [ A ] at &z.a values o f (a) 247 h '1 and (b) 55 h 1. Data taken 
from Figures 5.5 to 5.8 inclusive.
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Table 5.2 lists the p  values resulting from statistical analyses on the effect o f 
scale on profiles o f biomass concentration, soluble protein yield and substrate 
concentration at the MWP and 7.5 1 STR scales. All profiles apart from those o f 
glycerol were statistically similar at a significance level o f 0.05 indicating an 
excellent agreement between all growth and protein expression. Although the 
glycerol utilisation kinetics were not found to be significantly similar at this 
level, the overall fermentation profiles shown in Figures 5.5 and 5.7 do show the 
complete utilisation o f glycerol occurring at the same time point and coinciding 
with the maxima for cell growth.
Table 5.2 Comparison o f microwell fermentation kinetic profiles (Figure 5.5) to 
those from the laboratory scale fermentation (Figure 5.7) at matched kLa 
conditions (247 h 1). P  values shown are from F  tests on pairs of profiles for 
biomass concentration, soluble protein yield and substrate concentration as 
described in Section 5.4.4. The null hypothesis, which states that there is no 
overall difference between each pair o f profiles, is accepted if p > 0.05.
Kinetic profile
P  values
Plate P3 vs. 7.5 1 STR
Biomass growth 0.56
Glycerol utilisation 1.63 x 10"4
Soluble protein expression 0.08
5.5 Summary
The aim o f this chapter was to design an effective scale-up strategy for rapidly 
translating MWP fermentation performance to larger scales. In Chapter 4, 
shaking speed was identified as one o f the most significant factors affecting 
recombinant protein expression in E. coli MWP formats. Shaking speed is 
known to affect oxygen transfer (Hermann et al., 2003), thus kia  was assumed to 
be an important scale-up parameter.
130
5. Scale-up o f  M W P ferm entation perform ance to 7.5 1 STR scale Islam 2007
Consequently, in this chapter, MWP faa values were determined over a range of 
shaking speeds via the static gassing-out technique (Figure 5.2) and the results 
were used to establish a predictive correlation applicable to the square-well 
MWP formats used here (Equation 5.3). A similar range o f faa values was 
obtained within the 7.5 1 STR, using the same faa measurement technique, and 
these values also compared well to those predicted by existing correlations 
(Figure 5.4).
Fermentations were then performed at ‘high’ and ‘low’ matched kLa values. For 
scale-up at a ‘high’ matched faa  value o f 247 h '1, MWP fermentation kinetic 
profiles and yields were accurately reproduced at the larger scale o f operation, 
equivalent to a 1,700 fold scale-up. These results are significant for several 
reasons. Firstly, they confirm the initial scale-up hypothesis which proposed that 
^ a  was an important scale-up parameter. This hypothesis emerged in Chapter 4 
following the application o f Design o f Experiments (DoE) and so these results 
also provide further support for the use o f DoE as a bioprocess development tool. 
Finally, these results also confirmed a number o f recent studies which have 
suggested faa to be an important scale-up parameter for aerobic fermentations 
(Ferreira-Torres et al., 2005; Micheletti et al., 2006).
Scale-up of MWP fermentations at a ‘low’ matched faa value, in contrast, did not 
provide reproducible performance at the 7.5 1 scale. This difference was 
attributed to the poor gas-liquid distributions observed within the larger vessel at 
the agitation speed used to provide this ‘low’ kua value. Overall, a scale-up 
strategy based on relatively high matched faa values should be applicable to 
larger scales o f fermentation. Further scale-up of MWP results to the 75 1 scale 
using faa as a basis for scale-up is addressed in the next chapter.
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6 Scale-up of protein expression to 751 STR scalet
6.1 Aims and objectives
The final stage o f the proposed framework (Section 3.3.3) is to develop a scale- 
up strategy for translating MWP fermentation performance to a pilot scale STR. 
In Chapter 5, key fermentation kinetics such as those for cell growth and soluble 
protein yield were scaled up successfully on the basis of relatively high matched 
t o  values, i.e. t o  values corresponding to good gas-liquid distributions within 
the vessels.
The aim o f this chapter, therefore, is to further develop this scale-up strategy for 
application at the pilot scale o f operation where larger quantities o f protein can 
be generated. The specific objectives o f this chapter are:
• to measure the variation o f t o  within a pilot scale (75 1) STR over a 
range o f operating conditions and compare to values measured at the 7.5 1 
STR and MWP scales (Section 6.2);
• to validate the 75 1 t o  measurements through comparisons to existing 
correlations (Section 6.2);
• to determine if  equivalent fermentation performance can be obtained 
between the MWP and 75 1 STR scales on the basis o f ‘high’ matched t o  
values (Section 6.3).
6.2 Measurement and correlation of 751 STR  kLa  values
6.2.1 Measurement o f kLa values
As described in Section 5.3 it was necessary to first measure and then correlate 
t o  values within the stirred-tank reactor over a range o f operating conditions. 
The static-gassing out technique applied in Chapter 5 was again used to generate
^ h e  majority o f the results presented in this chapter have been submitted for publication as: 
Islam,R.S., Tisi,D., Levy,M.S., and Lye,G.J. (2007) Scale-up o f E. coli growth and recombinant 
protein expression conditions from microwell to laboratory and pilot scale based on matched kLa. 
Biotechnology and Bioengineering. In press. doi:10.1002/bit.21697
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dissolved oxygen tension (DOT) profiles, in this case within a conventional 75 1 
STR as described in Section 2.4.3, and a sample o f the resultant DOT profiles is 
shown in Figure 6.1. The range o f faa values measured from such profiles 
(Figure 6.2) spans a similar range to those obtained in the MWP and 7.5 1 STR 
experiments (Chapter 5) and kLa is again observed to increase with increasing 
agitation speed (the raw data from which Figure 6.2 was constructed is given in 
Appendix A). In Figure 6.2 the faa  values determined at the 75 1 scale are also 
compared to those obtained from the correlations o f van't Riet (1979) for pure 
water (Equation 5.4) and strong ionic solutions (Equation 5.5). In both cases Pg 
in the 75 1 STR was estimated according to the correlation proposed by 
Hughmark (1980) (Equation 5.6).
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Figure 6.1 Example DOT profiles obtained across the full range o f agitation 
speeds within the 75 1 STR. Experiments were performed as described in Section
2.4.3. A logarithmic transformation o f time is displayed on the x-axes such that 
the full range o f profiles for each bioreactor may be easily distinguished in one 
figure.
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Figure 6.2 Comparison o f experimental 75 1 STR kLa values with those predicted 
by van't Riet (1979) (Equations 5.4 and 5.5) for pure water [ ••• ] and strong ionic 
solutions [ — ] at an air flow rate o f 1 vvm. Values for Pg are calculated from 
Equation 5.6. Error bars indicate one standard deviation around the mean.
The experimental kLa values shown in Figure 6.2 lie mainly within the 
boundaries enclosed by the correlations for pure water and strong ionic solutions, 
similar to the trend observed within the 7.5 1 STR (Chapter 5). They are also o f a 
similar magnitude to kia  values determined at the 7.5 1 scale since measurements 
were performed at similar P /V  values. Visual observations of the 7.5 1 STR 
showed that all faa values below ~ 200 h '1 corresponded to poor gas dispersion 
throughout the vessel. Visual observations o f gas-liquid mixing within the 75 1 
STR, however, were not possible due to the stainless steel construction o f the 
vessel.
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6.2.2 Comparison o f kia values with other scales
Figure 6.3 compares the variation o f kLa values achieved in the 75 1 STR, in 
relation to agitation speed, with those achieved in the MWP and 7.5 1 STR 
(Chapter 5). The maximum faa value measured in the 75 1 STR (396 h '1) is 
significantly higher than those measured in the MWP and 7.5 1 STR (247 h 1 and 
279 h '1, respectively). From this figure, the observed range of common MWP / 
75 1 STR Hlo values is between 50 h '1 and 247 h 1, corresponding to MWP 
shaking speeds o f between 290 and 500 rpm.
400-
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Figure 6.3 Variation o f experimental faa values with shaking speed for plate P3 
[ ■ ] and with agitation speed for 7.5 1 STR [ □ ] and 75 1 STR [ A ]. The dashed 
lines represent boundaries on the common range o f faa values measured at both 
the MWP and 75 1 STR scales. The solid lines represent least-squares model fits 
o f the kia  data, described by Equations 5.8, 5.9 and 6.1. Error bars indicate one 
standard deviation around the mean.
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Figure 6.3 also shows the least squares model fits o f the kya data with respect to 
shaking / agitation speed. For the 75 1 STR this is:
The R2 value for this model was 0.99, indicating a good overall explanation o f 
the response variation.
Equation 6.1 was then combined with the corresponding MWP equation 
(Equation 5.8) and rearranged to obtain a relationship between MWP and 75 1 
STR shaking / agitation speeds at matched kLa\
This equation enabled the prediction o f suitable agitation speeds within the 75 1 
STR on fermentation scale-up.
6.3 Fermentations at matched kLa values
6.3.1 Selection tf/kLa values and experimental conditions
The next stage o f the scale-up process involved performing fermentations at both 
the MWP and 75 1 STR scales. In Chapter 5, key fermentation kinetics such as 
those for cell growth, soluble protein yield and substrate utilisation were scaled 
up successfully on the basis o f relatively high matched kLa values, i.e. faa values 
corresponding to good gas-liquid distributions within the vessels. To determine if 
this strategy also applied at the pilot scale o f operation, the ‘high’ kLa (247 h '1) 
MWP fermentation conditions from Chapter 5 would again be scaled up on the 
basis o f matched faa. This fermentation was identical to experiment N32 from 
the optimisation experiments o f Section 4.4 and the specific fermentation settings 
for this experiment are described in Table 2.4.
^ a  -  0.505 N -  78.7 (6.1)
N = 0.00337 n2 - 0.792 n + 198 (6.2)
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6.3.2 MWP fermentation kinetics
Initial experiments showed that fermentations within the MWP produced lower 
final biomass concentrations than those in the corresponding 75 1 STR 
fermentations (data not shown). This was attributed to differences in the method 
o f medium sterilisation between the two vessels, as described in Section 2.4, and 
the different temperature-time profiles achieved. Consequently, when performing 
MWP and 75 1 fermentations at a matched foa o f 247 h"1, the 75 1 vessel was first 
inoculated and then a sample o f the inoculated medium was rapidly removed and 
used to fill the wells in the parallel MWP fermentations as described in Section 
2.5.
Figure 6.4 illustrates a typical MWP fermentation profile at the ‘high’ foa value 
o f 247 h 1 and Table 6.1 shows a summary o f kinetic parameters measured for 
the same fermentation. Exponential growth started at ~ 2 h exhibiting a 
maximum specific growth rate, pmax, o f 0.66 h '1. At 7 h, the cells were induced 
with 500 pM IPTG and this coincided with the end of the exponential growth 
phase. At around 12 h, the biomass and soluble protein concentrations reached a 
maximum of ~ 5.4 g.l'1 and ~ 6.4 x 106 RLU.m l1 respectively, coinciding with 
the depletion o f glycerol. After this time the level o f expressed FFL fell rapidly 
suggesting utilisation o f proteins by E. coli as a more complex source o f carbon 
and energy once the glycerol was depleted as was seen previously at the MWP 
and 7.5 1 scales (Section 5.4).
6.3.3 751 STR fermentation kinetics
Figure 6.5 shows the fermentation profiles obtained within the 7.5 1 STR, at a 
matched kLa o f 247 h"1. Exponential growth started at ~ 2 h with a corresponding 
Pmax o f ~ 0.62 h*1 (Table 6.1) and the cells were induced at 7 h in the same way 
as for the MWP experiment and. Approximately 45 min post-induction, the DOT 
fell to a minimum o f ~ 27 %, and the CER and OUR reached a maximum of 48 
mm ol.I1.h"1 and 50 mmol.I'1.h'1 respectively. At 12 h the biomass and soluble
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protein concentrations reached a maximum of ~ 5.3 g.l'1 and ~ 6.4 x 106 RLU.ml' 
\  respectively, which again coincided with the depletion o f glycerol.
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Figure 6.4 MWP (plate P3) fermentation kinetic profiles at high faa (247 h '1). 
Profiles show biomass concentration [ - b-  ], soluble protein yield [ •  ] and 
glycerol concentration [ -A- ]. Arrow indicates time o f induction. Experiments 
performed as described in Section 2.5.1.
Table 6.1 Summary o f kinetic parameters for fermentations performed at the 
microwell and pilot scales at matched faa values. Parameters calculated from 
Figures 6.4 and 6.5. NA indicates data not obtainable.
Variable Units
kLa  = 247 h'
MWP vs. 75 1 STR
CERmax mmol.r'.h ' 1 NA 48
OURmax mmol.rVh' 1 NA 50
Pm ax h' 1 0 . 6 6 0.62
^max g-1 '1 5.4 5.3
[Soluble protein]max RLU.ml1 6.4 x 106 6.4 x 106
Specific [soluble protein]max RLU.mg' 1 1 . 2  x 1 0 6 1.5 x 106
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Figure 6.5 75 l STR fermentation kinetic profiles at high kLa (247 h '1): (a) offline 
data shows biomass concentration [ -b- ], soluble protein yield [ •  ] and glycerol 
concentration [ -A- ]; (b) online data shows DOT [ — ], OUR [ — ], CER[ — ] and 
pH [ — ]. Arrows indicate time of induction. Experiments performed as 
described in Section 2.5.2.
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6.3.4 Scale comparisons
For operation at the ‘high’ kLa of 247 h '1, the kinetic parameters summarised in 
Table 6.1 are largely similar between the MWP to 75 1 scales. In these 
experiments similar final biomass concentrations and maximum yields of soluble 
protein were obtained. The maximum specific soluble protein yields were also 
very similar and occurred at almost identical time points at both scales of 
operation.
Figure 6.6 further illustrates the similarity of fermentation profiles between each 
scale of operation at the ‘high’ kLa value of 247 h '1. It is evident that data 
gathered from these fermentations are very similar, with all measurements lying 
close to the line of parity. In combination with the summary data in Table 6.1 
these results show that effective scale-up of MWP fermentation results can be 
achieved at matched kia values.
As performed in Section 5.4.4, a rigorous statistical comparison of the 
fermentation data obtained at both scales was performed with regard to kinetic 
profiles for cell growth, protein expression and substrate utilisation. Appropriate 
models were fitted to each profile data set and analysed as described in Section
2.5.3. A summary of these model fits is given in Appendix B. Table 6.2 lists the 
p  values resulting from statistical analyses on the effect of scale on profiles of 
biomass concentration, soluble protein yield and substrate concentration. All 
profiles were statistically similar at a significance level of 0.05 indicating an 
excellent agreement between growth, substrate utilisation and protein expression.
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Figure 6.6 Parity plot comparing fermentation kinetics at ‘high’ kia  value of 247 
h '1 between MWP (plate P3) and 75 1 STR for biomass yield [ □ ], soluble protein 
yield [ •  ] and glycerol concentration (x2) [ A ]. Data taken from Figures 6.4 and 
6.5.
Table 6.2 Comparison o f microwell fermentation kinetic profiles (Figure 6.4) to 
those from the pilot plant scale fermentation (Figure 6.5) at matched kia  
conditions (247 h '1). P values shown are from F  tests on pairs of profiles for 
biomass concentration, soluble protein yield and substrate concentration as 
described in Section 6.3.4. The null hypothesis, which states that there is no 
overall difference between each pair o f profiles, is accepted if p > 0.05.
Kinetic profile
P values
Plate P3 vs. 75 1 STR
Biomass growth 0.26
Glycerol utilisation 0.06
Soluble protein expression 0.80
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6.4 Summary
In Chapter 5, a scale-up strategy was developed which enabled the reproduction 
of MWP fermentation performance within a laboratory scale STR on the basis of 
relatively high matched faa values. The aim of this chapter was to further 
develop this strategy for application at the pilot scale of operation. Consequently, 
kLa values within a conventional 75 1 STR were first rapidly quantified over a 
range of agitation speeds via the static gassing out technique and these values 
compared well to those predicted by existing correlations (Figure 6.2). This 
measurement technique was identical to those used at the MWP and laboratory 
scales and so the results were directly comparable. All three scales shared a wide 
range of common kLa values (50 h '1 to 247 h '1), but overall significantly higher 
^ a  values were achievable within the 75 1 STR (Figure 6.3).
In Section 3.3.3 several factors were identified which could lead to variations in 
fermentation performance between the MWP and pilot scales. To minimise 
variation all media components were sourced from the same manufacturer and 
the method of inoculum preparation was preserved on scale-up. Initial 
experiments, however, still showed a difference in fermentation performance 
between the MWP and 75 1 scales. This was attributed to differences in the 
method of medium sterilisation between the two vessels, as described in Section 
2.4, and hence the different temperature-time profiles achieved. The scale-up 
strategy was thus modified by using media sterilised in the 75 1 STR for 
subsequent fermentations at both scales.
MWP fermentations at a ‘high’ faa value of 247 h '1 (Figure 6.4) were then 
scaled-up to the 75 1 STR (Figure 6.5) on the basis of matched faa and kinetic 
profiles and yields were accurately reproduced (Figure 6.6). No studies have 
previously demonstrated the reproduction of MWP fermentation profiles to this 
scale, equivalent to a 15,000 fold scale-up, and this result provides final 
indication of the efficacy of the scale-up strategy developed here. In so doing, the 
work covered in this chapter completes the proposed framework for 
underpinning the generation of large quantities of soluble protein in a rapid and
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cost-effective manner. The validation of this approach and its application in 
bioprocess development are covered further in the next two chapters.
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7 Management benefits of the proposed framework
7.1 Aims and objectives
This thesis has addressed the major challenge o f rapidly generating sufficient 
quantities of soluble recombinant protein for analysis during drug discovery. The 
design of the proposed framework (Chapter 3) was optimised towards this goal 
and, therefore, offers time and cost savings over alternative approaches.
The aim of this chapter is to provide a thorough and quantitative analysis o f these 
management benefits over both stages of the proposed framework: the rapid 
optimisation of protein expression (Section 7.2) and the rapid scale-up o f 
fermentation and generation of protein samples (Section 7.3).
7.2 Protein expression optimisation
7.2.1 Background and general assumptions
Relatively few published studies exist regarding the optimisation o f protein 
expression within drug discovery and this suggests that it may be an uncommon 
industrial activity. This is most probably due to the shortcomings o f the 
traditional characterisation approaches. High-throughput expression screening 
(HTES), for example, is resource intensive and the one-factor-at-a-time (OFAT) 
approach is unable to model complex systems reliably (Section 1.3.1). Thus there 
are no published benchmarks against which the time and cost savings o f the 
present work can be evaluated and it is, therefore, necessary to develop 
hypothetical alternatives.
Within the current framework, the DoE and MWP experimentation components 
were key to the rapid optimisation of protein expression. Reasonable 
hypothetical alternatives may, therefore, include approaches which lack one or 
the other of these components. In the following sections, three cost scenarios are
^ h e  inclusion o f this chapter relates to the University o f London EngD requirement for 
consideration o f the bioprocess management implications o f the research work performed.
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presented: (1) the current framework, (2) the current framework minus the MWP 
experimentation component, and (3) the current framework minus the DoE 
component which is akin to the HTES approach. The costs associated with each 
scenario have been separated into four categories: inoculum preparation, 
fermentation, assay and labour. A complete breakdown o f costs is provided in 
Section C.5. The general assumptions for all three scenarios are:
• Material costs (Section C. 1) are limited to:
o the cost o f media (including antibiotic and inducer); 
o the cost o f disposable MWPs; 
o the cost o f luciferase assay buffer components;
• Labour costs are proportional to minimum fermentation time (Section 
C.2) which assumes:
o 24 h experimentation and instant turnaround; 
o inoculum preparation and assays are performed in parallel with 
fermentations; 
o the availability o f one technician payable at £ 10.h'1;
• Rate of fermentation limited to 72 microwells or 24 shake-flasks (SFs) in 
parallel assuming:
o a maximum sampling time of three minutes; 
o a maximum sampling rate of 24 microwells or 8 SFs per minute 
per technician;
• All other costs including utilities, labware and equipment maintenance 
are negligible;
• All fermentations are performed in quadruplicate;
7.2.2 Scenario 1: current framework
In this scenario, both the DoE and MWP framework components are applied and 
a cost analysis for this scenario is provided in Table 7.1.
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Table 7.1 Cost analysis summary for Scenario 1: current framework. These costs 
have been summarised from the more detailed analysis o f Section C.5.2.
Cost category Cost (£)
Inoculum preparation 94
Fermentation 261
Assay 252
Labour 2,750
Total 3,357
7.2.3 Scenario 2: current framework minus the MWP component
In this scenario, the DoE component is implemented but the MWP component is 
replaced by shake-flask (SF) experimentation and the costs associated with this 
change are estimated. Here it is assumed that SFs are processed at a slower rate 
than microwells (24 SFs versus 72 micro wells) for the following reasons. Each 
set of four replicate MWP fermentations were situated on the same MWP, 
covered with a single gas-permeable membrane. By comparison, four separate 
SFs were required to process the same set o f experiments, each o f which was 
covered with cotton wool and aluminium foil. In combination, these differences 
would result in longer processing times. A cost analysis for this scenario is 
provided in Table 7.2.
Table 7.2 Cost analysis summary for Scenario 2: current framework minus the 
MWP component. These costs have been summarised from the more detailed 
analysis o f Section C.5.3.
Cost category Cost (£)
Inoculum preparation 94
Fermentation 637
Assay 252
Labour 4,260
Total 5,243
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7.2.4 Scenario 3: current framework minus the DoE component
In this scenario, the MWP experimentation component is applied but the DoE 
component is removed and the costs associated with this change are estimated. 
Here, there are no statistical tools available to enable the selection o f a 
representative subset of experiments, and so all experimental combinations need 
to be performed in order to locate with confidence the optimum experimental 
region. A cost analysis for this scenario is provided in Table 7.3.
Table 7.3 Cost analysis summary for Scenario 3: current framework minus the 
DoE component. These costs have been summarised from the more detailed 
analysis o f Section C.5.4.
Cost category Cost (£)
Inoculum preparation 1,987
Fermentation 62,222
Assay 135,266
Labour 984,150
Total 1,183,625
7.2.5 Scenario comparison
Table 7.4 displays a summary o f the costs associated with each scenario 
presented in the previous sections. Scenario one which represents the current 
framework is clearly the cheapest approach, in terms of both materials and 
labour, with an overall cost o f £3,357. It is interesting to note here that the total 
cost o f disposable MWPs (£256) contributes to over 98 % of the fermentation 
cost (Table C.9).
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Table 7.4 Summary o f costs for each expression optimisation scenario. Details 
of each scenario are described in Sections 7.2.2 through 7.2.4 inclusive.
Associated costs
Cost Scenario Materials (£) Labour(£) Total (£)
1 Current framework (CF) 607 2,750 3,357
2 CF - MWP 983 4,260 5,243
3 CF - DoE 199,474 984,150 1,183,624
The overall cost associated with scenario two, in which the MWPs have been 
replaced with traditional SF fermentations, is approximately one and a half times 
larger at £5,243. This increased cost is mainly attributed to the increased labour 
requirements due to the lower processing rate of SFs vs microwells. Moreover, 
although the media requirements o f scenario two are much greater than for 
scenario one, the media savings in scenario one are largely offset by the 
relatively high costs o f MWPs (Table C.4). Furthermore, the costs of purchasing 
and cleaning the reusable SFs were ignored in scenario two in order to simplify 
calculations which, otherwise, would have increased the overall costs of scenario 
two.
Scenario three, a partial representation of the conventional HTES approach, has 
the largest overall cost by far, which at £1,183,624 is over 350 times higher than 
that of scenario one. In reality, this approach would not be attempted as the 
experimental workload is simply too high.
The purpose of including this scenario was to emphasise the importance of DoE. 
In scenario one, where DoE was used, only 110 experiments were performed 
(Section 4.6). In scenario three by contrast, approximately 60,000 experiments 
would be required (Section C.5.4) to obtain a similar level o f  process 
characterisation. This assumes that the optimal region lies within the 
experimental window; if not, the experiments would have to be repeated under 
new factor settings. It would also be difficult to analyse the results without using 
basic statistical tools, in which case, they could have been employed from the 
start in the form of DoE.
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Overall the costs involved in protein characterisation are minimised when the 
current framework is applied. Interestingly, the major costs involved in this stage 
of the framework are attributed to the labour requirements and hence the overall 
experimental timeframes. By comparing the labour costs o f scenarios two and 
three, it is possible to conclude that the application o f DoE results in far greater 
time savings than that of MWP experimentation. In the following section, the 
long-term effect of these time savings on the profitability o f a new drug is 
investigated.
7.3 Generation of protein samples
7.3.1 Background and general assumptions
Unlike protein expression optimisation, the generation of sufficient quantities of 
protein for drug discovery is a common and indeed essential activity within 
industry. It presents a major bottleneck within drug-discovery (Stewart et al., 
2002) which, consequently, impacts negatively on the time to market for a new 
drug. Aside from the obvious human costs, the delayed launch of an important 
new drug can cost a company on average between $1 million (Kerns, 2001; 
Martin, 2002) and $15 million (Nofifke, 2007) per drug, per day.
In the following exercise, the speed of protein generation is estimated for two 
different scenarios and the potential difference in sales revenue is calculated. The 
first scenario represents the current framework which consists o f DoE/MWP 
protein expression optimisation followed by optimised fermentations within a 
laboratory scale (7.5 1) stirred-tank reactor (STR). The second scenario consists 
of parallel shake-flask fermentations at a single set of conditions, which presents 
perhaps the most common method of protein generation within drug-discovery 
(Kumar et al., 2004). This exercise includes no estimation of materials and 
labour costs, as they are assumed to be insignificant in comparison to the daily 
sales revenue of a new drug. The general assumptions for both scenarios are:
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• 24 h experimentation with instant turnaround;
• Rate o f experimentation limited only by equipment availability (same as 
that o f Astex Therapeutics Ltd.):
o one HiGro incubator shaker;
o three SF incubator shakers, each capable o f housing eight 2 1 SFs 
(working volume = 0.5 1); 
o four STRs (working volume = 5 1); 
o Protein sample requirements as in Table 7.5;
Table 7.5 Typical protein sample requirements o f drug discovery. Each stage of 
drug discovery aims to reduce the number o f investigated protein constructs by 
identifying those which demonstrate several key properties. These include 
functional activity and ease o f protein expression, purification and 
characterisation. Protein requirements may differ widely between different drugs 
and different drug discovery companies; the requirements shown here are 
representative of the operating ranges o f Astex Therapeutics Ltd.
Drug discovery stage
Number o f protein 
constructs
Mass of protein 
required per construct 
(mg)
Min. Max. Min. Max.
1 Pre-screening (protein 
expression) 10 20 5 10
2 Pre-screening 
(purification + 
characterisation)
4 6 10 50
3 Screening, hits-to-leads 
and lead optimisation 1 1 1000 2000
7.3.2 Scenario 1: current framework
In this scenario, the protein constructs examined at each stage of drug discovery 
first undergo DoE/MWP protein expression optimisation studies as in Chapter 4. 
Protein samples of each construct are then generated at the STR scale under the 
optimised conditions as in Chapter 5. Key assumptions are:
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• DoE/MWP protein expression optimisation studies for all protein 
constructs are carried out in parallel;
• Minimum fermentation time for protein expression optimisation is same 
as that for the current framework, i.e. 275 h ~ 11 days (Table C.9);
• Optimised protein expression levels are reproduced within the STR;
• Range of optimised soluble protein expression levels is same as that 
typically obtained at Astex Therapeutics Ltd.: 1-5 mg.l'1;
• STR fermentation time is same as the optimised fermentation time o f the 
current framework, i.e. = 22 h (Section 4.5).
A sample calculation o f the total fermentation time required by this scenario at a 
single set of conditions is provided in Table 7.6. This calculation was then 
repeated for the complete range o f protein sample requirements (Table 7.5) and 
the resulting time window is illustrated in Figure 7.1 as a function of the mean 
soluble protein yield obtained in the STR (1-5 mg.l'1). The general trend 
observed here is that the total fermentation time required decreases with 
increasing optimised soluble protein expression levels.
Table 7.6 Sample calculation for scenario one: current framework. Calculations 
based on average protein sample requirements (Table 7.5) and a mean soluble 
protein yield of 3 mg.l'1.
Protein requirement Number o f STR runs 
per construct (mg) required per construct
Number of 
constructs
Sub-total number of  
STR runs required
1 7.5 1 15 15
2 30 2 5 10
3 1500 100 1 100
Total number of STR runs required 125
Minimum number of STR batches required 32
Minimum MWP fermentation time (days) 11
Minimum STR fermentation time (days) 29
Total fermentation time (days) 41
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350
3  150
Mean soluble protein yield in STR (mg.l'1)
Figure 7.1 Fermentation time window for the current framework (DoE / MWP 
experimentation) over the full range of protein sample requirements (Table 7.5).
7.3.3 Scenario 2: traditional SFfermentation approach
In this scenario, there are no protein expression optimisation studies. Protein 
samples of each construct are generated immediately through SF fermentations at 
a single set of experimental conditions. Key assumptions are:
• SF fermentation time is the same as that used in the reference SF 
experiments (6 h 40 min) as described in Section 2.3.5;
• Ratio of optimised MWP protein yield to SF protein yield is the same as 
that obtained experimentally (Section 4.5), approximately 6:1, i.e. SF 
soluble protein yield range assumed to be: 0.17-0.83 mg.l'1.
A sample calculation of the total fermentation time required by this scenario at a 
single set of conditions is provided in Table 7.7. This calculation was then 
repeated for the complete range of protein sample requirements (Table 7.5) and
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the resulting time window is illustrated in Figure 7.2 as a function of the mean 
soluble protein yield obtained in the SF (0.17-0.83 mg.l'1). Again, the general 
trend observed here is that the total fermentation time required decreases with 
increasing soluble protein expression levels.
Table 7.7 Sample calculation for scenario two: traditional SF fermentation 
approach. Calculations based on average protein sample requirements (Table 7.5) 
and a mean soluble protein yield of 0.5 mg.l'1.
Protein requirement 
Stage . . ,per construct (mg)
Number of SF runs 
required per construct
Number of 
constructs
Sub-total number of 
SF runs required
1 7.5 30 15 450
2 30 120 5 600
3 1500 6000 1 6000
Total number of SF runs required 7050
Total number of SF batches required 294
Total fermentation time (days) 82
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Figure 7.2 Fermentation time window for the traditional SF fermentation 
framework over the full range o f protein sample requirements (Table 7.5).
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7.3.4 Scenario comparison
Direct comparison o f Figures 7.1 and 7.2 illustrates that the total fermentation 
time of the current framework is generally less than that o f the traditional SF 
framework, over the entire range o f conditions tested (Table 7.5). The total 
fermentation time o f the current framework is also less sensitive to decreasing 
protein yields. This implies that the current framework would provide the largest 
time savings when applied to proteins which express poorly.
Figure 7.3 illustrates the overall cost savings provided by the current framework 
relative to the traditional SF framework, in terms o f increased drug sales revenue. 
Overall, the time savings provided by the current framework create the potential 
for significantly increased sales revenues.
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Figure 7.3 Increased drug sales revenue window o f the current framework in 
comparison to the traditional SF framework over the full range o f protein sample 
requirements (Table 7.5), assuming average daily sales o f $1 million per drug, 
per day. The results displayed in this figure are calculated by subtracting the 
boundary results illustrated in Figure 7.1 from those displayed in Figure 7.2.
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7.4 Summary
The aim of this chapter was to provide a thorough and quantitative analysis o f the 
time and cost savings provided by the current framework over traditional 
alternatives. In Section 7.2 the main costs of protein expression optimisation 
were attributed to labour costs. The DoE component of the current framework 
was then identified as a key factor in significantly reducing overall experimental 
timeframes and hence labour costs. In Section 7.3 these time savings were also 
seen to apply to the larger scale generation of protein samples for drug discovery 
research. Within this context, the current framework creates the potential for 
significantly increased drug sales revenues by accelerating drug discovery. These 
benefits would be especially large when the target protein expresses poorly. In 
the following chapter, further potential benefits of the current framework, 
including the application towards manufacturing scale fermentation and 
bioprocess validation, are explored.
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8 Development of the proposed framework to facilitate 
bioprocess validation1^
8.1 Aims and objectives
Although the framework presented in this thesis has been optimised for 
application within drug discovery, it also provides a foundation for generating 
much larger quantities o f protein. The key challenge here would be to maintain a 
fine degree of process control at the larger scales of fermentation and so the 
current framework would have to be developed towards achieving greater 
process understanding.
Moreover, the products o f large scale fermentations are often used in 
pharmaceutical drugs where product quality is of paramount importance. The 
regulatory authorities would thus require documented evidence (bioprocess 
validation) of a well-defined manufacturing process which performs consistently 
within predetermined specifications (U.S. Food and Drug Administration, 1987). 
A thorough characterisation o f the fermentation process during the early 
development stages would, therefore, greatly facilitate in the subsequent and 
mandatory validation process.
The aim of this chapter is to explore how the current framework may be 
developed towards this goal. The development approach is structured using a 
process improvement tool called Six Sigma and applied to a hypothetical 
scenario in which the MWP fermentation process described in Chapter 4 is to be 
scaled-up for manufacture o f a therapeutic protein.
fThe inclusion o f this chapter relates to the University o f London EngD requirement for 
consideration o f the bioprocess validation implications o f the research work performed.
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8.2 Bioprocess development through Six Sigma (DMAIC)
8.2.1 Introduction
Six Sigma is a disciplined, data-driven methodology for reducing the number of 
defects in any process to 3.4 defects per million opportunities (DPMO) (Brue, 
2002). A Six Sigma defect may be defined as any process output which lies 
outside of specifications.
Six Sigma has two key methodologies: DFSS and DMAIC. DFSS is an acronym 
for “Design For Six Sigma” and it is used to create new process designs. DMAIC 
is an acronym for “Define, Measure, Analyze, Improve and Control” and this 
methodology should be used when an existing product or process is not 
performing adequately. The flow o f a typical DMAIC project is illustrated in 
Figure 8.1. The following section explores how the existing fermentation process 
may be developed, using the DMAIC methodology as a guide.
i------------------------------------------    1
i i
Define —► Measure —► Analyse —► Improve —► Control
Figure 8.1 Typical flow o f a DMAIC project (Creveling, 2006). In practice, 
there may be significant overlap between each phase and an iterative approach to 
Six Sigma (indicated by the dashed line) may be required (Hayler and Nichols, 
2005).
8.2.2 Definition phase
The purpose of this phase is to introduce the overall problem and define the 
project goals. As already mentioned in Section 8.1, a hypothetical scenario is 
presented in which the MWP fermentation process described in Chapter 4 is to 
be scaled-up for manufacture of a therapeutic protein. An appropriate strategic 
goal would thus be to achieve greater control of the MWP fermentation process
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in order to facilitate the subsequent scale-up and validation o f the process. 
Corresponding process and project goals are proposed in Table 8.1.
The overall scope o f the project is limited to the development o f the MWP 
fermentations and the upstream inoculum shake-flask (SF) fermentations (Figure 
8.2). All analytical methods and all processes upstream of the inoculum 
preparation are assumed to be already developed / validated.
Table 8.1 Statement of goals at the strategic, process and project levels.
Strategic goal Process goals Project goals
• Increased • Identification o f more
characterisation responses
To achieve greater • Increased • All response
control of the reproducibility measurements lie within
MWP fermentation and predictivity 2% of predicted levels
process in order to and/or optimisation Q2
facilitate the for all fermentation
subsequent scale- response measurements
up and validation 
of the process.
>0.9
• Increased • Robustness Q2 for all
robustness fermentation response 
measurements < 0.1
8.2.3 Measurement phase
The goal of this phase is to measure the current performance of the process 
which consists here o f the inoculum SF and MWP fermentations. Key process 
responses should be identified (Table 8.2) and subsequently measured over an 
appropriate set of characterisation experiments. In order to obtain the relevant Q2 
values (Table 8.1), these experiments should be organised through DoE. The 
standard methods and conditions for inoculum preparation (Section 2.2.3) and 
those optimised for MWP fermentations (Chapter 4) would serve as references 
here. It should then be possible to define a process defect and calculate the 
DPMO of the current process.
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Inoculum SF 
fermentations
MWP
fermentations
Figure 8.2 Process map illustrating the overall scope of the Six Sigma project, 
complete with the flow o f process steps, factors and responses. The green arrows 
represent responses and the red and blue arrows represent controlled and 
uncontrolled factors, respectively; response measurements from the inoculum SF 
fermentation will serve as uncontrolled factors in the MWP fermentation step.
Table 8.2 List of key responses which may be used to measure process 
performance.
Biological responses Engineering responses
• biomass growth
• cell viability • ktci
• soluble protein yield • power per unit volume
• metabolite consumption • mixing / circulation time
• pH, DOT
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8.2.4 Analysis phase
At this stage o f the Six Sigma process, the gaps between current performance and 
project goal performance are quantified, and potential root causes of 
underperformance are identified. Various tools, such as the Ishikawa diagram 
(Brue, 2002; Creveling, 2006; Hayler and Nichols, 2005) are available at this 
stage to aid in root cause identification. Sources of variation to which future 
inoculum SF experiments may be susceptible are described in Table 8.3. Tables
8.4 and 8.5 list root causes for the variation / underperformance already observed 
from the MWP experiments and DOE analysis (Chapter 4), respectively.
Table 8.3 List of the sources o f variation to which inoculum SF experiments may 
be susceptible with corresponding suggested control measures.
Root causes of variation Suggested control measures
• Variable medium quality; • Use a defined medium;
• Un-optimised fermentation • Perform DoE and include all
performance; key fermentation responses: 
o Screen all critical factors -  
include all relevant factors 
from DoE screen (Table 
2.2);
o Determine optimal factor 
ranges; 
o Determine acceptable 
response ranges;
• Human error; • Implement robotic automation 
where possible;
• Variable incubator-shaker 
performance.
• Monitor incubator performance.
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8.2.5 Improvement phase
Here, all the root causes o f process underperformance identified during the 
Analysis phase should be controlled through implementation o f the suggested 
improvement measures. Thus, new rounds of DoE-driven experimentation are 
required to optimise each stage o f the process in sequence.
Once all improvements have been implemented, process performance should be 
re-evaluated and further improvements made if necessary. An iterative approach 
to the Measure-Analyse-Improve phases may, therefore, be required until all 
project goals (Table 8.1) are met as illustrated in Figure 8.1.
Table 8.4 Possible sources o f observed variation in the MWP fermentation 
performance (Chapter 4) with corresponding suggested control measures.
Root causes of variation Suggested control measures
• Variable inoculum quality; • Use improved inoculum;
• Variable medium quality; • Use a defined medium;
• Human error; • Implement robotic automation
where possible;
• Variable incubator-shaker • Monitor incubator performance.
performance.
161
8. Development o f  the proposed fram ew ork to facilitate bioprocess validation Islam 2007
Table 8.5 Possible sources o f observed underperformance in the DoE analysis 
(Section 4.5) with corresponding suggested improvements.
Root causes o f underperformance Suggested improvements
• Hidden effect o f unidentified • Include responses from previous
factor(s). process step as uncontrolled 
factors;
• Conduct further scouting 
experiments;
• Factor ranges too large; • Establish narrower factor ranges;
• Model lack of fit; • Remove qualitative factors from 
screen;
• Optimise fermentation responses 
using a cubic model if  necessary;
• Robustness of process • Perform robustness testing
uncertain around key factors and responses.
8.2.6 Control phase
The goal of this phase is to control future process performance. All operating 
procedures associated with the new process should be documented and a 
monitoring and control plan should be implemented for sustaining improvements 
(short and long-term). Since small-scale processes are usually part o f a short­
term development programme, application o f this phase may be more appropriate 
to the large-scale manufacturing process.
8.3 Summary
The aim of this chapter was to explore how the framework presented in this 
thesis could be developed to facilitate bioprocess validation. The need for greater 
process understanding and control was immediately identified and the principles 
of Six Sigma were applied to the current framework towards this goal. Using this 
methodology various framework improvements were proposed in the form of
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additional key responses (Table 8.2) and control measures against sources of 
process variation (Tables 8.3 and 8.4) and DoE analysis underperformance 
(Table 8.5). Overall, the suggested improvements should greatly facilitate the 
subsequent hypothetical scale-up and validation o f the process. In the following 
chapter, the main findings o f this thesis are summarised together with 
suggestions for future work.
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9 Conclusions and future work
9.1 Conclusions
At present, a major bottleneck within drug discovery involves the provision of 
sufficient quantities of recombinant protein for high-throughout screening 
(Stewart et al., 2002). This thesis has established a practical and generic 
framework to address this challenge which underpins the generation o f large 
yields of recombinant protein in E. coli in a rapid and cost-effective manner.
The underlying design o f the framework was first established in Chapter 3 
(Figure 3.1). This consisted o f two principle stages o f experimentation: (1) small 
scale protein expression characterisation followed by (2) scale-up of optimised 
protein expression. A wide range o f variables was known to affect heterologous 
protein expression (Section 1.2.3). Consequently, during the initial 
characterisation stage, Design o f Experiments (DoE) and experiments in 
microwell plate (MWP) formats were used in order to minimise the experimental 
costs and timeframes. A key requirement o f stage one was to provide insight into 
larger scales of performance (Fernandes and Cabral, 2006). Thus, in contrast to 
previous studies (Section 1.3.4), experiments were performed within a defined 
engineering environment through the manipulation of factors such as MWP 
shaking speed and fill volume. The information generated from stage one o f the 
framework then aided in the identification of key scale-up parameters and the 
subsequent design of a scale-up strategy. In order to meet the varying protein 
demands of different drug-discovery campaigns, separate strategies for 
laboratory scale and pilot scale protein expression were established.
In Chapter 4 the overall methodology for rapid protein expression 
characterisation was refined through practical experimentation and DoE was 
shown to lead to the rapid optimisation o f culture conditions. A mixture o f ten 
biological and engineering variables was initially chosen for investigation (Table 
4.1). After only three rounds of DoE, the protein induction period and shaking 
speed were identified as key factors (Figure 4.3) and a predictive model of
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protein expression was developed (Equation 4.1). In comparison to other high- 
throughout protein expression (HTPE) approaches, the application o f DoE led to 
a significant decrease (up to 98 %) in the number o f characterisation experiments 
required. At each stage of the DoE process a greater understanding o f the 
expression system was achieved and, overall, the soluble protein yield was 
increased approximately 9-fold over reference shake-flask conditions (Figure 
4.8). The use o f parallel MWP fermentations further helped to reduce the 
experimental timeframes. As mentioned previously, the shaking speed, which is 
known to strongly affect the oxygen mass transfer into microwells (Hermann et 
al., 2003), was identified as a key factor o f protein expression. This suggested 
that careful control o f agitation and aeration conditions would be important in 
maintaining optimal protein expression levels upon scale-up.
In Chapter 5 the oxygen mass transfer coefficient, kia , was shown to be a 
suitable basis for scale-up and microwell results were accurately reproduced at 
the laboratory scale. Here, MWP fermentations were scaled-up to a 7.5 1 stirred- 
tank reactor (STR) over a range of matched kia values. MWP fermentation 
kinetic profiles and yields were accurately reproduced at a ‘high’ matched kia  
value of 247 h"1, equivalent to a 1,700 fold scale translation (Figure 5.9 (a)). This 
result confirmed the initial DoE-driven hypothesis that kia  was an important 
scale-up parameter and in so doing, demonstrated the importance o f DoE within 
the current framework. This result also confirmed a number o f recent studies 
which have suggested kia  to be an important scale-up parameter for aerobic 
fermentations (Ferreira-Torres et al., 2005; Micheletti et al., 2006). In contrast, 
scale-up of MWP fermentations at a ‘low’ matched kia value o f 55 h '1 did not 
provide reproducible performance at the 7.5 1 scale. This difference was 
attributed to the poor gas-liquid distributions observed within the larger vessel at 
the ‘low’ kia  conditions.
This information was exploited in Chapter 6 to develop a scale-up strategy for 
translating MWP fermentation performance to pilot scale where kia  was again 
shown to be a suitable basis for scale-up. Here, MWP fermentations were scaled- 
up to a 75 1 stirred-tank reactor (STR) on the basis o f a ‘high’ matched kia  value
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of 247 h 1. Initial experiments showed a difference in fermentation performance 
between the MWP and 75 1 scales. This was attributed to differences in the 
method o f medium sterilisation between the two vessels (Section 2.4) and hence 
the different temperature-time profiles achieved. The scale-up strategy was thus 
further refined by first sterilising all fermentation media within the STR. This 
subsequently led to the accurate reproduction o f MWP fermentation kinetic 
profiles at the 75 1 scale (Figure 6.6). No previous studies have translated MWP 
fermentation performance to this scale, equivalent to a 15,000 fold scale-up. In 
so doing, this result clearly demonstrates the validity and efficacy o f the overall 
framework for underpinning the generation of large yields o f recombinant 
protein in a rapid and cost-effective manner.
Chapter 7 presented a thorough and quantitative analysis of the inherent time and 
cost savings provided by the current framework in which the DoE component 
was shown to be o f principal benefit. Overall, in comparison to the traditional 
approach for protein sample generation the current framework was predicted to 
provide significantly increased drug sales revenues by accelerating drug 
discovery. These benefits would be especially large when the target protein 
expresses poorly.
Finally, Chapter 8 explored how this framework could be developed towards the 
generation of manufacturing scale quantities o f protein and validation o f the 
subsequent process. The need for greater process understanding and control was 
immediately identified and various minor framework improvements were 
proposed towards this goal in the form o f additional key responses (Table 8.2), 
control measures against sources o f process variation (Tables 8.3 and 8.4) and 
measures to improve DoE analysis performance (Table 8.5). Overall, the 
suggested improvements would greatly enhance process control, thereby 
widening the applications o f the framework to include the production o f larger 
quantities of protein and subsequent bioprocess validation.
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9.2 Future Work
Throughout the course of this research, several areas for further work were 
identified. Based upon the experimental results obtained in this work, immediate 
follow-up studies should address the following points:
• The scale-up o f protein expression within this framework was achieved 
on the basis of a single, high matched kia  value. Further work is thus 
necessary to establish more accurately the range o f kia  values over which 
MWP fermentation kinetics can be reliably scaled-up;
• The cause(s) o f the observed lack-of-fit o f the optimisation model
(Section 4.5) should be investigated. Analysis of why some MWP
experiments yielded unusually low protein yields and why other 
experiments resulted in high degrees of cell lysis (Section 4.5) should 
facilitate this investigation. Ultimately, the process may have been 
affected by unidentified factors or the identified factor ranges may have 
been unsuitably high;
• Within the current work, kia  values were measured in cell-free media
under static conditions. Measurements of kia values within live media
over the course o f a fermentation would provide greater insight into the 
oxygen mass transfer characteristics o f the process which should in turn 
facilitate scale-up;
• The underlying cause o f why initial experiments within the MWP 
produced lower final biomass concentrations than those in the 
corresponding 75 1 STR fermentations should be further studied.
Based on the wider considerations of this framework the following points could 
also be addressed:
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• Further characterisation of the engineering environment within the MWP 
and STRs through, for example, mixing time studies, towards the 
visualisation of gas-liquid dispersion;
• Having reproduced near-optimal MWP protein expression levels at 
laboratory and pilot scales, further optimisation of protein expression 
could be performed at these larger scales. This may, for example, be 
accomplished through additional applications of DoE combined with the 
implementation of fed-batch culture to overcome the decrease in soluble 
protein yield once the glycerol supply is exhausted (Figures 5.5, 5.7, 6.4 
and 6.5);
• The key principles o f the current framework are also likely to apply to 
other expression hosts, recombinant proteins and expression mechanisms 
such as extracellular expression. In this case, further work would be 
required to identify additional key factors, responses and experimental 
techniques involved in small-scale protein expression and the subsequent 
scale-up strategy would have to be refined as appropriate;
• The level of process understanding and control provided by the current 
framework could also be easily developed. Chapter 8 describes in detail 
simple improvements to fermentation and DoE methods towards these 
goals. Ultimately, the improved framework could be applied to the rapid 
generation o f manufacturing scale quantities of protein in addition to the 
subsequent validation o f such a process.
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Appendix A -  Bioreactor mixing data
Table A.1 MWP kia values ( h 1) measured as described in Section 2.4.1.
Plate
geometry
Shaking speed (rpm)
100 200 300 400 500
PI 0.7 ±0.2 3.2 ±0.1 22.7 ±1.5 59.5 ±3.9 88.9 ±6 .4
P2 1.6 ±0.4 5.1 ± 0 .6 29.0 ±5.1 95.5 ±21.2 187.6 ±20.6
P3 2.1 ±0.2 5.0 ± 0 .7 47.7 ±8.0 148.0 ±7.0 241.3 ±28.7
Table A.2 MWP a f /a t values (dimensionless) measured as described in Section 
2.4.2. NA indicates data not obtainable.
Plate
geometry
100
Shaking speed (rpm)
200 300 400 500
PI 0.89 ±0.15 0.99 ±0.15 1.21 ±0.31 2.06 ±0.20 NA
P2 0.93 ± 0.03 0.97 ±0.02 1.17 ±0.07 1.63 ±0.19 2.22 ±0.07
P3 0.95 ± 0.02 0.97 ±0.03 1.28 ±0.04 2.10 ±0.05 2.58 ±0.11
Table A.3 STR kia values (h '1) measured as described in Section 2.4.3.
STR Agitation speed (rpm)
size 200 256 400 600 800 937
7.5 1 9.7 ± 0 .6 167.5 ± 1 2 .0 184.1 ± 17.9 272.1 ± 3 2 .9
75 1 48.4 ± 1 .8 129.1 ± 3 .6 211.1 ± 14.5 346.7 ± 2 2 .3 384.9 ± 2 3 .9
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Table A.4 STR gassed-power, Pg, values (W.rrT3) calculated using Equation 5.6
STR size Agitation speed (rpm)
200 256 400 600 800 937
7.5 1 0.23 1.66 5.26 11.95
75 1 7.6 26.8 84.4 199.0 311.6
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Appendix B - Fermentation response modelling
B.l Basis
All statistical modelling and analytical methods are described in Section 2.5.3.
B.2 MWP and 7.5 1 STR: [Biomass] comparison
Equation of model used: In — (logistic curve)
5
4
3>toto•
E
2
CD5toto•
E
.26
3
2
£
1
0
0 2 8 10 1264
3
a
E
2ffi
to
9
Eo&
0 2 8 104 6 12
Time (h) Time (h)
Figure B.l Logistic curves fitted separately to Figure B.2 Single logistic curve fitted to 
MWP [biomass] data ( ■ ) and 7.5 l STR combined MWP and 7.5 l STR [biomass] data, 
[biomass] data ( □ ).
Table B.l Summary o f model parameters Table B.2 Summary of modelling
correct to 3 s.f. correct to 3 s.f.
Parameter Value Std. Error RSSsep 0.231
CL. a 5.11 0.158 RSScomb 0.294
2
b
c
4.96
0.615
0.180
0.0510
DFsep
DFcomb
F
8
1 1
0.733i n
a
b
5.17
5.21
0.224
0.257
c 0.551 0.0589 P 0.561
_b a 5.14 0.130
so b 5.08 0.149
D
c 0.581 0.0378
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B.3 MWP and 7.5 1 STR: [Glycerol] comparison
Equation o f model used: v = -------
^  |  +  J Q ( f - l 0 g/>)
4
3
t
1
0
0 5 10 1 5 20 25
Time (h)
Figure B J  One site competition curves fitted 
separately to MWP [glycerol] data ( ■ ) and 7.5 
1 STR [glycero] data ( □ ).
Table B.3 Summary o f model parameters 
correct to 3 s.f.
Parameter Value Std. Error
CL
£
a 3.70 0.0814
2 log b 7.76 0.0833
a 4.03 0.0748
log b 8.24 0.0726
j6
B
a 3.86 0.106
u lo g b 8 . 0 0 0.0977
(one site competition curve)
3
I
o 2«£O
1
0
0 5 10 2515 20
Time (h)
Figure B.4 Single one site competition curve 
fitted to combined MWP and 7.5 1 STR 
[glycerol] data.
Table B.4 Summary o f modelling statistics 
correct to 3 s.f.
RSSsep 0.288
RSScomb 1.233
DFsep 1 2
DF comb 14
F 19.7
P 1.63E-04
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B.4 MWP and 7.5 1 STR: Soluble protein yield comparison
Equation o f model used: y  = y 0 + cexp(-exp(-*/) -  d  +1)
where d  = ——— (extreme peak function curve)
35x10*
~  20x10*-
10x10*-
0 5 10 15 2520
Time (h)
Figure B.5 Extreme peak function curves fitted 
separately to MWP soluble protein yield data ( ■ ) 
and 7.5 1 STR soluble protein yield data ( □ ).
Table B.5 Summary o f model parameters correct 
to 3 s.f.
Parameter Value Std. Error
yo 1.29E+05 1.02E+05
f t .
£ a 1 1 . 8 0 . 2 2 2
b 2.96 0.230
c 2.82E+06 1.64E+05
yo 1.32E+05 9.14E+04
m a 12.7 0.170
r-- b 3.09 0.209
c 3.19E+06 1.32E+05
yo 1.27E+05 1.16E+05
X )
E a 12.3 0.236o
U b 3.07 0.254
c 2.98E+06 1.76E+05
3 0x10* -
2 5*10* -
0 5 10 15 20 25
Time (h)
Figure B.6 Single extreme peak function curve 
fitted to combined MWP and 7.5 l STR soluble 
protein yield data.
Table B.6 Summary o f modelling statistics 
correct to 3 s.f.
RSSsep 6.59E+10
RSScomb 3.77E+11
DFsep 4
DFcomb 8
F 4.72
P 0.0811
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B.5 MWP and 75 1 STR: [Biomass] comparison
Equation of model used: In' y . '
J o /
a
\ + e
(logistic curve)
3 >  3 -
0 2 6 8 104 12
Time (h)
o 2 4 6 8 10 12
Time (h)
Figure B.7 Logistic curves fitted separately to 
MWP [biomass] data ( ■ ) and 75 l STR 
[biomass] data ( □ ).
Table B.7 Summary 
correct to 3 s.f.
o f model parameters
Parameter Value Std. Error
eu a 4.28 0.0577
£ b 4.12 0.0803
c 0.836 0.0460
a 4.31 0 . 1 1 0
75 b 4.35 0.153
c 0.740 0.0654
x a 4.29 0.0653
Eo b 4.23 0.0910
U
c 0.784 0.0447
Figure B.8 Single logistic curve fitted to 
combined MWP and 75 l STR [biomass] data.
Table B.8 Summary o f modelling statistics 
correct to 3 s.f.
RSSsep 0.082
RSScomb 0.131
DFsep 8
DF comb 1 1
F 1.60
P 0.264
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B.6 MWP and 75 1 STR: [Glycerol] comparison
Equation of model used: v = ------- , ,
1 + 10* g)
4
3
2
1
0 5 10 150 20 25
Time (h)
Figure B.9 One site competition curves Fitted 
separately to MWP [glycerol] data ( ■ ) and 75 
l STR [glycerol] data ( □ ).
Table B.9 Summary o f  model parameters
correct to 3 s.f.
Parameter Value Std. Error
CL a 3.98 0.0588
£
2 l o g b 8.73 0.105
a 4.12 0.038
l o g b 8.84 0.0792
.d a 4.05 0.0400
B
u l o gb 8.78 0.0767
(one site competition curve)
4
3
2
1
0
0 5 10 15 20 25
Time (h)
Figure B.10 Single one site competition curve 
fitted to combined MWP and 75 1 STR 
[glycerol] data.
Table B.10 Summary o f modelling statistics 
correct to 3 s.f.
RSSsep 0.136
RSSComb 0.203
DFsep 14
DFcomb 16
F 3.438
P 0.061
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B.7 MWP and 75 1 STR: Soluble protein yield comparison
Equation of model used: y  = y 0 + cexp (-exp (-d ) - d  + 1)
where d  = ——— (extreme peak function curve)
0 5 10 15 
T im e (h)
20 25
Figure B .ll Extreme peak function curves fitted 
separately to MWP soluble protein yield data ( ■ ) 
and 75 1 STR soluble protein yield data ( □ ).
Table B .ll Summary o f model parameters 
correct to 3 s.f.
Parameter Value Std. Error
yo 6.95E+05 2.77E+05
a.
£ a 13.0 0.434
£ b 2.51 0.775
c 6.17E+06 6.65E+05
yo 3.95E+05 4.70E+05
«n a 13.2 0.354
r^ b 3.03 0.672
c 6.51E+06 5.85E+05
y<> 5.60E+05 2.07E+05
.o
£ a 13.1 0.195o
U b 2.77 0.374
c 6.31E+06 2.98E+05
7*10*
6x10* -
5x10* -
3x10*-
1x10*-
5 10 150 20 25
T im e (h)
Figure B.12 Single extreme peak function curve 
fitted to combined MWP and 75 l STR soluble 
protein yield data.
Table B.12 Summary o f modelling statistics 
correct to 3 s.f.
RSSSep 3.38E+11
RSScomb 6.14E+11
DFsep 2
DFcomb 6
F 0.410
P 0.797
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Appendix C -  Experimental costs and timeframes 
C.l Cost of consumables
All media costs shown below include the cost of an average addition of 500 pM 
(= 0.12 g.l'1) IPTG for all fermentations. All components were purchased from 
Sigma-Aldrich Chemical Company (Dorset, UK) unless otherwise stated in 
Chapter 2.
Table C.l Cost of LB media
Component Concentration Unit cost (£) Unit quantity Cost (£.r1)
Y east extract 5 g.l'1 126.50 1000 g 0.63
T ryptone 10 g .l1 24.10 1000 g 0.24
NaCI 10 g.l'1 16.40 1000 g 0.16
Kanamycin 30 mg.I'1 59.60 5000 mg 0.36
IPTG 0.12 g .l1 216.60 10 g 2.58
3.98
Table C.2 Cost of TB media
Component Concentration Unit cost (£) Unit quantity Cost (£J 1)
Y east extract 24 g.l'1 126.50 1000 g 3.04
Tryptone 12 g .f1 24.10 1000 g 0.29
Glycerol 4 ml.I'1 29.80 1000 ml 0.12
KH2P 0 4 2.31 g.l'1 25.00 1000 g 0.06
K2HPO4 12.54 g.l'1 76.40 2500 g 0.38
Kanamycin 30 mg.I'1 59.60 5000 mg 0.36
IPTG 0.12 g.l'1 216.60 10 g 2.58
Total 6.82
Table C.3 Cost of GM9Y media
Component Concentration Unit cost (£) Unit quantity Cost (£.r1)
GM9Y 15.5 g.l'1 25.69 500 g 0.80
Kanamycin 30 mg.I'1 59.60 5000 mg 0.36
IPTG 0.12 g.l'1 216.60 10 g 2.58
Total 3.73
Table C.4 Cost of MWPs including cost o f breathable membranes (£0.83 per 
membrane)
MWP geometry Unit cost (£) Unit quantity Cost per MWP
P1 220.00 25 9.63
P2 220.00 25 9.63
P3 74.86 25 3.82
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Table C.5 Cost o f luciferase assay buffer (LAB)
Component Concentration Unit cost (£) Unit quantity Cost (£J 1)
MgS04 1.20 g.l'1 15.80 100 g 0.19
Tris 1.21 g.l'1 15.60 100 g 0.19
ATP 0.28 g.l'1 38.60 1 9 10.64
Luciferin 0.13 g.l'1 643.90 0.05 g 1696.68
Co-A 0.22 g.l'1 424.70 0.1 g 928.33
DTT 4.86 g.l'1 11.70 0.25 g 227.40
Total 2863.42
Per 200pl assay (Section 2.6.3) 0.57
C.2 Optimal schedules for the theoretical MWP fermentation 
scenarios (Sections 7.2.2 and 7.2.4)
The following schedules assume 24 h experimentation, instant turnaround and a 
maximum processing throughput of 72 wells in parallel. These schedules also 
account for the fact that the HiGro incubator shaker can only be operated at one 
shaking speed at a time.
Shaking speed 
I 150 rpm
Y///A30Q rpm 
I 1500 rpm
 ■------ 1------ 1---------1---- ------- 1-----------’--1------ ------- 1-----■------- 1------ '------ r
0 10 20 30 40 50 60 70
Fermentation time (h)
Figure C .l An optimal schedule for the MWP familiarisation experiments 
described in Table 2.3, showing minimum theoretical number o f hours required 
to complete all fermentations. Experiments from Table 2.3 are arranged in 
fermentation batches according to those with identical pre-I and post-I shaking 
speeds. Numbers to the right of each bar represent number of fermentations per 
batch (including replicates).
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t   r i   --- 1---   1---   r
2 -
D 3 * c
§
tS  4 -
5 -
28
28
28
Shaking speed 
I 1100 rpm 
V ///A  300 rpm 
1500 rpm
1 2 -
10 20 30 40 50 60 70
Fermentation time (h)
Figure C.2 An optimal schedule for the MWP screening experiments described 
in Table 4.2, showing minimum theoretical number of hours required to 
complete all fermentations. Experiments from Table 4.2 are arranged in 
fermentation batches according to those with identical pre-I and post-I shaking 
speeds. Numbers to the right of each bar represent number of fermentations per 
batch (including replicates).
§ 8 - 
<2
32
32
Shaking speed 
I 1100 rpm 
EZZ3300 rpm 
1500 rpm
32
32
20 40 60 80 100
Fermentation time (h)
120 140
Figure C.3 An optimal schedule for the MWP optimisation experiments 
described in Table 4.3, showing minimum theoretical number of hours required 
to complete all fermentations. Experiments from Table 4.3 are arranged in 
fermentation batches according to those with identical pre-I and post-I shaking 
speeds. Numbers to the right of each bar represent number of fermentations per 
batch (including replicates).
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I 1100 rpm 
Y///A 300 rpm 
1500 rpm
a n  36
36
^ 3 6
YA 136 -
20 40 80 100 120
Fermentation time (h)
Figure C.4 An optimal schedule for the MWP optimisation experiments, 
identical to that of Figure C.3, in which the maximum number of fermentations is 
performed (72 wells in parallel). Numbers to the right of each bar represent 
number of fermentations per batch (including replicates).
C.3 Optim al schedules for the theoretical shake-flask (SF) 
ferm entation scenario (Section 7.2.3)
The following schedules assume the availability of three SF incubator shakers, 
each of which can be operated at a separate shaking speed. It is also assumed that 
a maximum of 24 SF experiments can be processed in parallel.
180
Appendix C -  Experimental costs and timeframes Islam 2007
? ' I " I - - - - - - - - - - - -   1- - - - - - - - - - - -   T
2A
. 3 
%
i  4
i -
6
7-1
24
24
Shaking speed 
I 1 50 rpm 
Y///A 300 rpm 
1500 rpm
m u  24
^ 8
20 40 60 80
Fermentation time (h)
120
Figure C.5 An optimal schedule showing the minimum theoretical number of 
hours required to complete the familiarisation experiments described in Table 
2.3, if performed in SFs. Experiments from Table 2.3 are arranged in 
fermentation batches according to those with identical pre-I and post-I shaking 
speeds. Numbers to the right o f each bar represent number of SF fermentations 
per batch (including replicates).
1
2
3 -
1 5 
(2 6
7 4
Shaking speed 
I -  1100 rpm
Y777A 300 rpm 
1500 rpm
24
J24
I U ^ S * l24
^ 1 2
20 40 60 80
Fermentation time (h)
120
Figure C . 6  An optimal schedule showing the minimum theoretical number of 
hours required to complete the screening experiments described in Table 4.2, if 
performed in SFs. Experiments from Table 4.2 are arranged in fermentation 
batches according to those with identical pre-I and post-I shaking speeds. 
Numbers to the right of each bar represent number of SF fermentations per batch 
(including replicates).
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Figure C.7 An optimal schedule showing the minimum theoretical number of 
hours required to complete the optimisation experiments described in Table 4.3, 
if performed in SFs. Experiments from Table 4.3 are arranged in fermentation 
batches according to those with identical pre-I and post-I shaking speeds. 
Numbers to the right o f each bar represent number of SF fermentations per batch 
(including replicates).
C.4 Disposable M W P requirem ents
The following requirements for MWPs assume that each MWP is disposed of 
after each batch.
Table C . 6  Minimum number of MWPs required at the familiarisation stage when 
experiments are arranged as described in Figure C.l.
Batch MWP requirements
Number P1 P2 P3
1 1 1 1
2 1 1 1
3 1 1 1
4 1 1 1
5 1 0 0
Total 5 4 4
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Table C .l Minimum number of MWPs required at the screening stage when 
experiments are arranged as described in Figure C.2.
Batch MWP requirements
Number P1 P2 P3
1 1 1 1
2 1 1 1
3 1 1 1
4 1 1 1
5 0 0 1
Total 4 4 5
Table C . 8  Minimum number of MWPs required at the optimisation stage when 
experiments are arranged as described in Figure C.3
. requirementsNumber --------^ p3------
1 2
2 1
3 3
4 1
5 2
6 2
7 2
8 1
9 1
Total 15
C.5 Cost scenarios 
C. 5.1 Background
The cost analyses in the following sections refer to the protein expression 
optimisation scenarios defined in Section 7.2. Section 7.2 also provides the 
general assumptions for all three cost analyses. In each analysis, 1 unit = 1 1 
media /1  MWP / 1 assay /1  h pay.
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C.5.2 Scenario one: current framework (Section 7.2.2)
In this scenario, both the DoE and MWP framework components are applied and 
the experimental requirements are considered at each stage of the DoE process: 
familiarisation (F), screening (5) and optimisation (O). A detailed cost analysis 
for this scenario is provided in Table C.9. Specific assumptions are as follows:
• Total number o f fermentations performed = 440 (Chapter 4);
• Mean micro well fermentation volume = 2 ml.
C.S.3 Scenario two: current framework minus the MWP component (Section 
7.2.3)
In this scenario, the MWP component is replaced by shake-flask (SF) 
experimentation and the costs associated with this change are estimated. Again, 
the experimental requirements at each stage of the DoE process are considered. 
A detailed cost analysis for this scenario is provided in Table C.10. Specific 
assumptions are as follows:
• The same number o f fermentations (440) is performed as in scenario one 
(Section C.5.2);
• The DoE factor related to MWP geometry is exchanged for SF geometry;
• Mean SF fermentation volume = 250 ml.
• Same number o f inoculum SFs and assays as for scenario one (Table 
C.9).
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Table C.9 Cost analysis for scenario one: current framework. 'Unit costs 
calculated in Section C .l. Requirements are in accordance with experimental 
methods (Chapter 2). 3> Requirements are calculated in Sections C.4 and C.2 , 
respectively.
________ Requirements by stage________  Unjt Cost of Cost
Variable „ „ ^  ^ , cost materials .____________ F S O  Total (£)i (£) labour
Inoculum preparation
Number of 500 ml (working volume) SFs2
LB 4 4 0 8 3.98 15.90
TB 4 5 9 18 6.82 61.41
M9Y 5 4 0 9 3.73 16.81
94.12
Fermentation
Minimum number of MWPs3
P1 5 4 0
P2 4 4 0
P3 4 5 15
Number of 2 ml MWP fermentations
9 9.63 86.67
8 9.63 77.04
24 3.82 91.79
255.50
LB 32 32 0 64 3.98 0.51
TB 40 48 200 288 6.82 3.93
M9Y 48 40 0 88 3.73 0.66
5.10
Assay
Number of assays2
120 120 200 440 0.57 251.98
Labour
Minimum fermentation time (h)4_____
___________ 70______ 70______ 135 275 10______________2,750
Total costs 607 2,750
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Table C.10 Cost analysis for scenario two: current framework minus the MWP 
component. 'Unit costs calculated in Section C .l. 2Minimum total fermentation 
times calculated in Section C.3.
________ Requirements by stage  Unjt Cost of Cost
Variable _ „ „  ^ , cost materials .F S O Total yy labour
Inoculum preparation
Number of 500 ml (working volume) SFs
LB 4 4 0 8 3.98 15.90
TB 4 5 9 18 6.82 61.41
M9Y 5 4 0 9 3.73 16.81
94.12
Fermentation
Number of 250 ml SF fermentations
LB 32 32 0 64 3.98 63.61
TB 40 48 200 288 6.82 491.31
M9Y 48 40 0 88 3.73 82.16
637.09
Assay
Number of assays
120 120 200 440 0.57 251.98
Labour
Minimum total fermentation time (h f
__________ 105 105 216 426 10.00____________ 4,260
Total costs 983 4,260
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C.5.4 Scenario 3: current framework minus the DoE component (Section 
7.2.4)
In this scenario, the DoE component is removed and the costs associated with 
this change are estimated. Here, the DoE stages of familiarisation, screening and 
optimisation do not exist and so it is necessary to investigate each factor at three 
levels from the start. A detailed cost analysis for this scenario is provided in 
Table C.l 1. Specific assumptions are as follows:
• Total number o f factor combinations
= 2 qualitative factors (3 levels each) x 8  quantitative factors (3 levels 
each)
= 32 x 3 8 
= 59,049
• Total number o f experiments (including replicates)
= 4 x 59,049
= 236,196
• Mean microwell fermentation volume = 2 ml;
• 1 SF inoculates 9 MWPs = 3x48 + 6x24 exps = 288 exps;
• Minimum number o f MWPs required = total number experiments / 
individual MWP capacity;
• The schedule o f experimentation is the same as that of the optimisation 
experiments o f scenario one (Section C.5.2), where the maximum rate of 
experimentation = 324 fermentations in 135 h (Figure C.4).
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Table C .l l  Cost analysis for scenario three: current framework minus the DoE 
component. 'Unit costs calculated in Section C .l.
Unit Cost of Cost of 
Variable Total requirements cost materials labour
_____________________________________ (^ l1_____ £1______£L_
Inoculum preparation
Number of 500 ml (working volume) SFs
LB 273 3.98 543
TB 273 6.82 933
M9Y 273 3.73 510
1,987
Fermentation
Minimum number of MWPs
P1
P2
P3
1,640
3.281
3.281
Number of 2 ml MWP fermentations
9.63
9.63 
3.82
15796
31591
12546
59,933
LB 78,732 3.98 626
TB 78,732 6.82 1074
M9Y 78,732 3.73 588
2,289
Assay
Number of assays
236,196 0.57 135,266
Labour
Minimum total fermentation time (h)
______________________ 98,415________________ 10_____________ 984,150
Total costs 199,474 984,150
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Appendix D -  List of publications
• Chapter 4: Islam,R.S., Tisi,D., Levy,M.S., and Lye,G.J. (2007)
Framework for the Rapid Optimization of Soluble Protein Expression in 
Escherichia coli Combining Microscale Experiments and Statistical 
Experimental Design. Biotechnology Progress. 23, 785-793.
• Chapters 5 + 6: Islam,R.S., Tisi,D., Levy,M.S., and Lye,G.J. (2007) 
Scale-up o f E. coli growth and recombinant protein expression conditions 
from microwell to laboratory and pilot scale based on matched kia. 
Biotechnology and Bioengineering. In press, doi: 10.1002/bit.21697
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